(fJ GILEAiJ 
CLINICAL STUDY PROTOCOL 
Study Title: A Phase 3, Randomized, Open Label Study to Evaluate the 
Safety and Efficacy of Switching to a Fixed Dose Combination 
(FDC) of GS-9883/Em tricitabine/Tenofovir Alafenamide 
(GS-9883/F IT AF) from Elvitegravir/Cobicistat/Emtricitabine/ 
Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/ 
Emtricitabine/T enofovir Disoproxil Fmnarate (E/C/F /TDF) or 
Atazanavir + Ritonavir + Emti·icitabine/Tenofovir Disoproxil 
Fmnarate (ATV+RTV+FTC/TDF) in Virologically Suppressed 
HIV -1 Infected Women 
Sponsor: Gilead Sciences, Inc. 
333 Lakeside Drive 
Foster City, CA 94404 
IND Number: 125589 
EudraCT Number: Not Applicable 
Clinical Trials.gov Identifier: Not Available 
Indication: HIV -1 Infection 
Protocol ID: GS-US-380-1961 
Gilead Clinical Program 
Manager: 
Gilead Medical Monitor: 
Protocol Version/Date: Name: 
Telephone: 
Fax: 
Name: 
Telephone: 
Fax: 
Mobile: 
Original: PPD 
Huyen Cao, MD 
PD 
PPD 
PPD 
20 November 2015 
CONFIDENTIALITY STATEME NT 
The infonnation contained in this docmnent, particularly m1published data, is the prope1iy or 
under conti·ol of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an applicable 
Institutional Review Board or Independent Ethics Committee. The info1mation is only to be used 
by you in connection with autho rized clinical studies of the investigational dmg described in the 
protocol. You will not disclose any of the info1mation to others without w ritten authorization 
from Gilead Sciences, Inc., except to the extent necessruy to obtain infmmed consent from those 
persons to whom the dmg may be administered. 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page2 20 November 2015TABLE OF CONTENTS
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABLES ................................................................
........................................................................ 5
LIST OF IN- TEXT FIGURES ...................................................................................................................................... 5
PROTOCOL SYNOPSIS .............................................................................................................................................. 6
GLOSSARY OF ABBREVIA TIONS AND DEFINITION OF TERMS .................................................................... 11
1.INTRODUCTION .............................................................................................................................................. 14
1.1.Background ............................................................................................................................................ 14
1.2.GS-9883................................................................................................................................................. 15
1.2.1. General Information ............................................................................................................. 15
1.2.2. Preclinical Pharmacology and Toxicology ........................................................................... 15
1.2.3. Clinical Trials of GS -9883................................................................................................... 17
1.3.Information About Emtricitabine (Emtriva®, FTC)............................................................................... 26
1.4.Information About Tenofovir Alafenamide (TAF, GS -7340)................................................................ 26
1.4.1. Clinical Trials of Single Agent Tenofovir Alafenamide (TAF, GS -7340) 
or Fixed Dose Combination Emtricitabine/Tenofovir Alafenamide 
(FTC/TAF) ........................................................................................................................... 26
1.4.2. Clinical Trials of FTC/TAF as Part of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) ......................................................................................................................... 28
1.5.Information About GS -9883/Emtricitabine/Tenofovir Alafenamide (GS -9883/F/TAF) ....................... 29
1.5.1. GS-US-141-1233: Relative Bioavailability of GS -9883, FTC, and TAF 
Between GS-9883/F/TAF and GS -9883 + F/TAF............................................................... 30
1.6.EVG/COBI/FTC/TDF (E/C/F/TDF or Stribild®)................................................................................... 31
1.7.Emtricitabine/Tenofovir Disoproxil Fumar ate (FTC/TDF, Truvada®).................................................. 31
1.8.Ritonavir (RTV, /r, Norvir®)...............................................................
................................................... 31
1.9.Atazanavir (ATV, Reyataz®).................................................................................................................. 31
1.10.Rationale for This Study ...............................................................
......................................................... 31
1.11.Risk/Benefit Assessment for the Study .................................................................................................. 32
1.12.Rationale for Dose Selection ...............................................................
................................................... 33
1.13.Compliance............................................................................................................................................ 35
2.OBJECTIVES ................................................................................................
..................................................... 36
3.STUDY DESIGN ................................................................................................................................................ 37
3.1.Endpoints ............................................................................................................................................... 37
3.2.Study Design .......................................................................................................................................... 37
3.3.Study Treatments ................................................................................................................................... 37
3.4.Duration of Treatment ............................................................................................................................ 38
3.5.Biomarker Testing .................................................................................................................................. 38
3.5.1. Biomarker Samples for Optional Future Research ............................................................... 38
4.SUBJECT POPULATION .................................................................................................................................. 40
4.1.Number of Subjects and Subject Selection ............................................................................................ 40
4.2.Inclusion Criteria .................................................................................................................................... 40
4.3.Exclusion Criteria ................................................................................................................................... 41
5.INVESTIGATIONAL MEDI CINAL PRODUCTS........................................................................................... 43
5.1.Randomization ....................................................................................................................................... 43
5.2.Description and Handling ....................................................................................................................... 43
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page3 20 November 20155.2.1. Formulation.......................................................................................................................... 43
5.2.2. Packaging and Labeling ....................................................................................................... 45
5.2.3. Storage and Handling ........................................................................................................... 46
5.3.Dosage and Administration of GS -9883/F/TAF, E/C/F/TAF, E/C/F/TDF and 
ATV+RTV+FTC/TDF ........................................................................................................................... 46
5.4.Prior and Concomitant Me
dications....................................................................................................... 46
5.5.Accountability for Investigational Medicinal Product (IMP) ................................................................
.48
5.5.1. Investigational Medicinal Product Return or Disposal ......................................................... 48
6.STUDY PROCEDURES .................................................................................................................................... 49
6.1.Subject Enrollment and Treatment Assignment ..................................................................................... 49
6.2.Pretreatment Assessments ...................................................................................................................... 49
6.2.1. Screening Visit ..................................................................................................................... 49
6.2.2. Day 1 Assessments ............................................................................................................... 51
6.3.Randomization ....................................................................................................................................... 52
6.4.Treatment Assessments (Weeks 4 -48)................................................................
................................... 52
6.5.Treatment Assessments (Post Week 48) ................................................................................................ 55
6.5.1. Post Week 48 Assessments .................................................................................................. 55
6.6.Post-Treatment Assessments .................................................................................................................. 56
6.6.1. Early Study Drugs Discontinuation (ESDD) Assessments ................................................... 56
6.6.2. 30 Day Follow Up ................................................................................................................ 58
6.7.Criteria for Discontinuation of Study Treatment .................................................................................... 59
6.8.Other Evaluations ................................................................................................................................... 59
6.8.1. Markers of Renal Tubular Function ..................................................................................... 59
6.9.Blood and Urine Storage ........................................................................................................................ 60
6.10.Assessments for Premature Discontinuation from Study ....................................................................... 60
6.11.End of Study ........................................................................................................................................... 60
6.12.Post Study Care ...................................................................................................................................... 60
6.13.Virologic Failure .................................................................................................................................... 60
6.13.1. Management of Virologic Rebound ..................................................................................... 60
6.13.2. Subjects with HIV -1 RNA ≥ 50 copies/mL at Study Discontinuation or 
Week48............................................................................................................................... 62
7.ADVERSE EVENTS AND T OXICITY MANAGEMENT ............................................................................... 63
7.1.Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events .................................... 63
7.1.1. Adverse Events ..................................................................................................................... 63
7.1.2. Serious Adverse Events ........................................................................................................ 63
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events ......................................................................... 64
7.2.Assessment of Adverse Events and Serious Adverse Events ...............................................................
..64
7.2.1. Assessment of Causality for Study Drugs and Procedures ................................................... 64
7.2.2. Assessment of Severity ........................................................................................................ 65
7.3.Investigator Requirements and Instructions for Reporting Advers
e Events and Serious 
Adverse Events to Gilead ....................................................................................................................... 65
7.3.1. Adverse Events ..................................................................................................................... 65
7.3.2. Serious Adverse Events ........................................................................................................ 66
7.4.Gilead Reporting Requirements ............................................................................................................. 67
7.5.Toxicity Management ................................................................
............................................................ 67
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .................................................. 67
7.5.2. Grade 3 Laboratory Abnormality or Clinical Event ............................................................. 68
7.5.3. Grade 4 Laboratory Abnormality or Clinical Event ............................................................. 68
7.5.4. On-Treatment ALT Flare and Post -Treatment Exacerbation of Hepatitis B 
Management ......................................................................................................................... 68
7.5.5. Management of Hyperbilirubinemia .................................................................................... 70
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page4 20 November 20157.5.6. On-Treatment Hepatitis C Management ............................................................................... 71
7.5.7. Management of Potential Nephrotoxicity ............................................................................. 71
7.6.Special Situations Reports ...................................................................................................................... 71
7.6.1. Definitions of Special Situations .......................................................................................... 71
7.6.2. Instructions for Reporting Special Situa tions....................................................................... 72
8.STATISTICAL CONSIDER ATIONS................................................................................................................ 74
8.1.Analysis Objectives and Endpoints ........................................................................................................ 74
8.1.1. Analysis Objectives .............................................................................................................. 74
8.1.2. Primary Endpoint ................................................................................................................. 74
8.1.3. Secondary Endpoint ............................................................................................................. 74
8.2.Analysis Conventions ............................................................................................................................. 74
8.2.1. Analysis Sets ........................................................................................................................ 74
8.3.Data Handling Con ventions................................................................................................................... 75
8.4.Demographic Data and Baseline Characteristics ................................................................................... 76
8.5.Efficacy Analysis ................................................................................................................................... 76
8.5.1. Primary Analysis ...............................................................
................................................... 76
8.5.2. Secondary Analyses ............................................................................................................. 77
8.6.Safety Analysis ....................................................................................................................................... 78
8.6.1. Extent of Exposure ............................................................................................................... 78
8.6.2. Adverse Events ..................................................................................................................... 78
8.6.3. Laboratory Evaluations ........................................................................................................ 79
8.6.4. Other Safety Evaluations ...................................................................................................... 79
8.7.Pharmacokinetic Analysis ................................
...................................................................................... 79
8.8.Sample Size............................................................................................................................................ 79
8.9.Independent Data Monitoring Committee .............................................................................................. 79
9.RESPONSIBILITIES ................................................................
.......................................................................... 81
9.1.Investigator Responsibilities .................................................................................................................. 81
9.1.1. Good Clinical Practice .......................................................................................................... 81
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval ........................................................................................................... 81
9.1.3. Informed Consent ................................................................................................................. 81
9.1.4. Confidentiality ...................................................................................................................... 82
9.1.5. Study Files and Retention of Records .................................................................................. 82
9.1.6. Case Report Forms ...............................................................
................................................ 83
9.1.7. Investigational Medicinal Product Accountability and Return ............................................. 84
9.1.8. Inspections ............................................................................................................................ 84
9.1.9. Protocol Compliance ............................................................................................................ 84
9.2.Sponsor Responsibilities ........................................................................................................................ 84
9.2.1. Protocol Modifications ......................................................................................................... 84
9.2.2. Study Report and Publications ............................................................................................. 85
9.3.Joint Investigator/Sponsor Responsibilities ........................................................................................... 85
9.3.1. Payment Reporting ............................................................................................................... 85
9.3.2. Access to Information for Monitoring .................................................................................. 85
9.3.3. Access to Information for Auditing or Inspections .............................................................. 86
9.3.4. Study Discontinuation .......................................................................................................... 86
10.REFERENCES ................................................................................................................................................... 87
11.APPENDICES .................................................................................................................................................... 88
Appendix 1.Investigator Signature Page .................................................................................................... 89
Appendix 2.Study Procedures Table .......................................................................................................... 90
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page5 20 November 2015Appendix 3.Management of Clinical and Laboratory Adverse Events ...................................................... 93
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities ............... 94
Appendix 5.Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)........................... 117
Appendix 6.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements ................................................................................................. 119
LIST OF IN -TEXT TABLES
Table1
-1. GS-US-141-1218: GS -9883 Mean (%CV) PK Parameters Follow ing Single Doses 
of GS-9883 in Healthy Subjects (GS -9883PKAnalysisSet; Part A: Single Dosing) ...........19
Table1-2. GS-US-141-1218: GS -9883 Plasma Pharmacokinetic Parameters by GS-9883 Dose 
Following Multiple -Dose Administration of GS -9883 (Analysis Set: GS -9883 PK 
Part B: Multiple- Dose)........................................................................................................... 20
Table1
-3. GS-US-141-1218: Statistical Comparison of GS -9883 Pharmacokinetic Parameters 
Following Single -Dose Adm inistration of GS -9883 in the Fasted and Fed States 
(GS-9883 PK Analysis Set) ...............................................................
..................................... 20
Table1-4. Trough GS -9883 Plasma Concentrations at Steady State Follow ing GS-9883 
Administration Under Fasting Conditions and Corresp onding Protein -Adjusted IQ 95
Values(GS-9883PKAnalysis Set)...............................................................
......................... 21
Table1-5. GS-US-141
-1219: Trough GS -9883 Plasma Concentrations at Steady State 
Following GS-9883 Administration Under Fasting Conditions and Corresponding 
Protein-Adjusted IQ 95Values................................................................................................
.33
Table5-1. Prior and Concomitant Medications (GS -9883/F/TAF Regimen) .......................................... 47
Table5-2. Prior and Concomitant Medications (E/C/F/TAF, E/C/F/TDF, and 
ATV+RTV+FTC/TD FRegimens) ...............................................................
.......................... 48
LIST OF IN -TEXT FIGURES
Figure1-1.GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV -1 RNA 
(log10copies/mL) (PP Analysis Set) ....................................................................................... 22
Figure3
-1.Study Schema ......................................................................................................................... 38
Figure6
-1.Virologic Rebound Schema .................................................................................................... 62
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page6 20 November 2015PROTOCOL SYNOPSIS
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404
Study Title: A Phase 3, Randomized, Open Label Stud y to Evaluate the Safety 
and Efficacy  of Switching to a Fixed Dose Combination (FDC) of 
GS-9883/Emtricitabine/Tenofovir Alafenamide (GS -9883/F/TAF) 
from Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF), Elvitegravir/Cobi cistat/Emtricitabine/ Tenofovir
Disoproxil F umarate (E/C/F/TDF) or Atazanavir +Ritonavir + 
Emtricitabine/Tenofovir Disoproxil F umarate 
(ATV+RTV+FTC/TDF) in Virologicall y Suppressed 
HIV-1Infected Women
IND Number:
EudraCT Number:
Clinical Trials.gov 
Identifier:125589
Not Applicable
Not Available
Study Centers Planned: Approximately  47 centers in North America
Approximately  2 centers in Dominican Republic
Approximately  6centers in Thailand
Approximately  20 centers in Russia
Approximately  1 center in Uganda
Objectives: The primary  objective of this study  is:
To evaluate the efficacy  of switching to an FDC of 
GS-9883/F/TAFversus continuing on a regimen consisting of 
E/C/F/TAF, E/C/F/TDF or ATV+RTV+FTC/TDF in 
virologicall y suppressed HIV -1 infected women as determined 
by the proporti on of subje
cts with virologic failure 
(HIV-1RNA≥ 50 copies/mL ) at Week 48
The secondary objective of this study  is:
To evaluate the safet yand tolerability  of thetreatment groups 
through Week 48
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page7 20 November 2015Study Design: Randomized, open label, multicenter, active-controlled study  to 
evaluate the safet y and efficacy of switching to a nFDC of 
GS-9883/F/TAF in HIV -1 infected women who are virologically 
suppressed (HIV -1 RNA < 50 copies/mL) on a regimen consisting 
of Elvitegravir/Cobicistat/Emtricitabine/Tenofov ir Alafenamide 
(E/C/F/TAF), Elvitegravir/Cobi cistat/Emtricitabine/Tenofovir 
Disoproxil F umarate (E/C/F /TDF), or ATV+RTV+FTC/TDF for 
≥12 consecutive weeks prior to screening.    
All subjects will be HIV positive women drawn from pre -defined 
Gilead clinica l studies and must be virologicall y suppressed. 
Women in Gilead stud yGS-US-236-0128 who completed the 
Week48 open-label extension (OL E) visit or any post Week 48 
OLE visits or women in study GS-US-
292-0109 who completed the 
Week 96 visit or anypost Week 96 visits may  be eligible to enroll. 
Subjects who provide written consent and meet all eligibility  
criteria will be randomized in a 1:1 ratio to receive open label 
medication as follows: 
Treatment Group 1: FDC of GS -9883 50 mg/
emtricitabine 200 mg/tenofovir alafenamide 25 mg 
(GS-9883/F/TAF) administered orall y, once dail y, without 
regard to food (n =200) 
Treatment Group 2: Stay on baseline regimen (SBR), 
including E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF
administered orall y, once daily , with food (n=200) 
Randomization will be stratified b y the prior treatment regimen 
group (ie, E/C/F/TAF, E/C/F/TDF and ATV+RTV+FTC/TDF).
Number of Subjects 
Planned:Approximately  400 subjects total
Target Population: HIV-1 infected womenwho are virologically  suppressed 
(HIV-1RNA < 50 copies/mL ) on a stable regimen ofE/C/F/TAF, 
E/C/F/TDF, or ATV+RTV+FTC/TDF for ≥12 weeks prior to 
screening
Duration of Treatment: Subjects will be treated for at least 48 weeks. At the Week 48 Visit , 
subjects in a country  where GS -9883/F/TAF FDC is not available 
will be given the option to receive GS-9883/F/TAF FDC for an 
additional 48 weeks, or until the product becomes accessible to 
subjects through an access program, or until Gilead Sciences elect s 
to discontinue the study  in that country , whichever occurs first.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page8 20 November 2015Subjects who complete the study through the Week 48 Visit and 
donot continue participation in the study will be required to return 
to the clinic 30 day s after the Week 48 Visit for a 30 Day 
Follow-Up Visit.
Diagnosis and Main 
Eligibility  Criteria:Medically  stable HIV -1 infected womenwho meet the following 
criteria:
Currently on a stable antiretroviral regimen consisting of 
E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF continuously  
for ≥ 12 consecutive weeks preceding the screening visit
Documented plasma HIV -1 RNA levels < 50 copies/mL  for 
≥12 weeks preceding the Screening visit. After reaching 
HIV-1RNA < 50 copies/mL , single values of HIV
-1 RNA 
≥ 50copies/mL  followed by  re-suppression to < 50 copies/mL  
isallowed
HIV-1 RNA <50 copies/mL  at screening
Estimated glomerular filtration rate (eGFR) ≥ 50mL/min 
according to the Cockcroft- Gault (C-G) formula at the 
screening visit
Study Procedures/
Frequency:After screening procedures, eligible subjects will be randomized 1:1 
to Treatment Group 1 or Treat ment Group 2 and treated for 
48weeks. Following the Screening and Day  1 visits, subjects will 
return for stud y visits at Weeks 4, 8, 12, and then every 12 weeks 
until the Week 48 visit. 
For all eligible subjects, blood and urine will be collected at Day  1, 
Weeks 4, 8, 12, and then ever y 12 weeks through the Week 48 visit. 
Laboratory  analyses (including hematology , chemistry , 
andurinalysis), HIV-1 RNA, CD4+ cell count, and complete or 
symptom directed ph ysical examinations will be performed at the 
Screening, Day  1, and all subsequent st udy visits. 
Adverse events and concomitant medications will be assessed at 
each visit.
Test Product, Dose, and 
Mode of Administration:FDC of GS-9883 50 mg/emtricitabine 200 mg/
tenofovir alafenamide 25 mg (GS-9883/F/TAF) administered 
orally,
once daily, without regard to food .
Reference Therapy, 
Dose, and Mode of 
Administration:Current antiretroviral drug regimen consisting of E/C/F/TAF, 
E/C/F/TDF, or ATV+RTV+FTC/TDF administered orally ,
oncedaily,with food.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page9 20 November 2015Criteria for Evaluation:
Safety: Adverse events and clinical laboratory tests to evaluate the safety  
and tolerability  of the treatment regimens.  
Efficacy: The primary  efficacy endpoint is:
The proportion of subjects with virologic failure (HIV -1 RNA 
≥50 copies/mL  at Week 48, as defined b y the modified 
UnitedStates (US) Food and Drug Administration (FDA) 
snapshot algorithm).
The secondary  efficacy endpoint s include:
The proportion of subjects with HI V-1 RNA < 50 copies/mL  at 
Week 48 as defined b y the US FDA snapshot algorithm
The change from baseline in CD4+ cell count at Week 48
Pharmacokinetics: For all subjects on GS -9883/F/TAF (Treatment Group 1), a single 
anytime pre or post -dose PK blood sample will be collected at 
Weeks 8, 24, and 36. 
For all subjects on GS -9883/F/TAF (Treatment Group 1), a trough 
PK blood sample will be obtained 20-28 hours following the last 
dose at Weeks 4 and 12. Following an observed dose, one PK blood 
sample will be collected between 1 and 4 hours post- dose. 
The concentration of GS -9883 may  be summarized using 
descriptive statistics. 
Statistical Methods: The primary  analysis will consist of a non- inferiority  test of 
switching to GS -9883/F/TAF FDC versus stayingon baseline 
regimen (SBR) with respect to the proportion of subjects with 
virologic failure (HIV -1 RNA ≥ 50 copies/mL) at Week 48 as 
defined b y the modified US FDA snapshot algorithm. I t will be 
concluded that GS -9883/F/TAF is non -inferior to SBR if the upper 
bound of the 2- sided 95% confidence interval (CI) of the difference 
between treatment groups (GS -9883/F/TAF – SBR) in the virologic 
failure rate is less than 4%; ie,a margin of 4% is applied to 
non-inferiority assessment. The 2- sided 95% CIs will be 
constructed based on the exact method.
The proportion of subjects with HI V-1 RNA < 50 copies/mL  at 
Week48 as defined b y the FDA snapshot algorithm will also be 
summarized. The 95% CIs will be constructed in the same manner 
as described for the primary  efficacy endpoint. 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page10 20 November 2015The change from baseline in CD4+ cell count at Week 48 will be 
summarized by  treatment using descriptive statistics. The 
differences and the associated 95% CIs will be constructed using 
Analysis of Variance (ANOVA) model, including treat ment 
(GS-9883/F/TAF vs. SBR) as a fixed effect in the model. 
Adverse events and clinical laboratory  assessments will be 
summarized using descriptive statistics.
A total of approximately  400 HIV -1 infected women, randomized 
in a 1:1 ratio to 2 treatment gr oups (200 subjects per treatment 
group), achieves at least 80% power to detect a non- inferiority 
margin of 4% in Week 48 virologic failure rate (HIV- 1 RNA 
≥ 50copies/mL ) difference between the 2 treatment groups. 
For sample size and power computation, it is assumed that both 
treatment groups have a virologic failure rate of 2% (based on the 
historical Gilead E/C/F/TAF and Stribild®(STB)studies), that a 
non-inferiority margin is 4%, and that the significance level of the 
test is at a one -sided 0.025 level.
This study  will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) 
including archiving of essential documents.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page11 20 November 2015GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS
C degrees Celsius
F degrees Fahrenheit
ABC/DTG/3TC abacavir/dolutegravir/lamivudine, Triumeq®
AE adverse event
ALT alanine aminotransferase
ANC absolute neutrophil counts
ARV antiretroviral
AST aspartate aminotransferase
ATV atazanavir, Reyataz®
AUC area under the plasma/serum/peripheral blood mononuclear cell concentration versus 
time curve
BID twice a day 
BUN blood urea nitrogen
CBC complete blood count
CI confidence interval
CLcr creatinine clearance
Cmax the maximum observed serum/plasma/peripheral blood mononuclear (PBMC) 
concentration of drug
CMH Cochran-Mantel-Haenszel
CNS central nervous system
COBI,C,/co cobicistat ( GS-9350)
Ctau the observed drug concentration at the end of the dosing interval
CPK creatine phosphokinase
CRF case report form(s)
CRO contract (or clinical) research organization 
CYP cytochrome P450
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DSPH Drug Safety and Public Health
DTG dolutegravir, Tivicay®
EC50 50% effective inhibitory concentration
ECG electrocardiogram
eCRF electronic case report form(s)
EVG, E elvitegravir
E/C/F/TAF elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 
E/C/F/TDF elvitegravir/cobicistat/emtricitabine /tenofovir disoproxil fumarate, Stribild®
FAS full analysis set
FDA (United States) Food and Drug Administration
FDC fixed dose combination
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page12 20 November 2015FSH follicle-stimulating hormone
FTC, F emtricitabine, Emtriva®
FTC/TAF emtricitabine/tenofovir alafenamide 
FTC/TDF emtricitabine/tenofovir disoproxil fumarate, Truvada®
GCP Good Clinical Practice (Guidelines)
GGT gamma glutamyl transferase
GSI Gilead Sciences, Inc.
GS-9883/F/TAF GS-9883/emtricitabine/tenofovir alafenamide
HAART highly active antiretroviral therapy
HBV hepatitis B virus
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HCV hepatitis C virus
HDPE high-density polyethylene
hERG human Ether -à-go-go-Related Gene
HIV Human Immunodeficiency Virus
HIV Sx HIV Symptoms Distress Module
HLA human leukocyte antigen
IB investigator’s brochure
IC50 50% maximal inhibitory concentration
ICH International Conference on Harmonisation
IDMC Independent Data Monitoring Committee
IEC institutional ethics committee
IND Investigational New Drug (Application)
INSTI integrase strand -transfer inhibitors
IRB institutional review board
IWRS interactive web response system
KS Kaposi’s sarcoma
LDH lactate dehydrogenase
LLN lower limit of the normal range
MedDRA Medical Dictionary for Regulatory Activities
mg milligram
MH Mantel-Haenszel
min minute
mmHg millimeters mercury
MT4 human t cell leukemia cell line
nM nanoMolar
NNRTI non-nucleoside reverse transcriptase inhibitor
NOAEL no observed adverse effect level
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page13 20 November 2015NRTI nucleoside/nucleotide reverse transcriptase inhibitor
OCT2 organic cation transporter 2
PI protease inhibitor
PK pharmacokinetic
PT preferred term 
PT prothrombin time 
QD once daily 
RAL raltegravir
RNA ribonucleic acid
RTV ritonavir, Norvir®
SAE serious adverse event
STB Stribild®, elvitegravir/cobicistat/emtricitabine/ tenofovir disoproxil fumarate
SUSAR Suspected Unexpected Serious Adverse Reaction
TAF tenofovir alafenamide , GS-7340
TDF tenofovir disoproxil fumarate, Viread®
TFV-DP tenofovir diphosphate (TFVpp)
tmax the time (observed time point) of C max
TSH thyroid stimulating hormone
UGT1A1 uridine 5'-diphospho -glucuronosyltransferase 
UGT uridine glucuronosyltransferase
ULN upper limit of the normal range
US United States
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page14 20 November 20151. INTRODUCTION
1.1. B ackground
Human immunodeficiency virus -1 (HIV-1) infection is a life -threatening and serious disease that 
is of major public health interest around the world. There are approximately  2.4millionpeople in 
North America and Western and Central Europe living with HIV -1 and 36million people 
worldwide {36201}. The infection, if left untreated or suboptimally  treated, is characterized by  
deterioration in immune function, ultimately  resulting in death. Therapeutic strategies for the 
treatment of HIV -1 disease have been significantly  advanced by  the availability  of highly active 
antiretroviral therapy (HAART); the introduction of HAART was associated with a dramatic 
decrease in acquired immune d eficiency syndrome (AIDS) -related morbidity  and mortalit y 
{27881}, 
{5125}, {8284}.
The success of potent and well- tolerated ART means that m orbidity and mortality  in the 
HIV-infected population is increasingly  driven by  non-AIDS–
associated comorbidities. C linical 
attention has become more focused on the optimization of tolerability , long-term safety , and 
adherence of potent ART regimens { 29705}. In addition, t here remains a significant medical need 
for new,effectivetherapies that take into consideration HIV genetic variability , 
the aging 
HIV-infected population, ARV resistance, non-HIV comorbidities, and regimen simplification.
For ART-naive HIV -infected patients, current treatment guidelines suggest that initial therapy  
consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI) and either an integrase 
strand
-transfer inhibitor (INSTI)or the boosted protease inhibitor darunavir {34898}. 
Virologically  suppressed, HIV-infected patients may  switchfrom their current regimen because 
of safety or tolerability concerns or for regimen simplification . All patient populations may  
benefit from once -daily fixed-dose combination (FDC) regimens as these have been shown to 
provideincreased adherence and improved clinical and virologic outcomes {21053
},{29702}.
Tenofovir (TFV) is a nucleotide analog that inhibits HI V-1 reverse transcription. While tenofovir 
disoproxil fumarate (TDF), an oral prodrug of TFV, i s apreferred NtRTI for initial therapy , 
nephrotoxicity  is an identified risk, and reduc tions in bone mineral densit y (BMD) have been 
shown that are larger than those seen with other NRTI s
. Tenofovir alafenamide (TAF) is also an 
oral prodrug of TFV. TAF is more stable in plasma than TDF ,provides higher intracellular 
levels of the active phosphory lated metabolite tenofovir diphosphate (TFV -DP),and
approximately  90% lower circulating levels of TFV relative to TDF
at the clinical doses. 
Thedistinct metaboli sm of TAF offers the potential for an improved clinical profile compared 
with TDF .
GS-9883 is a potent inhibitor of HIV -1 integrase that is being evaluated for the treatment of 
HIV-1 infection. Antiviral testing has shown that GS-9883 is active against a broad panel of 
HIV-1 viral lab strains and clinical isolates. GS-9883 is fully  active against a panel of mutant 
viruses with resistance to NRTI’s, non-nucleoside reverse -transcriptase inhibitors (NNRTIs), and 
protease inhibitors (PIs). Integrase mutant viruses that are resistant to the INSTI s raltegravir 
(RAL) and elvitegravir (EVG) remain largel y sensitive to GS-9883.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page15 20 November 2015Gilead Sciences (Gilead)has coformulated GS-9883 with the N RTI emtricitabine (FTC; F ) and 
the NtRTI  tenofovir alafenamide (TAF) into an FDC tablet that is suitable for once -daily use. 
This GS-9883/F/TAF FDC may  provide a potent, convenient, tolerable, and practical regimen 
for the lon g-term treatment of patients with HIV infection.
1.2. GS-9883
1.2.1. General Information
GS-9883, a potent inhibitor of HIV -1 integrase is being evaluated for the treatment of HIV 
infection. Antiviral testing has shown that GS-9883 is active against a broad panel of H IV-1 viral 
lab strains and clinical isolates. GS-9883 is fully  active against a panel of mutant viruses with 
resistance to NRTIs , NNRTIs, and PIs.Integrase mutant viruses that are resistant to the I NSTIs
RAL and EVG remain largely  sensitive to GS-9883.
1.2.2. Preclinical Pharmacology and Toxicology
A core battery  of safety pharmacology studies have been conducted with GS-9883. These 
include assessments of cytotoxicity , off-target receptor and ion -channel binding, effects on 
human Ether -à-go-go-
Related Gene (hERG)potassium current and papillary  muscle action 
potential, and in vivo studies in rats and dogs that evaluated effects of GS-9883 on all major 
organ systems. The volume of distribution of GS-9883 ranged between 0.09 and 0.22 L/kg in the 
preclinical species, which indicates that the distribution of GS-9883 is limited to the extracellular 
compartment due to its high binding to plasma proteins. The projected half -life of GS -9883 in 
humans is approximately  20 hours based upon the estimates of clearance and volume of 
distribution .
1.2.2.1. Pharmacology
GS-9883 has half maximal inhibitory  concentration (IC50)values ranging from 1.5 to 2.4 nM, 
similar to the inhibitory  effect of DTG and EVG. GS-9883 is highly  potent against HIV 
replication in the human T cell leukemia MT4 celllinewith an EC 50(50% effective inhibitory 
concentration) value of 1.9 nM and a protein adjusted EC 95value of 361 nM. GS-9883does not 
show significant cy totoxicity  against dividing and non -dividing human PBMCs, primary  human 
hepatocytes and vari ous non-target human cell lines.
GS-9883 is mainly  metabolized by  uridine 5'-diphospho -glucuronos yltransferase (UGT1A1) and 
CYP3A. GS-9883 does not inhibit major human CYP isoforms or UGT1A1 at concentrations up 
to 25μM. Consequently , GS-9883 is unlikely  
to be a clinicall y relevant inhibitor of these
enzymes, and is not expected to inhibit the metabolic clearance of drugs metabolized by  these 
enzymes. GS-9883 onl y modestly inhibits renal transporter organic cation transporter 2 ( OCT2)
(IC50= 0.42 
μM). As a result, GS-9883 is not expected to significantly  interfere with the key  
transporter responsible for creatinine tubular elimination at the clinically  projected C max. 
Additionally , the risk that 
GS-9883 will affect the OCT2 -mediated excretion of co -administered 
drugs is considered to be low.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page16 20 November 2015GS-9883 does not activate AhR and onl y weakly activates PXR at concentrations up to 50 μM 
(less than 5% and 40% of activation, respectivel y, compared to positive control compound). 
Therefore, GS -9883 is not expec ted to act as an inducer through PXR- or AhR-mediated 
pathways at the doses and exposure lev els projected in clinical use.
1.2.2.2. Toxicology
Single oral doses of GS-9883 up to 1000 mg/kg were well -tolerated in rats (AD -141-2286). The 
increase in exposure was limi ted (< 2-fold) between 100 and 300 mg/kg and similar exposure 
was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg 
(AUC0
-242205 μg•h/mL  and 1931 μg• h/mL, respectively ). In monkey s, single oral doses of 
GS-9883 up to 100 0mg/kg were well -tolerated (AD -141-2284). The increase in exposure was 
limited (< 2-fold) between 300 to 1000 mg/kg (AUC 0-24803 μ g•h/mL and 1078 μg•h/mL, 
respectivel y).
In 2-week (TX -141-2029) and 26- week (TX -141-2031) oral toxicity  studies in rats at do ses up to 
300mg/kg/day, GS-9883 was well- tolerated with no GS-9883- related effects on clinical 
observations, bod y weight, food consumption, ophthalmic examinations, and anatomic 
pathology .  The high dose of 300 mg/kg/day was considered the maximum feasibl e dose based 
upon saturation of absorption. The no observed effect level (NOEL) in the 26- week stud y was 
considered to be the high dose of 300 mg/kg/day. At the NOEL, GS -9883 exposures in the rat 
were considered to be approximately  12
-/31-fold higher (males/females) than the projected 
steady state human exposure of GS -9883 following administration of GS -9883/F/TAF 
(50/200/25 mg) QD under fed conditions.
In a 39-week study  in monkey s (TX-141-2032), following administration of 1000 mg/kg/day 
(high dose) of GS-9883 for 39 weeks , pathology  data indicated minimal to marked bile duct 
hyperplasia and minimal or moderate hepatocy te hypertrophy  in both sexes, and minimal 
regenerativ e hyperplasia and minimal or slight n eutrophil infiltrate in males. The macroscopic 
finding of rough surface on the liver in one male administered 1000 mg/kg/day correlated with 
moderate hepatocy te hypertrophy and marked bile duct hyperplasia .
After a 4-week recovery 
period, GS -9883-related microscopic liver findings included marked bile duct hy perplasia, slight 
hepatocyte hypertrophy, minimal regenerative h yperplasia, and slight lymphocyte infiltrate in 
one male and slight bile duct hy perplasia in one fema le administered 1000 mg/kg/day, while the 
other two animals in the high dose group had no hepatobiliary  findings. Minimally to mildly  
increased ALT activities (≤ 3.5-fold versus baseline values) , 
likelyassociated with liver findings, 
exhibited reversibili ty. There were no other adverse findings in the study , including clinical 
observations ,or effects on body  weight, bod y weight change, food consumption, ECGs, 
hematology , coagulation, clinical chemistry , u
rinalysis, and ophthalmoscopy .
No GS-9883-related e ffects were observed in the mid- dose group (200 mg/kg/day) which was 
considered the no
-observed- effect-level (NOEL). The estimated margin of exposure at the NOEL 
was approximately  4.7-fold based on expected human exposure with the once dail y dosing of the 
GS-9883/F/TAF (50/200/25 mg) tablet.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page17 20 November 2015A standard battery  of in vitro and in vivo studies was performed to assess the genotoxic potential 
of GS-9883. There was no evidence of mutagenic or clastogenic activity  in an in vitro bacterial 
reverse mutation assay  (Study TX-141-2026), a chromosomal aberration assay  in human 
lymphocytes (Study  TX-141-2027), or in a rat micronucleus test (Stud y TX-141-2029).
1.2.3. Clinical Trials of GS-9883
Clinical trials entailing the use of GS-9883 include:
GS-US-141-1218, a Phase 1 double blind, randomize d, placebo- controlled, first -in-human, 
single-and multiple -ascending dose stud y evaluating the safet y, tolerability, and PK of oral 
GS-9883 in healthy  subjects and a randomized, open
-label, 2-cohort, 3- period, crossover, PK 
study evaluating the drug interaction potential 
between F/TAF FDC tablet and GS-9883 in 
healthy subjects (completed)
GS-US-141-1219, a Phase 1b randomized, double -blinded, sequential cohort
placebo
-controlled study  of the safet y, PK, and antiv iral activity  of GS-9883 in HIV -1 
infected subjects (5mg, 25mg, 50mg, 100mg) (completed)
GS-US-
141-1233, 
a Phase 1,Open -label, Two- Cohort, Multiple -Period, Fixed- Sequence, 
Crossover Study  to Evaluate 1) the Relative Bioavailability  of Two 
GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mgand 50/200/25 mg) 
Fixed-
Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a 
Emtricitabine/Tenofovir Alafenamide (200/25 mg) Fixed-Dose Combination Tablet 
Administered Simultaneously  and 2) the Effect of Food on the Pha rmacokinetics of 
GS-9883, Emtricitabine and Tenofovir Alafenamide When Administered as 
GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mgand 50/200/25 mg) 
Fixed-Dose Combination Tablets (ongoing)
GS-US-141-1479, a Phase 1, open- label, parallel -group, adaptive single -dose study  to 
evaluate the PK of GS-9883 in subjects with normal and impaired renal function (completed)
GS-US-141-
1480, a Phase 1 partially- blinded, randomized, placebo- and positive -controlled 
study to evaluate the effect of GS-9883 on the QT/QTc interval in healthy  subjects 
(completed)
GS-US-
141-1481, a Phase 1 study  to evaluate the pharmacokinetics, metabolism, and 
excretion of GS-9883 in healthy  subjects (completed)
GS-US-141-1485, a Phase 1 adaptive stud y to evaluate transporter, CYP -mediated and 
UGT1A1 drug-drug interactions between GS-9883 and probe drugs (ongoing)
GS-US-141-1487, a Phase 1 randomized, Blinded, Placebo- Controlled Phase 1 Study 
Evaluating the Effect of GS-9883 on Renal Function as Assessed b y Markers of Glomerular 
Filtration Rate (ongoing)
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page18 20 November 2015GS-US-311-1790, a Phase 1 Randomized, Open Label, Drug Interaction Study  Evaluating 
the Effect of F/TAF FDC Tablet or GS-9883 on the Pharmacokinetics of a Representative 
Hormonal Contraceptive Medication, Norgestimate/Ethiny l Estradiol (ongoing)
GS-US-
380-1761, a Phase 1 Study  to Evaluate Pharmacokinetic Drug -Drug Interaction 
Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide Fumarate 
(GS-9883/F/TAF) and Led ipasvir/Sofosbuvir (LDV/SOF) Fixed -Dose Combination (FDC) 
Tablets (ongoing)
GS-US-141-1475, a Phase 2 Randomized, Double -Blinded Study  of the Safety  and Efficacy  
of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus 
Dolutegravir +Emtricitabine/Tenofovir Alafenamide in HIV -1 Infected, Antiretroviral 
Treatment -Naive Adults (ongoing).
Please refer to the 
GS-9883/F/TAF Investigators’ Brochure for further information about these 
studies.
1.2.3.1. Phase 1 Safet yand Pharmacokinetics
StudyGS-US-141-1218 was a four part , first-in-human study .  Parts A and B were randomized, 
double-blind, placebo -controlled, single and multiple ascending dose studies of GS-9883 in 
healthy male and female subjects.  Part C was an open label, fixed sequence food effect study  
evaluating the effect of food on the PK of GS -9883.  Part D was a randomized, open -label, 
2-cohort, 3
-period, crossover PK study  evaluating the drug interaction potential between 
FTC/TAF FDC tablet and GS-9883 in healthy  subjects.
There was no difference in the overall i ncidence or ty pe of AEs when GS-9883 was administered 
in the fasted and fed states. There was no difference in the overall incidence of AEs when 
GS-9883 or FTC/TAF was each administered alone or in combination.
No deaths or pregnancies were reported. No Gr ade 3 or 4 AEs or SAEs, were reported in any  
cohort.
Increases 
in serum creatinine were observed in this study , presumabl y via inhibition of the renal 
transporter OCT2. In the MAD cohorts (fasted), serum creatinine change at Day  14 ranged from 
0.05mg/dL for the 5mgcohort to 0.18 mg/dL for the 300 mg/dL cohort. In Part D (DDI), 
conducted in the fed state (regular meal), subjects received 100 mgGS-9883 monotherapy  for 
7 days and 100 mgGS-9883 with FTC/TAF for 7 day s, the mean serum creatinine change at 
Day 7 was 0.14 mg/dL following GS -9883 and 0.17 mg/dL following GS -9883 + FTC/TAF. All 
changes returned to baseline after discontinuation of GS -9883.
The majority  of laboratory  abnormalities were Grade 1 or Grade 2 in severity . Grade3 laboratory  
abnormali ties included 10 subjects with Grade 3 urine dipstick tests for blood. All of these 
subjects were female, none of the labs were considered b y the Investigator to be clinically 
significant, and all were associated with menstruation. No other Grade 3 or 4 laboratory  
abnormalities were observed.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page19 20 November 2015Based on results in study GS -US-141-1218, pharmacokinetic profile of GS-9883 was 
characterized b y rapid absorption with time to peak plasma concentrations (median t max
ofcohorts) ranging between 1 and 4 hours follow ing administration under fasted conditions. 
GS-9883 exposures were appropriatel y dose proportional following single dose 25 -100mgdose 
administration, with decreasing dose proportional at higher doses. The half -life of GS -9883 was 
approximately  18hours, with no changes observed across studied dose range as evidenced b y 
parallel terminal phase slopes . A high-fat meal increased AUC infand Cmax(geometric mean, 
84%and 101%, respectively ) following 100 mgsingledoseadministration. Steady  state was 
achieved after 4-6days of once dail y dosing of GS-9883 with average accumulation ratios for 
AUC24hrof1.6.
Table1-1. GS-US-141-1218: GS-9883 Mean (%CV) PK Parameters Following 
Single Doses of GS -9883 in Healthy Subjects 
(GS-9883PKAnalysis Set; Part A: Single Dosing)
GS-9883 
PKParameter
Mean (%CV)5mg
(N= 6)25mg
(N= 6)50mg
(N= 6)100mg
(N= 6)300mg
(N= 6)600mg
(N= 6)
Cmax(ng/mL)691.2
(22.1)1618.3
(26.7)3965.0
(40.1)6998.3
(36.1)14605.0 
(27.1)20050.0
(7.5)
Tmax(hr)1.25 
(1.00-1.50)2.00
(1.00-3.00)3.00
(1.50-4.00)2.25
(1.50-3.00)3.50
(2.00-6.00)3.5
(2.00-4.00)
AUCinf(ng•hr/mL)13059.7
(25.1)35718.2 
(21.3)78399.5 
(29.7)163028.2 
(24.3)355917.3 
(32.9)454446.8 
(19.9)
T1/2(hr)18.51
(16.81-19.99)18.08
(16.63-19.64)16.72
(15.77-17.11)18.90
(17.96-20.05)18.14
(17.86-20.53)17.89
(16.38-19.52)
T1/2and Tmax: Median (Q1, Q3)
Table1-2presents GS -9883 plasma PK parameters following administration of GS-9883 
(5,25,
50, 100,and 300mg) once dail y for 7 days. Following administration of either GS-9883 
(5,25, 50, 100, or300 mg) once dail y for 7 days, the PK absorp tion profile observed on 
Days 1 and 7 was similar to that observed in Part A (SAD). The median T maxvalues ranged from 
1.5 to 2.5 hours on Day  1 and 1.5 to 4.0 hours on Day 7. Linearity was observed comparing 
GS-9883 AUC and C maxon Days 1 and 7 over the dose range of 25 to 50 mg. Steady state levels 
of GS-9883 were achieved between Stud y Days 4 to 6of dosing and maintained through Day 14. 
Accumulation is approximately  1.6-fold, which is consistent with the observed half -life of the 
GS-9883 (approximately  18 hours).
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page20 20 November 2015Table1-2. GS-US-141-1218: GS-9883 Plasm a Pharmacokinetic Parameters by 
GS-9883 Dose Following Multiple -Dose Administration of GS-9883 
(Analysis Set: GS -9883 PK Part B: Multiple -Dose)
GS-9883 PK Param eter Mean
(%CV)aMultiple-Dose GS-9883
5mg
(N=6)25mg
(N=6)50mg
(N=6)100mg
(N=6)300mg
(N=6)
Day 1AUC0-24(hr•ng/mL)9033.6
(8.2)27,775.1
(28.3)58,371.4
(18.9)79,773.8
(18.9)180,714.3
(17.6)
Cmax(ng/mL)709.7
(9.5)2220.0
(35.6)4648.3
(18.7)6248.3
(26.8)13,716.7
(19.1)
Tmax(hr)1.50
(1.50, 1.50)1.75
(1.00,3.00)1.50
(1.00, 2.00)2.50
(2.00, 3.00)2.50
(2.00, 4.00)
Day 7AUCtau(hr•ng/mL)14,392.0
(16.7)50,008.2
(26.6)89,710.1
(22.7)126,785.8 
(23.7)277,200.2 
(16.7)
Cmax(ng/mL)982.5
(7.9)3455.0
(24.1)6538.3
(17.6)9396.7
(20.8)19,900.0 
(21.2)
Ctau(ng/mL)400.83
(26.9)1322.00
(27.8)2241.67
(28.2)3145.00 
(26.1)6758.33 
(21.6)
Tmax(hr)1.50
(1.00, 2.00)3.00
(2.00, 3.00)1.75
(1.50,2.00)1.75
(1.50,3.00)4.00
(2.00, 4.00)
Accumulation Ratio of AUC (%)160.5
(19.0)182.2
(17.1)154.0
(15.9)158.5
(12.1)157.5
(22.6)
aData are presented as mean (%CV), except for T max, andt½, which are presented as median (Q1, Q3)
Table1-3presents the geometric least squares mean ( GLSM)ratios and associated 90% CIs for 
the test (fed) versus reference (fasted) treatments for the primary  plasma PK parameters of 
GS-9883. Administration of a single dose of GS-9883 100 mgwith food 
(high-calorie/high -fatbreakfast) increased the GLSM values of Cmaxand AUC inf101% 
(90%CIof GLSM ratio 165.93% to 242.74%) and 84% ( 90% CI of GL SM ratio 
152.05% to222.59%), respectively. There were no apparent changes in clearance and t 1/2
following administration with food, indicating that food enhanced the bi oavailability  of 
GS-
9883by improving its solubility  and/or absorption.
Table1-3. GS-US-141-1218: Statistical Comparison of GS-9883 Pharmacokinetic 
Parameters Following Single -Dose Administration of GS-9883 in the 
Fasted and Fed States ( GS-9883 PK Analysis Set)
GS-9883 PK Param eter Mean (%CV)
% GLSM Ratio 
(90% CI)Test
GS-9883 100 mgFed
(n=8)Reference
GS-9883 100 mgFasted
(n=8)
AUCinf(hr•ng/mL) 214,146.3 (15.9) 117,777.1 (23.3) 183.97 (152.05, 222.59)
AUClast(hr•ng/mL) 209,259.9 (15.1) 115,681.7 (24.0) 183.58 (151.91, 221.86)
Cmax(ng/mL) 11,268.8 (15.1) 5885.0 (34.9) 200.69 (165.93, 242.74)
CI = confidence interval; GLSM = geometric least squares mean
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page21 20 November 20151.2.3.2. Phase 1 b Proof of Concept
The first HIV -1 positive human subjects were dosed in the fasted state with 10 day s of GS-9883 
in study (GS-US-141-1219). Four cohorts of 5 subjects each were randomized 4:1 to receive 
GS-9883 or placebo to match at doses of 5 mg, 25mg, 50mg, and 100 mgonce daily for 
10days.
GS-9883 was generall y well tolerated at the doses evaluated. A total of 9 of 20subjects had an 
AE in this study . The most frequentl y reported AEs across all subjects were diarrhea (2 subjects), 
and headache (3subjects). No other A E was reported in more than 1 subject. There was no 
increase in the incidence of AEs with increasing doses of GS-9883.
The majority  of AEs were considered by  the investigator to be not rel ated to study  drug. A total 
of 2 subjects experienced mild diarrhea that was considered related to study  drug 
(
1inthe5mgcohort, 1 in the 100 mgcohort).
No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to 
discontinuation of study  drug were reported in any  cohort.
The majority  of labora tory abnormalities were Grade 1 or Grade 2 in severity . No Grade 3 
treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at 
Day 10 were: 0.05 mg/dL (5mg), 0.04mg/dL (25mg), 0.06mg/dL (50mg), and 0.15 mg/dL 
(100mg). These changes in serum creatinine appeared to be transient and returned close to 
baseline values on discontinuation of study  drug. One Grade 4 new onset laboratory  abnormality  
was seen in 1 subject who received 5 mgGS-9883. This was a Grade 4 CPK seen o n Day17, 
7days following his last dose of study  medication. The subject was as ymptomatic. The 
Investigator felt that this was unrelated to study  medication and was due to resumption of cry stal 
methamphetamine use b y the subject. An adverse event of eleva ted CK was reported unrelated to
study medication.
Based on PK information collected in study GS-US-141-1219, which was in line with PK 
observed in stud y GS-US-141-1218, the median IQ for each dose were calcu lated and are 
presented in the t able below.
Table1-
4. Trough GS-9883 Plasma Concentrations at Steady State Following 
GS-9883 Administration Under Fasting Conditions and 
Corresponding Protein -Adjusted IQ 95Values
(GS-9883PKAnalysis Set)
GS-9883Dose N Median (range) C tau, SS(ng/mL) Median (range) paIQ 95a
5mg 4 206.5 (146.0 to 342.0) 1.3 (0.9 to 2.1)
25mg 4 797.5 (714.0 to 1900.0) 4.9 (4.4 to 11.7)
50mg 4 2170.0 (852.0 to 3020.0) 13.4 (5.3 to 18.6)
100mg 4 4190.0 (3730.0 to 5970.0) 25.9(23.0 to 36.9)
aThe protein adjusted IQ 95(paIQ95) value is estimated based on steady -state C tauvalues and the in vitro paIC 95value for 
wild-type HIV-1 (162ng/ml).
GS-9883/F/T AF 
Protocol GS-US-380-1961 
Gilead Sciences, Inc. Final 
Original 
The mean and 95% Cis of change from baseline in HIV -1 RNA (log10 copieslmL) are presented 
in Figure 1-1. 
Figure 1-1. 
<( z 
n:: -1 
~ J: 
c -2 
-~ 
8i 
~ -3 
E ,g 
~ -4 
~ (.) 
GS-9883 5 mg <~ ): 
GS-9883 25 mg (~): 
GS-9883 50 mg (~): 
GS-9883 100 mg (~): 
Placebo(~): GS-US-141-1219: Mean and 95% Cis of Change from Baseline in 
HIV-1 RNA (log10 copies/mL) (PP Analysis Set) 
e = GS-9883 5 mg 
0 = GS-9883 25 mg 
b. = GS-9883 50 mg 
0 = GS-9883 100 mg 
0 =Placebo 
BL 2 3 4 
3 3 3 3 
4 3 4 3 
4 4 4 4 
4 4 4 3 
4 4 4 4 7 8 9 
Day 
3 3 3 
4 4 4 
4 4 4 
4 4 4 
4 4 4 --------
10 11 14 17 
3 3 3 3 
4 4 4 3 
4 4 4 4 
4 4 4 4 
4 4 4 4 
NOTE: Baseline value was the last available value collected prior to the time of the first dose of study drug. 2 
0 
-1 
-2 
-3 
-4 
-5 
Mean viral load change on Day 11 was -2.08log 10 in the 25 mg cohort, -2.06log10 in the 50 mg 
cohott, and -2.43 log10 in the 100 mg cohort. Time weighted average change from baseline at 
Day 11 (DAVGll) was -0.92log 10 in the 5 mg coho t1~ -1.33log 10 in the 25 mg cohort, 
-1.37log10 in the 50 mg cohort and -1.61log10 in the 100 mg cohmt. Viral suppress ion 
(HIV-1 RNA< 50 copieslmL) was ever achieved by the end of the study (Day 17) by 1 subject 
(25.0%) in the GS-9883 50 mg group and 2 subjects (50%) in the GS-9883 100 mg group. 
1.2.3.3. Summaty of Phase 2 Study (GS-US-141-1475) 
Study GS-US-141-1475 is an ongoing Phase 2, randomized, double-blind , multicenter, 
active-controlled study to assess the safety and efficacy of a regimen containing 
GS-9883+F IT AF versus dolutegravir (DTG)+F IT AF in HIV -infected, antiretroviral therapy 
(ART)-naive adult subjects. 
CONFIDENTIAL Page22 20 November 2015 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page23 20 November 2015Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, 
stratified by  HIV-1 RNA level ( ≤ 100,000 copies/mL , >100,000 copies/mL to 
≤ 400,000 copies/mL , or >400,000 copies/mL) at screening:
Treatment Group 1: GS-9883 75 mg+ F/TAF (200/25 mg) + placebo -to-match DTG 
50mgonce dail
y
Treatment Group 2: DTG 50mg+ F/TAF (200/25 mg) + placebo -to-match GS-9883 
75mgonce daily
Week 24 interim data are summarized below. 
1.2.3.4. Subject Disposition and Baseline Characteristics
A total of 98 subjects were randomized and treated in the study : 65 subjects in the 
GS-9883+F/TAF group and 33 subjec ts in the DTG+F/TAF group. At the time of the Week 24
data analysis, 2 subjects (2.0%) had prematurel y discontinued study  treatment, one in each 
treatment group; both subjects were lost to follow-
up.
Demographic and baseline characteristics were similar be tween the 2 treatment groups.
Key baseline disease characteristics (ie, viral load, CD4 cell count, and estimated glomerular 
filtration rate [eGFR] using the Cockcroft -Gault method [eGFR CG]) were similar between the 
2treatment groups.
Median (Q1, Q3) base line HIV-1 RNA was 4.45 (3.96, 4.79) log 10copies/mL , with 
82.7%of subjects having ≤ 100,000 copies/mL  at baseline; 5 subjects had > 400,000copies/mL 
at baseline ; 4 of these subjects were randomized to GS-9883+F/TAF and 1 subject was 
randomized to DTG+F/ TAF.
Median (Q1, Q3) baseline CD4 cell count was 444 (316, 595) cells/μL , with 
41.8%of subjects having ≥ 500 cells/ μL at baseline . Median (Q1, Q3) baseline eGFR CGwas 
125.3(105.7, 147.0) mL /min.
1.2.3.5. Efficacy Results
Virologic success at Week 12 and 24wasassessed using the US FDA snapshot algorithm, 
defined as plasma HIV -1 RNA < 50 copies/mL . At Weeks 12 and 24, virologic success was high 
andsimilar between the 2 treatment groups as follows: Week 12 GS-9883+F/TAF 93.8%; 
DTG+F/TAF 93.9% (stratum- adjusted 
difference in percentages: −1.3%; 95% CI : 
−12.9%to10.2%; p =0.79); Week 24 GS -9883/F/TA F 95.4%, DTG+F/TAF 93.9% 
(1.0%;95%CI: -10.7% to 12.7%; p = 0.84) .
Of the 5 subjects with baseline viral load > 400,000 copies/mL , 4 had HIV -1 RNA 
<50copies/mL at Week 24, and 1 was considered a virologic failure b y US FDA snapshot 
algorithm with HIV -1 RNA of 60 copies/mL.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page24 20 November 2015Following initiation of study  drug, the increases from baseline in CD4 cell count were similar 
between treatment groups. Mean (SD) ba seline CD4 c ell counts were as follows: 
GS-9883+F/TAF 471 (190.9) cells/μL ; DTG+F/TAF 507 (271.0) cells/μL ; p=0.35. The mean 
(SD) change in CD4 cell count from baseline to Week 12 was similar between the 2 treatment 
groups as follows: GS -9883+F/TAF +170 (150.0) c ells/μL; DTG+F/TAF +173 (220.5) cells/μL 
(difference in L SM: 0; 95% CI : −76 to 76; p = 1.00).There were similar increases in the mean 
(SD) CD4 cell count in both treatment groups Week 24: GS- 9883/F/TAF, +189 (177.8) cells/µL  
(difference in L SM: 39; 95% CI : -35 to 113; p = 0.30
Interim Virology Resistance Data
Through Week 24, no emergent drug resistance was detected.
1.2.3.6. Safety Results
Adverse Events
The overall incidence of treatment -emergent AEs was balanced between treatment groups as 
follows: GS -9883+F/TAF 58 .5%, 38 subject s; DTG+F/TAF 57.6%, 19 subjects. The most 
common TEAEs (occurring in > 1 subject) b
y treatment group were as follows:
GS-9883+F/TAF: diarrhea and headache (7.7 %, 5subjects each); and nausea, decreased 
appetite, arthralgia, and cough (4.6%, 3subjects each)
DTG+F/TAF: nausea (12.1%, 4 subjects); diarrhea (9.1%, 3 subjects)
Most treatment -emergent AEs were Grade 1 in severity . Grade 3 or 4 AEs were reported in onl y 
1 subject ( Grade 3 diabetic ketoacidosis) , in the GS -9883/F/TAF group ; this event was also 
reported as an SAE, and 1other SAE (appendicitis) , also in the GS -9883/F/TAF group, was 
reported. Neither SAE was considered related to study  drug by the investigator, resulted in stud y 
drug discontinuation, or required interruption of stud y drug, and both SAEs resolved.
The overall incidence of study  drug-related treatment -emergent AEs was balanced between 
treatment groups as follows: GS -9883+F/TAF 15.4%,10subjects; DTG+F/TAF 18.2%, 
6subjects. Most study  drug-related treatment
-emergent AEs were Grade 1 in severit y. Grade2 
study drug-related treatment -emergent AEs were repor ted in 1subjectin the GS -9883/F/TAF 
group (somnolence and headache) and 1 subject in the DTG+F/TAF group (vomiting) .There 
were no Grade 3 or 4 treatment -emergent AEs or SAEs thatwere considered related to study  
drug.
NoGrade 4 AEs, deaths, pregnancies, or AEs leading to premature study  drug discontinuation 
were reported in either treatment group .
Clinical Laboratory Evaluations
The percentage of subjects with at le ast 1 treatment -emergent laboratory  abnormality  (ie,atleast
1grade level increase from baseline in graded abnormality) was similar between treatment groups 
as follows: GS-9883+F/TAF 7 6.6%, 49subjects; DTG+F/TAF 7 8.1%, 25subjects. The majority  
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page25 20 November 2015of treatment-emergent laboratory  abnormalities were Grade 1 or2 in severity . The percentage of 
subjects with at least 1 Grade 3 or 4 treatment -emergent laboratory  abnormality  was similar 
between treatment groups as follows: GS -9883+F/TAF 1 7.2%, 11subjects; DTG+F/TAF 12.5%, 
4 subjects. Grade 3 or4 treatment -emergent laboratory  abnormalities occurring in at least 
2subjects in either treatment group were as follows: creatine kinase (GS-9883+F/TAF, 3.1% 
[2subjects]), and fasting low -density lipoprotein (LDL) (GS-9883+F/TAF, 3.1% [2 subjects]). 
The only Grade 4 laboratory  abnormalities were for creatine kinase, reported in 2 subjects (3.1%) 
in the GS-9883+F/TAF group. All increased creatine kinase values appeared to be transient, and 
none were associated with A Es. Of the 2 subjects with increased AST, 1 subject had Grade 3 AST 
and Grade 3 ALT at Week 24 in the setting of alcohol abuse; the other subject had Grade 3 AST 
at Week 8 that returned to normal by  Week 24.
There were no clinicall y significant changes fro m baseline or differences between treatment 
groups in the median values for hematology , chemistry , or metabolic parameters. There were 
similar increases from baseline in median (Q1, Q3) serum creatinine in both treatment groups at 
Week 24: GS -9883+F/TAF 0. 12(0.06,0.18)mg/dL; DTG+F/TAF 0.1 3(0.05, 0.21)mg/dL. 
There were decreases in median (Q1, Q3) eGFRCGat Week 2 4, which were smaller in the 
GS-9883+F/TAF compared with the DTG+F/TAF group: GS-9883+F/TAF 
−13.3
(−19.9, −4.0)mL/min; DTG+F/TAF −17.2 (−25.7, −6.9) mL/min.
Conclusions
Key Week 24 conclusions from Study  GS-US-141-1475 include the following:
Virologic success at Week 24 when assessed using the FDA -defined snapshot algorithm, 
defined as plasma HIV -
1 RNA < 50 copies/mL, was similar between the 2 treatment groups 
as follows: GS -9883+F/TAF 95.4%; DTG+F/TAF 93.9%; stratum- adjusted difference in 
percentages: 1.0%; 95% CI : -10.7% to 12.7%; p = 0.84. There was a similar increase in the 
mean (SD) CD4 cell count between the 2 treatment groups, GS -9883+F/T AF,
+189(177.8)cells/μL; DTG+F/TAF, +157 (163.2) cells/μL  (difference in LSM: 39; 95% CI : 
−35 to 113; p = 0.30).
No resistance to an y INSTIs, NRTIs, NNRTIs or PI s was detected through Week 24.
No AEs led to study  drug discontinuation in either treatment group.
Both GS-9883+F/TAF and DTG+F/TAF were generall y well tolerated through 24 weeks of 
treatment. The most commonly  reported treatment- emergent AEs were diarrhea and 
headache (7.7% each) in the GS-9883+F/TAF group and nausea (12.1%) and diarrhea (9.1%) 
in the DTG+F/TAF group. There were 2 SAEs, 1 of which was also a Grade 3 AE; neither of 
these events was considered related to study  drug by the investigator, or led to study  drug 
discontinuation. There were no other Grade 3 or 4 AEs, and no deaths, pregna ncies, or AEs 
leading to premature study drug discontinuation reported. The percentage of subjects with at 
least 1 treatment -emergent laboratory  abnormality was similar between treatment groups. 
The majority  of treatment -emergent laboratory  abnormalities w ere Grade 1 or 2 in severit y. 
There were similar increases from baseline in serum creatinine in both treatment groups at 
Week 24.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page26 20 November 20151.3. Information About Emtricitabine (Emtriva®, FTC)
Emtricitabine ( 5-fluoro-1-[(2R, 5S)-2-(hydroxymethyl)-[1, 3]-oxathiolan -5-yl] cytosine, FTC) is 
a NRTI that has demonstrated potent and selective inhibition of the HI V. In HIV-infected adults, 
FTC is administered as a 200 mgQD dose concurrently  with other ARVdrugs. The 
200mgFTC 
capsule formulation was approved b y the US Food and Drug Administration (FDA) for 
marketing on 2 July 2003 and is available under the name Emtriva®. In the European Union 
(EU), marketing authorization was granted for both the 200 mgEmtriva®capsule formulation 
and a 10mg/mL Emtriva®oral Solution formulation on 24 October2003, with indications for the 
treatment of HIV infection concurrently  with other antiretroviral drugs in both adult and 
pediatric patients.
Further information is available i n the current Prescribing Information for Emtriva®.
1.4. Information About Tenofovir Alafenamide (TAF, GS-7340)
Tenofovir alafenamide ( GS-7340, TAF) is a second generation oral prodrug of tenofovir (TFV), 
a nucleotide analog that inhibits HI V-1 reverse transcription. Tenofovir is metabolized 
intracellularl y to the active metabolite, tenofovir diphosphate (TFV -DP), a competitive inhibitor 
of HIV-1 reverse transcriptase (RT) that terminates the elongation of the viral DNA chain. The 
intracellular metabolis m of TAF and TFV are consistent with the 600 -fold enhancement in 
anti-HIV activity  in cell culture of TAF over TFV.
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
1.4.1. Clinical Trials of Single Agent Tenofovir Alafenamide (T AF, GS-7340) or 
Fixed Dose Combination Emtricitabine/Tenofovir Alafenamide (FTC/TAF)
Clinical trials entailing the use of tenofovir alafenamide include:
GS-US-120-1101, a Phase 1/2 study  of the pharmacokinetics and antiviral activity  of 
GS-7340 (50 mgand 150mg) in HIV-infected subjects (completed)
GS-US-120-0104, a Phase 1b study  of the pharmacokinetics and antiviral activity  of 
GS-7340 (8mg, 25mg, 40mg) in HIV infected subjects (completed)
GS-US-
120-0107, a Phase 1, partiall
y-blinded, randomized, plac ebo-and positive controlled 
study to evaluate the effect of GS-7340 on the QT/QTc interval in healthy  subjects 
(completed)
GS-US-120-0108, a Phase 1, open
-label, parallel -design stud y to evaluate the 
pharmacokinetics of GS-7340 in subjects with severe ren al impairment (completed)
GS-US-120-0109, a Phase 1 study  to evaluate the pharmacokinetics, metabolism and 
excretion of GS-7340 (completed)
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page27 20 November 2015GS-US-120-0114, a Phase 1, open- label, parallel -group, single dose study  to evaluate the 
pharmacokinetics of tenofov ir alafenamide in subjects with normal and impaired hepatic 
function (completed)
GS-US-120-0117, a Phase 1 single -dose study  evaluating the pharmacokinetic drug 
interaction potential between rilpivirine and tenofovir alafenamide (completed)
GS-US-120-0118, a Pharmacokinetic study  evaluating the drug interaction potential of 
tenofovir alafenamide with a boosted protease inhibitor or unboosted integrase inhibitor in 
healthy subjects (completed)
GS-US-
311-1386, a Phase 1 study  to determine the effect of food on the pharmacokinetics of 
tenofovir alafenamide when administered as F/TAF FDC in health y volunteers (completed)
GS-US-311-0101, a Phase 1 healthy  volunteer study  evaluating the drug interaction potential 
between once -daily FTC/GS-7340 fixed -dose combinati on and efavirenz (EFV) or 
COBI-boosted darunavir (DRV) (completed)
GS-US-311-1088, a Phase 1, r elative bioavailability  study of 
Emtricitabine/Tenofovir Alafenamide fixed dose combination tablet to evaluate the 
formulation performance of emtricitabine (FTC) and tenofovir alafenamide (TAF) fixed dose 
combination tablets relative to co -administration of individual agents (completed)
GS-US-311-1089, a Phase 3 study  of the safety  and efficacy  of FTC/TAF in HIV infected, 
virologicall y suppressed patients (ongoing )
In StudyGS-US-311-1386, the effect of food (high- calorie, high- fat meal) on the PK of the TAF 
component of the F/TAF FDC was evaluated. The GL SM ratio of the AUC lastof TAF when 
administered with a high -fat meal was 177% (90% CI: 166% to 188%), and the TAF C max
GLSM ratio was 84.5% (90% CI:74.9% to 95.4%). This ~75% increase in TAF plasma 
exposure and ~15% decrease in TAF plasma C maxwhen administered with food was 
accompanied b y a delay in T max(increase from 1.00 hour under fasted conditions to 2.00 hours 
under fed conditions). The exposures of TAF observed under fed or fasted conditions in this 
study are within the range of exposures observed in the E/C/F/TAF clinical development 
program and are commensurate with safe and effective plasma levels of TA F 
(seeinvestigator brochure for further details). Therefore, the changes in TAF exposures when 
F/TAF is administered with food should not result in differences in efficacy and thus are not 
clinically relevant. TAF can be administered without regard for fo od and these findings can be 
extrapolated to F/TAF (as FTC can be taken without regard to food). 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page28 20 November 20151.4.2. Clinical Trials of FTC/TAF as Part of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
Clinical trials using tenofovir alafenamide, cof ormulated into the E/C/F/TAF STR include: 
GS-US-292-0101, a Phase 1 healthy  volunteer study  evaluating the relative bioavailability  of 
EVG, FTC, TFV, and COBI administered as E/C/F/TAF STR relative to E/C/F/TDF or TAF 
(completed)
GS-US-292-0103, a Phase 1 healthy volunteer study to evaluate the pharmacokinetics and 
relative bioavailabilit y of the E/C/F/TAF STR relative to the individual components at 
GS-7340 doses of 10 mg(STR) or 25 mgSingle Agent (SA) (completed)
GS-US-292-0102, a Phase 2 randomized, double -blinded study  of the safet y and efficacy of 
E/C/F/TAF STR versus E/C/F/TDF STR in HIV- 1 infected, antiretroviral treatment -naive 
adults (ongoing)
GS-US-
292-0104 and GS -US-292-0111, Phase 3 randomized, double -blinded study  of the 
safety and efficacy of E/C/F/TAF STR versus E/C/F/TDF STR in HIV -1 infected, 
antiretroviral treatment- naive adults (ongoing)
GS-US-292-0109, a Phase 3 open- label study  to evaluate switching from a TDF- containing 
combination regimen to a TAF -containing combination single table t regimen (STR) in 
virologicall y
-suppressed, HIV -1 positive subjects (ongoing)
GS-US-292-0112, a Phase 3 Open -label Safet y Study of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide single -tablet Regimen in HIV -1 
positive patients with mild to mo derate renal impairment (ongoing)
GS-US-
292-0117, a Phase 3, two-part study to evaluate the efficacy of Tenofovir 
Alafenamide versus placebo added to a failing regimen followed by  treatment with 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide i n HIV-1 positive, 
antiretroviral treatment-experienced adults (ongoing)
GS-US-
292-0119, a Phase 3 open- label study  to evaluate switching from optimized stable 
antiretroviral regimens containing darunavir to 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet 
regimen (STR) plus darunavir (DRV) in treatment experienced HIV- 1 positive adults 
(ongoing)
GS-US-
292-0106, a Phase 2/3, open-label stud y of the pharmacokinetics, safety, and 
antiviral activity  of the Elvitegravir/Cobic istat/Emtricitabine/Tenofovir Alafenamide 
(E/C/F/TAF) single tablet regimen (STR) in HIV- 1 infected antiretroviral treatment -naive 
adolescents (ongoing)
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page29 20 November 2015Study GS-US-292-0101 is a Phase 1 study  of 40 subjects evaluating the relative bioavailability  
of two different formulations of E/C/F/TAF STR, each with TAF dose of 25 mgor 40mg, versus 
E/C/F/TDF STR or TAF 25 mgalone. Exposures of EVG, COBI, and FTC were comparable 
between E/C/F/TAF vs E/C/F/TDF regardless of formulation (monolay er or bi-layer). In 
contrast, TAF exposures were ~2.2 -fold higher (and corr esponding tenofovir exposures 
~
3-foldhigher) when administered as E/C/F/TAF (25 mg) vs TAF single agent (SA) 25 mgfor 
both formulations of the E/C/F/TAF, likely  mediated by  inhibition of P -gp-mediated in testinal 
secretion of TAF b y COBI.
Study GS-US-292-0103 is a completed Phase 1 healthy  volunteer study  which evaluated the PK 
and relative bioavailability  of the E/C/F/TAF STR relative to the individual components at TAF 
doses of 10 (STR) or 25 mgSA. Resu lts indicate that when dosed as the E/C/F/TAF 10 mgSTR, 
TAF and TFV exposures were comparable to those observed with TAF 25 mgdosed alone. 
Exposures of EVG, COBI, and FTC were also comparable between the STR and individually  
dosed formulations. 
Study GS-US-292-0102 is an ongoing, randomized, active -controlled Phase 2 study, compares 
E/C/F/TAF (10 mg) versus Stribild®(STB, E/C/F/TDF) in treatment- naïve, HIV -1 infected 
subjects. At Week 48, the E/C/F/TAF demonstrated poten t antiviral efficacy  
(HIV-
1RNA<50copies/mL ) similar to STB (88.4% [99/112] vs 87.9% [51/58] using the 
snapshot algorithm); in the E/C/F/TAF group, no patient had e mergent resistance to 
1 ormorecomponents of the E/C/F/TAF. Importantly , E/C/F/TAF demonstrated a potential 
benefit over E/C/F/TDF in terms of renal and bone safet y: smaller median decreases in e GFR 
(mL/min) (atWeek48, E/C/F/TAF −5.5 vs E/C/F/TDF − 10.0 [P<0.001) and smaller median 
percentage decreases in BMD (at Week 48, spine E/C/F/TAF − 1.00 vs E/C/F/TDF −3.37 
[p<0.001], hip −0.62 vs −2.39[p<0.001]).
Studies GS-US-292-0104and GS-US-292- 0111 are ongoing , Phase 3 randomized, 
double-blinded studies of the safet
yandefficacyof E/C/F/TAF versus E/C/F/TDF in HI V-1 
infected, antir etroviral treatment -naive adults. Th e interim Week 48 key conclusions from pooled 
data showed that E/C/F/TAF once dai ly was noninferior to STB once daily when administered 
for48 weeks to HIV- infected, ART -naive adults, as asse ssed using the US Food and Drug 
Administration (FDA )-defined snapshot algorithm with H I
V-1 RNA < 50copies/mL  
(E/C/F/TAF 92.4%; STB 90.4%; diff erence in percentages: 2.0%, 95%CI: − 0.7% to 4.7%). 
Administration of E/C/F/TAF resulted in > 90% lower plasma TFV and higher intracellular 
TFV-DP relative to STB. E/C/F/TA F showed an improved renal and bone safe typrofile with 
significant ly less decline in hip and spine BMD, less increase in serum creatinine and reduction 
in estimated glomerular filtration rate (eGFR).
1.5. Information About GS -9883/Emtricitabine/Tenofovir Alafenamide 
(GS-9883/F/TAF )
Please refer to the GS -9883/F/TAF Investigator’s Brochure for further information.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page30 20 November 20151.5.1. GS-US-141-1233: Relative Bioavailability of GS-9883, FTC, and TAF 
Between GS -9883/F/TAF and GS-9883 + F/TAF
Study GS-US-141-
1233 is an ongoing Phase 1, open -label,2-cohort, multiple -period,
fixed-sequence, crossover study  conducted at a single center in the US to evaluate 1) the relative 
bioavailability  (BA) of 2 GS-9883/F/TAF (75/200/25 mgand 50/200/25 mg) FDC tablets 
compared wi th the GS -9883 (75 mg) tablet and the F/TAF (200/25 mg) FDC tablet administered 
simultaneously  and 2)the effect of food on the PK of 
GS-9883, FTC, and TAF when 
administered as GS-9883/F/TAF (75/200/25 mgand 50/200/25 mg) FDC tablets. 
Cohort 1 evaluated the relative BA and food effect of GS-9883/F/TAF (75/200/25 mg) FDC 
tablet in a 3 -period sequence. Following review of preliminary  data from Cohort 1, Cohort 2 was 
added to the study  via protocol amendment. Cohort 2 will evaluate the rel ative BA and food 
effect of 
GS-9883/F/TAF (50/200/25 mg) FDC tablet in a 4-period sequence. 
The in-life portion of Cohort 1 is complete; preliminary  results are summarized below. The 
in-life portion of Cohort 2 is ongoing.
Cohort 1 Results:
Pharmacokineti c Results
Under fasted conditions, GS-9883 AUC infand Cmaxwere 27% and 31% higher, respectivel y, 
following GS -9883/F/TAF (75/200/25 mg) FDC administration than following administration of 
single-agent GS-9883 (75 mg) with the F/TAF (200/25 mg) FDC. FTC an d TAF exposure was 
similar following administration of GS-9883/F/TAF (75/200/25 mg) or single -agent GS-9883 
(75mg) with the F/TAF (200/25 mg) FDC. Compared with administration under fasted 
conditions, administration of the GS-9883/F/TAF (75/200/25 mg) FDCwith a high- fat meal 
resulted in a 46% higher GS-9883 AUC infand a 27% higher GS -9883 C max. The impact of food 
on TAF and FTC exposure was similar to that previ ously observed for F/TAF 
(StudyGS-US-311-1386). GS-9883/F/TAF may  betaken without regard to f ood. Based on these 
results, Cohort 2 was added to the study  via protocol amendment to evaluate the relative BA of 
the GS-9883/F/TAF (50/200/25 mg) FDC tablet compared with the single -agent GS-
9883 
(75mg) tablet and the F/TAF (200/25 mg) FDC tablet admini stered simultaneously .
Safety Results
Of the 28 subjects included in the Safet y Analysis Set for Cohort 1, 12 subjects (43%) had at 
least 1treatment -emergent AE. All treatment emergent AEs were assessed as Grade1 or2 in 
severity. No deaths or other SAEs occurred during this study, and no subject discontinued the 
study due to an AE.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page31 20 November 2015Cohort 2 Results:
Pharmacokinetic Results
Preliminary  data of Cohort 2 showed that GS -9883 and C maxand AUC inffollowing 
GS-9883/F/TAF FDC (50/200/25 mg) administration under fasted conditions were 
78%and79%, respectively  as the exposures following administration of single- agent GS-9883 
(75 mg) with the F/TAF FDC (200/25 mg). FTC and TAF exposure was similar following 
administration of GS -9883/F/TAF (50/200/25 mg) or single -agent GS-9883 (75 mg) with the 
F/TAF FDC (200/25 mg). 
Food had a small effect on GS-9883 exposure following GS 9883/F/TAF (50/200/25 mg) single 
dose. A high fat meal increased GS -9883 C maxand AUC infby 13% and 24%, res pectively 
compared to exposure under fasted conditions. Similarly , a moderate fat meal increased GS-9883 
Cmaxand AUC infby 20% and 24%, respectivel y.The impact of food on TAF and FTC exposure 
was similar to that previously  observed for F/TAF (Study  GS-US-311-1386).
GS-9883 exposures following admi nistration of the GS -9883/F/TAF (75/200/25 mg and 
50/200/25 mg) FDC tablets are approximately  dose proportional under fasted and fed conditions. 
GS 9883/F/TAF may  be taken without regard to food .
1.6. EVG/COBI/FTC/TD F (E/C/F/TDF or Stribild®)
Further information is available in the US Prescribing Information and Investigator’s Brochure 
for E/C/F/TDF.
1.7.
Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF , Truvada®)
Further information is available in the Prescribing Information for Truvada®.
1.8. Ritonavir (RTV, /r, Norvir®)
Furtherinformation is available in the Prescribing Information for Norvir®.
1.9. Atazanavir (ATV , Reyataz®)
Furtherinformation is available in the Prescribing Information for Reyataz®.
1.10. Rationale for This Study
HIV standard of care has relied upon nucleos(t)ide backbones for effective and durable virologic 
suppression, but nucleos(t)ide -associated toxicities are increasingl y important as HIV -infected 
patients are often diagnosed earlier, initiate therapy  earlier, and look toward lifelong therapy  
(often greater than 50 years). Where patients have access to treatment, morbidity  and mortality  
are driven b y non–AIDS-associated comorbidities, which are observed earlier than in 
HIV-uninfected age -matched controls despite the best available ART. The contribution of 
specific nucleos(t)ides, including abacavir and tenofovir disoproxil fumarate, to long -term 
morbidity  and mortality  is increasingl y important in this co ntext.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page32 20 November 2015The GS-9883/F/TAF FDC has the potential to offer a simple, once -daily regimen containing a 
second generation INSTI that provides a high barrier to resistance, does not require a boosting 
agent, and offers an effective and safer alternative to standa rd nucleos(t)ide based regimens, 
without the need for HLA testing or close monitoring of renal or bone toxicities. I t could provide 
anFDC treatment that avoids the risk of hy persensitivity  reactions, would not contribute to an 
increased risk of cardiovascular events, could be used in patients with chronic hepatitis B or C 
infection or renal impairment, and that could be continued as patients age and confront 
non-HIV-related comorbidities. Approximately  50% of the global population of HIV -infected 
persons are women, however they  remain under -
represented in most clinical HIV studies. In 
general, studies to date have not shown gender differe nces in virologic responses to antiretroviral 
therapy (ART), but a number of studies have suggested that gender may  influence the frequency , 
presentation, and severity  of selected ARV -related adverse events. Although data are limited, the
pharmacokinetics for some ARV drugs may  differ between men and women, possibly  because of 
variations in factors such as body  weight, plasma volume, gastric empt ying time, plasma protein 
levels, CYP450 activity , drug transporter function, and excretion activity . It is impor tant to 
understand potential gender -specific safet y and efficacy issues in women when assessing 
virologic response, tolerability , and adherence. This study  will ensure that there is adequate 
safety data in H IV-1-infected women in the Phase 3 program for GS-9883/F/TAF.
The objective of this study  is to evaluate the safet y and efficacy of anFDC containing 
GS-9883/F/TAF versus continuing on a regimen consisting of E/C/F/TAF, E/C/F/TDF or 
ATV+RTV+FTC/TDF in women who are virologically  suppressed. Switching to 
GS-9883/F/TAF offersthe advantages of a single -tablet FDC containing the unboosted, 
next-generation INSTI, GS -9883, combined with a TAF -basednucleotide backbone.
GS-9883/F/TAF FDC which includes TAF, has the potential to offer an effective and safer 
alternative to standard nucleos(t)ide based regimens, without the need for close monitoring of 
renal or bone toxicities or increase risk of cardiovascular complications as patients age and 
confront non HIV -related comorbidities.
1.11. Risk/Benefit Assessment for the Study
All patients with HI V-1 infection should receive effective anti -retroviral therap y. Potential risks
associated with all classes of ARVs include immune reconstitution sy ndrome, lipody strophy, and
lactic acidosis with steatosis. The risk of class effects is considered to be low. I mportant
identified risks appropriately  managed by  study inclusion/exclusion criteria as well as through
close clinical and laboratory  monitoring during the study  are as follo ws: allergy  to any 
components of the tablets. Protease inhibitors may be associated with increased lipid levels and 
gastrointestinal side effects. I f patients are currently infected with hepatitis B and discontinue 
their existing or new therapy , there is a risk of severe acute exacerbations of hepatitis B.
Potential benefits may  include provision of a new antiretroviral therapy  that is not currently
available and which may  have fewer side effects than alternative therapies. Other potential
benefits include provisions of fixed dose combination therapy , and the knowledge that patient
participation will contribute to the body  of knowledge of HIV therapies.
The overall benefit- risk assessment for GS -9883/F/TAF is favorable at this time.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page33 20 November 20151.12. Rationale for Dose Select ion
FTC
The 200 mg dose of FTC represents the marketed dose for this agent that is currentl y available as
single agent capsules (EMTRI VA) and as a component of a number of fixed -dose combination
tablets, including: TRUVADA, ATRIPLA, COMPLERA (EVIPLERA), and STRI BILD.
TAF
Based upon results of the Phase 1 Study  GS-US-120-0104, in which various doses of TAF 
(8mg, 25mg, and 40mg) were administered to HIV -infected subjects in 10 day s of 
monotherap y, the range of exposure achieved with TAF 25 mgwas chosen as the reference 
exposure. I n this study , TAF 25 mgresulted in near -maximal antiviral activity  and plasma TFV 
exposure > 90% lower relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF s ystemic exposure 
that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg
when administered with the boosting agent COBI as E/C/F/TAF, for which an extensive safet y 
and efficacy  database exists. Specifically , TAF 25 mgis recommended with third agents that do 
not have a clinicall y relevant effect on TAF exposure. Study GS-US-141-1418 showed that 
GS-9883 does not have a clinically  relevant effect on TAF exposure. Therefore, the dose of TAF 
25mgis appropriate for the GS-9883/F/TAF FDC.
GS-9883
The dose of GS -9883 for Phase 2 was selected based upon data from Study GS-US-141-1219 
(Table1-5), in which HIV-1 -infectedsubjects were administered 5, 25, 50, or 100 mgdoses of 
GS-9883 monotherap y under fasting conditions for 10 day s.
Table1-5. GS-US-141-1219: Trough GS -9883 Plasma Concentrations at Steady 
State Following GS -9883 Administration Under Fasting Conditions 
and Corresponding Protein -Adjusted IQ 95Values
GS-9883 Dose n Median (range) C tau,SS(ng/mL) Median (range) paIQ 95a
5mg 4 206.5 (146.0 –342.0) 1.3 (0.9 –2.1)
25mg 4 797.5 (714.0 –1900.0) 4.9 (4.4 – 11.7)
50mg 4 2170.0 (852.0 –3020.0) 13.4(5.3 – 18.6)
100mg 4 4190.0 (3730.0 –5970.0) 25.9(23 – 36.9)
aThe paIQ 95value is estimated based on steady -state C tauvalues and the in vitro paIC 95value for wild -type HIV -1 
(162ng/mL).
Source: Data on File
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page34 20 November 2015Single-agent GS-9883 was well toleratedatall doses admi nistered.The range of GS -9883 
plasma exposure at steady state (C tau,SS) observed in the 50 -mg cohort correlated with protein 
adjusted 95% inhibitory  quotient (paIQ 95) values ranging from 5 .3to19, while the range of 
GS-9883 plasma exposure at stead y state (C tau,SS) observed in the 100 -mg cohort correlated with
paIQ95values ranging from 23 to 37 ( Table1-5).
Based on PK/PD analy ses, exposure following a 75 -mg dose of single- agent GS-9883 is 
expected to provide near -
maximal virologic response, with a predicted paIQ 95of approximately 
20, providing considerable c overage above the target concentration of 162 ng/mL (paI C95).
GS-9883 (75 mg) single agent c oadministered with F/TAF (200/25 mg) is currentl y being 
evaluated in a Phase 2 study , 
GS-US-141-1475 ( GS-9883+F/TAF vs DTG+F/TAF). The 
Week24interim data from this study, support the safet y and efficacy of GS-
9883 exposures 
obtained with the 75 mgdose of the single agent .
GS-9883/F/TAF FDC Dose Selection
A fixed dose formulation of GS-9883/F/TAF is being developed for use in Phase 3 studies. 
Preliminary  results from the relative bioavailability  (rBA) study  (GS-US-141-1233) of 
GS-9883/F/TAF (75/200/25 mg) showed that 
GS-9883 plasma exposure was higher (with C max
and AUC infincrease of 31% and 27%, respectively) following administration of the FD C as 
compared with exposure following administration of GS-9883 (75 mg) + F/TAF (200/25 mg) 
under fasted conditions. The increase in GS-9883 exposures associated with the FDC 
formulation results in an estimated mean paIQ 95of 24.3, compared to an estimated mean paIQ 95
of 19.2 for the GS -9883 (75 mg) single agent coadministered with F/TAF, in the fasted state.
In order to bridge exposures of GS-9883 in the FDC to the exposure observed with GS-9883 
75mgadministered as a single agent, and to bridge to the safe and effective exposures observed 
in the Phase 2 study  GS-US-141-1475, a lower strength GS-9883/F/TAF FDC is being 
developed for use in the Phase 3 studies. Comparability  of GS-9883 exposures will be confirmed 
in an rBA study of GS-9883/F/TAF (50/200/25 mg) and GS-9883 (75 mg) +F/TAF prior to 
initiation of dosing in the Phase 3 studies.  
E/C/F/TAF
EVG/COBI/FTC/TAF (200/25/25 mg) is a fixed dose combination, with only  one dose 
combination available; and has been approve d by the United States Food and Drug Administration 
(FDA)for the treatment of human immunodeficiency  virus type 1 (HIV-1) infection in adults and 
pediatric patients 12 y ears of age and older with no ARV treatment history  or to replace the current 
ARV regi men in those who are virologicall y suppressed on a stable ARV regimen with no history  
of treatment failure and no known substitutions associated with resistance. This FDC contains the 
equivalent doses of EVG ,COBIand FTCin the marketed product, Stribild®(STB).
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page35 20 November 2015E/C/F/TDF (STB)
EVG/COBI/FTC/TDF ( 150/150/200/300 mg ) is a fixed dose combination, with only  one dose 
combination available; and is approved for use (Stribild®)in the United States by  the 
FoodandDrug Administration (FDA), for the treatment of HIV-1 infection in treatment- naïve 
adults.
ATV+RTV+FTC/TDF
ATV (300 mg), RTV (100 mg) and FTC/TDF (200/300 mg) representthe current marketed 
dosesof these products .
1.13. Compliance
This study  will be conducted in compliance with this protocol, Good Clinical Practice (GCP), 
and all applicable regulatory  requirements.  
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page36 20 November 20152. OBJECTIVES
The primary  objective of this study  is:
To evaluate the efficacy  of switching to an FDC of GS -9883/F/TAF versus continuing on a 
regimen consisting of E/C/F/TAF, E/C/F/TDF or ATV+RTV+FTC/TDF in virologicall y 
suppressed HIV -1 infected women as determined by  the proportion of subjects with virologic 
failure (HIV -1 RNA ≥ 50 copies/mL ) at Week 48. 
The second ary objective of this study is :
To evaluate the safet yand tolerability  of the treatment groups through Week 48.  
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page37 20 November 20153. STUDY DESIGN
3.1. Endpoints
The primary  endpoint of this study  is:
The proportion of subjects with virologic failure (HIV -1 RNA ≥ 50 copies/mL  at Week 48 , 
as defined by themodified United States (US) Food and Drug Administration (FDA) 
snapshot algorithm) . 
The secondary  endpoints include:
The proportion of subjects withHIV-1 RNA < 50 copies/mL  at Week 48 as defined by  the 
US FDA snapshot algorithm.
The change from baseline in CD4+ cell count at Week 48. 
3.2. Study Design
This protocol describes a randomized, open label , multicenter, active -controlled study to evaluate 
the safety and efficacy of switching to a GS -9883/F/TAF FDCin HIV-
1 infected womenwho 
are virologically  suppressed (HIV -1 RNA < 50 copies/mL ) on a regimen consisting of 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF), 
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF), or 
ATV+RTV+FTC/TDF for ≥ 12consecutive week s prior to screening .
3.3. Study Treatments
Subjects who complete the following criteria will be given the option to participate in this study :
Completion of the Week 48 OLEvisitoranypost Week 48 OLE visits in study
GS-US-236-
0128, or
Completion of the Week 96 visitoranypost Week 96 visits in study GS-US-292-0109 
Subjects who provide written informed consent and meet all eligibility  criteria will be 
randomized in a 1:1 ratio toreceive open label medication :
Treatment Group 1 : FDC of GS -9883 50 mg/
emtricitabine 200mg/tenofoviralafenamide 
25mg(GS-9883/F/TAF) administered orall y,once daily ,without regard to food (n=200)
Treatment Group 2 : Stay on baseline regimen (SBR), including E/C/F/TAF , E/C/F/TDF or
ATV+RTV+FTC/TDF administered orally ,once daily, withfood (n=200)
GS-9883/F /T AF 
Protocol GS-US-380-1961 
Gilead Sciences, Inc. 
3.4. Duration of Treatment Final 
Original 
Subjects will be treated for at least 48 weeks. At the Week 48 Visit, subjects in a colliltly where 
GS-9883/F /TAF FDC is not available will be given the option to receive GS-9883/F /TAF FDC 
for an additional48 weeks and attend study visits evety 12 weeks, or lliltil the product becomes 
accessible to subjects through an access program, or lliltil Gilead Sciences elects to discontinue 
the study in that colliltty, whichever occurs first. 
Subjects who complete the study through the Week 48 Visit and do not continue post Week 48 
will be required to retum to the clinic 30 days after the Week 48 Visit for a 30 Day Follow-Up 
Visit. 
Figure 3-1. 
Screening 
~ 30 days pl'iot· 
to Day 1 Study Schema 
Dayl a 
Treatment Group 1: GS-9883/F/TAF FDC 
N=200 
Treatment Group 2: Stay on baseline 
regimen (E/C/F/TAF, EICIFITDF or 
ATV+RTV+FTCITDF) N=200 b Wet>k48 30 
Day 
Ftu' 
a Following the Day 1 visit, subje.cts will be required to return for study visits at Weeks 4, 8, 12 and then every 12 weeks 
tlu·ough Week 48 
b Aftet· Week 48, subjects in a cmmtry where GS-9883/F!TAF FDC is not available will be given the option to receive 
GS-9883/F!TAF for an additional48 weeks, or tmtil the product becomes accessible to subjects through an access program, 
or tmtil Gilead Sciences elects to discontinue the study in that cotmtry, whichever occurs fu·st 
c Subjects who complete the study tlu·ough Week 48 and do not wish to receive GS-9883/F!TAF FDC will be required to 
rettun to the clinic 30 days after the completion of study dmg for a 30-day follow-up visit 
3.5. Biomarker Testing 
3.5.1. Biomarker Samples for Optional Future Research 
CONFIDENTIAL Page 38 20 November 2015 
GS-9883/F/T AF 
Protocol GS-US-380-1961 
Gilead Sciences, Inc. 
p 
CONFIDENTIAL Page 39 Final 
Original 
20 November 2015 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page40 20 November 20154. SUBJECT POPULA TION
4.1. Number of Subjects and Subject Selection
Approximately  400subjects who meet the eligibility  criteria will be enrolled. 
4.2. Inclusion Criteria
Subjectsmust meet allof the following inclusion criteria to be eligible for participation in this 
study.
1)The ability  to understand and sign a written informed consent form, which must be obtained 
prior to initiation of study procedures
2)Female, (at birth), Age ≥ 18years
3)Currently  on a stable antiretroviral regimen of E/C/F/TAF, E/C/F/TDF, or 
ATV+RTV+FTC/TDF continuously  for ≥ 12 consecutive 
weeks preceding the screening 
visit
4)Completion of the Week 48 OLEvisitoranypost Week 48 OLE visits in 
studyGS-US-236-0128 or completion of the Week 96 visit 
or any post Week 96 visits in 
study GS-US-292-0109
5)Documented plasma HIV -1 RNA levels < 50 copies/mL  for ≥ 12 weeks preceding the 
Screening V isit. After reaching HIV -1 RNA < 50 copies/m L, single values of HIV -1 RNA 
≥50 copies/mL  followed by  resuppression to < 50 copies/mL are allowed
6)HIV-1RNA <50 copies/mL at screening
7)Normal ECG (or if abnormal, determined b y the Investigator to be not clinically significant) 
8)Adequate renal function:
Estimated glomerular filtration rate ≥
50mL/min according to the Cockcroft -Gault formula 
{2202}:
(140–age in years) (wt in kg)
72(serum creatinine in mg/dL)0.85 = CrCL (mL/min)
(140–age in years) (wt in kg)
72(serum creatinine in μmol/L )0.85
0. 6786CrCL(mL/sec)
9)Hepatic transaminases (AST and ALT) ≤ 5 ×upper limit of normal (ULN).
10)Total bilirubin 1.5mg/dL (26 μmol/L), or normal direct bilirubin.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page41 20 November 201511)Adequate hematologic function (absolute neutrophil count ≥750/mm3(≥0.75 GI/L); 
platelets ≥50,000/mm3(≥50 GI/L); hemoglobin ≥ 8.5 g/dL(≥85 g/L)).
12)Serum amy lase ≤ 5 ×ULN (subjects with serum amy lase > 5 ×ULN will remain eligible if 
serum lipase is ≤ 5
×ULN).
13)Womenof childbearing potential must agree to utilize protocol recommended highl y 
effective contraceptive methods or be non -heterosexually  active or practice sexual abstinence 
(as defined in Appendix 6) from screening, throughout the duration of the study  period, and 
for 30 day s following the last dose of study  drug.
a)Womenwho utilize hormonal contraceptive as one of their birth control methods must 
have used the same method for at least 3 months prior to study  drug dosing . 
b)Female subjects who have stopped menstruating for 
≥ 12 months but do not have 
documentation of ovarian hormonal failure must have a serum follicle stimulating 
hormone (FSH) level at screening within the post- menopausal range based on the 
CentralLaboratory  reference range.
14)Have no documented or suspected resistance to FTC, TFV, ATVor EVG including, but not 
limited to the reverse transcriptase resistance mutations K65R and M184V/I
4.3. Exclusion Criteria
Subjects who meet any of the following exclusion criteria are not to be enrolled in this study .
1) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to 
screening (refer to Appendix 5)
2) Subjects experiencing decompensated cirrhosis (eg, ascit es, encephalopathy , or 
varicealbleeding)
3)Have been treated with immunosuppressant therapies or chemotherapeutic agents within 
3months of study  screening, or expected to receive these age nts or systemic steroids 
duringthe study (eg, corticosteroids, immunogl obulins, and other immune -or 
cytokine-basedtherapies)  
4)Current alcohol or substance use judged b y the Investigator to potentiall y interfere with 
subject study  compliance   
5)A history of or ongoing malignancy  (including untreated carcinoma in -situ) other than 
cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non -invasive cutaneous 
squamous carcinoma. Subjects with biopsy -confirmed cutaneous KS are eligible, but must 
not have received an y systemic therap y for KS within 30 days of 
Day 1andare not 
anticipated to require s ystemic therap y during the study
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page42 20 November 20156)Active, serious infections (other than HIV -1 infection) requiring parenteral antibiotic or 
antifungal therap y within 30 days prior to Day  1 
7)Participation in any  clinical trial other than GS-US-236-0128 or GS -US-292-0109 , including 
observational studies, without prior approval from the sponsor is prohibited while 
participating in this trial
8)Any other clinical condition or prior therapy  that, in the opinion of the I nvestigator, would 
make the subject unsuitable for the stud y or unable to comply with the dosing requirements
9)Any known allergies to the excipients of GS-9883/F/TAF FDC , E/C/F/TAF , E/C/F/TDF, 
ATV, RTV, or FTC/TDF
10)Women who are pregnant (as confirmed b y positive serum pregnancy  test)
11)Women who are breastfeeding  
12)Subjects receiving ongoing therap y with any of the medications in Table5-1or Table5-2.
Administration of any  disallowed agent must be discontinued at least 30 day s prior to the 
Day 1 visit and for the duration of the study
13)Acute hepatitis in the 30 day s prior to study  entry
14)Active tuberculosis infection
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page43 20 November 20155. INVESTIGA TIONAL  MEDICINAL PRODUCTS
5.1. Randomization
Subjects will be assigned a screening number at th e time of consent. Randomization and Day1 
visit cannot occur until subject eligibility has been confirmed .  
Once eligibility  has been confirmed and prior to or during the Day 1 visit the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been as signed to a subject, it will not be reassigned to any other subject. 
The 
subject number assignment and randomization may be perform ed up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedures have been completed and subject 
eligibility  has been confirmed.
Subjects will be randomized in a 1 :1ratio to Treatment Group1 or Treatment Group 2. 
Treatment Group 1 : FDC of GS -
9883 50mg/emtricitabine 200mg/tenofovir alafenamide 
25mg(GS-9883/F/TAF) administered orall y,once daily ,without regard to food (n=200)
Treatment Group 2 : Stay on baseline regimen (SBR), including E/C/F/TAF, E/C/F/TDF or 
ATV+RTV+FTC/TDF administered orally ,once daily, with food 
(n=200)
The IWRS will assignstudy drug bottle numbers of 
open label FDC of GS-9883/F/TAF , 
openlabelE/C/F/TAF, open label E/C/F/TDF or open label ATV+RTV+FTC/TDF at each study  
visitfor each subject .  
Randomization will be stratified by  the prior treatment regimen group (ie, E/C/F/TAF, E/C/F/TDF 
and ATV+RTV+FTC/TDF) .
5.2. Description and Handling
5.2.1. Formulation
5.2.1.1. GS-9883/Emtricitabine/Tenofovir Alafenamide ( GS-9883/F/TAF) Tablets
GS-9883 50 mg/emtricitabine 200 mg/tenofovir a lafenamide 25 mgtablets are capsule -shaped, 
film-coated purplish -brown, debossed with "GSI" on one side of the tablet and "9883" on the 
other side of the tab let. Eachtablet core contains 5 0mgof GS-9883, 200 mgof emtricitabine, 
and 25mgof tenofovir alafenamide. In addition to the active ingredients, the GS-9883/F/TAF
tablets contain croscarmellose sodium, magnesium stearate, and microcry
stalline cellulose. The 
tablet cores are film -coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl 
alcohol, talc, and titanium dioxide .
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page44 20 November 20155.2.1.2. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF)
Tablets
E/C/F/TAF tablets are capsule-shaped, film -coated green tabletsand are debossed with “GSI” on 
one side of the tablet and “510” on the other side of the tablet. E/C/F/TAF tablets contain 150 mg
of elvitegravir , 150mgofcobicistat , 200mgofemtricitabine , and 10mgof tenofovir 
alafenamide .In addition to the active ingredi ents, the E/C/F/TAF tabletscontain colloidal silicon 
dioxide, croscarmellose sodium, hy droxypropyl cellulose, lactose monohy drate, magnesium 
stearate,microcrystalline cellulose, and sodium laury l sulfate. The tablet cores are film -coated 
with indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, titanium 
dioxide, and yellow iron oxide .
5.2.1.3. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate
(E/C/F/TDF , Stribild®) Tablets
E/C/F/TDF tablets are capsule -shaped, film -coated green tablets and are debossed with either 
“GSI” on one side and the number “1” surrounded by  a square box on the other side, or 
“GILEAD” on one side and plain -facedon the other side of the tablet. E/C/F/TD
F tablets contain 
150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtrici tabine, and 300 mg of 
tenofovir disoproxil fumarat e. In addition to the active ingredients, the E/C/F/TDF tablets 
contain colloidal silicon dioxide, croscarmellose sodium, hy droxypropyl cellulose, lactose 
monohydrate, magnesium stearate, microcry stalline cellulose, and sodium laury l sulfate. The 
tablet cores are film- coated with indigo carmine (FD&C Blue #2) aluminum lake, poly ethylene
glycol, polyvinyl alcohol, talc, titanium dioxide, and y ellow iron oxide .
5.2.1.4. Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF , Truvada®) Tablets
FTC/TDF tablets are capsule shaped film-coated blue and ar e debossed with “GILEAD” on 
oneside of the tablet and the number “701” on the other side. FTC/TDF tablets contain 
200mgofemtricitabine and 300 mg of tenofovir disoproxil fumarate. Further information is 
available in the Prescribing Information for Truvada®.
5.2.1.5. Ritonavir (RTV , Norvir®) Tablets
RTV tablets
, 100 mg, are ovaloid shaped film coated white andare debossed with “aNK” on 
oneside and plain faced on the other side. Further information is available in the Prescribing 
Information for Norvir®.
5.2.1.6. Atazanavir (ATV, Rey ataz®) Capsules
ATV capsules , 300 mg, have a red and blue bod y and have “BMS 300 mg” in white characters 
on the cap of the capsule and “3622” in white characters on the bod y of the capsule .Further 
information is available in the Prescribing Information for Rey ataz®. 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page45 20 November 20155.2.2. Packaging and Labeling
5.2.2.1. GS-9883 50 mg/Emtricitabine 200 mg/Tenofovir Alafenamide 25 mg
(GS-9883/F/TAF) Tablets
GS-9883/F/TAF tablets are packaged in white, high density  polyethylene (HDPE) bottles. Each 
bottle contains 30 tablets, silica gel desiccant a nd polyester packing materia l. Each bottle is 
enclosed with a white, continuous thread, child- resistant poly propylene screw cap with an 
induction- sealed and aluminum -faced liner.
5.2.2.2. Elvitegravir 150 mg/Cobicistat 150 mg/Emtricitabine 200 mg/
Tenofovir Alafenamide 10 mg(E/C/F/TAF) Table ts
E/C/F/TAF tablets are packaged in white, high density  polyethylene (HDPE) bottles. Each bottle 
contains 30 tablets, silica gel desiccant and polyester packing material. Each bottle is enclosed 
with a white, continuous thread, child -resistant poly propylene screw cap with an 
induction- sealed and aluminum -faced liner.
5.2.2.3. Elvitegravir 150 mg/Cobicistat 150 mg/Emtricitabine 200 mg/
Tenofovir Disoproxil Fumarate300 mg(E/C/F/TDF , Stribild®) Tablets
E/C/F/TDF tablets are packaged in white, high density  polyethylene (HDPE) bottles. Each bottle 
contains 30 tablets and a silica gel desiccant with or without poly ester coil fiber . Each bottle is 
enclosed with a white, continuous thread, child- resistant pol ypropylene screw cap with an 
induction- sealed and aluminum -faced liner.
5.2.2.4. Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg 
(FTC/TDF,Truvada®) Tablets
Refer to commerciall y available Prescribing Information.
5.2.2.5. Ritonavir (RTV, Norvir®)Tablets
Refer tocommerciall y available Prescribing Information.
5.2.2.6. Atazanavir (ATV, Rey ataz®) Capsules
Refer to commerciall y available Prescribing Information.
All study drug(s) to be distributed to centers in the US and other participating countries shall be 
labeled to mee t applicable requirements of the United States Food and Drug Administration 
(FDA), EU Guideline to Good Manufacturing Practice −Annex13 
(Investigational Medicinal Products), and/or other local regulations .
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page46 20 November 20155.2.3. Storageand Handling
Study drugs GS-9883/F/TAF FDC, E/C/F/TAF andE/C/F/TDFshould be stored at controlled 
room temperature of 25 °C (77°F); excursions are permitted between 15 °C and 30 °C 
(59°Fand86°F). Storage conditio ns are specified on the label. Until dispensed to the subjects, 
all bottles o
f study drugs should be stored in a securely  locked area, accessible only  to authorized 
site personnel.
Commercial product of Norvir®(RTV),Reyataz®(ATV),and Truvada®(FTC/TDF) will be used 
for the stud y. Further information regarding storage and handli ng are available in the 
Prescribing Information for commercial products.
To ensure the stability and proper identification, study drug(s) should not be stored in a container 
other than the container in which they  were supplied.
Consideration should be give n to handling, preparation, and disposal through measures that 
minimize drug contact with the body . Appropriate precautions should be followed to avoid direct 
eye contact or exposure through inhalation when handling.
5.3. Dosage and Administration of GS-9883/F/TAF,E/C/F/TAF , E/C/F/TDF and 
ATV+RTV+FTC/TDF
Study drugsGS-9883/F/TAF FDC,E/C/F/TAF , E/C/F/TDF, and ATV+RTV+FTC/TDF will be 
provided b y Gilead Sciences.
Treatment Group 1 : FDC ofGS-9883 50 mg/emtricitabine 200mg/tenofovir 
alafenamide 
25mg(GS-9883/F/TAF) administered orall y,once daily ,without regard to food (n=200)
Treatment Group 2 : Stay on baseline regimen (SBR), including E/C/F/TAF, E/C/F/TDF or 
ATV+RTV+FTC/TDF administered orally ,once daily, with food 
(n=200)
Subjects will be instructed to bring all stud y medication in the original container at each clinic 
visit for drug accountability . T
he Investigator will be responsible for maintaining accurate 
records for all stud y drug bottles dispensed and tablets returned. The inventory  and dispens ing 
logs must be available for inspection by  the study  monitor. Study  medication supplies, including 
partially used or empt y bottles, must be accounted for b y the stud y monitor prior to destruction 
or return. 
5.4. Prior and Concomitant Medications
The use of m edications for the treatment of HIV, other than study  drug, is prohibited.
Medications listed in the following table sand use of herbal/natural supplements are excluded or 
should be used with caution while subjects are participating in the study . Subjects will refrain 
from consumption of grapefruit juice and Seville orange juice throughout participation in the 
study. 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page47 20 November 2015Table5-1. Prior and Concomitant Medications (GS-9883/F/TAF Regimen)
Drug Class Agents Disallowed* Use Discouraged and To Be Used With Caution
Acid Reducing Agents
Antacids
Buffered medications Concentration of study drug may decrease w ith 
antacids. Subj ects may not take antacids 
(eg,Tumsor Rolaids); the ulcer medication 
sucralfate (Car afate); or vitamin or mineral 
supplements that contain calcium, iron or zinc for 
a minimum of 2 hours before and 6 hours after any 
dose of study drug.
Antiarrhythmic Agent Dofetilide
AnticonvulsantsPhenobarbital, Phenytoin, 
Carbamazepine, Oxcarbazepine
Antimycobacterials Rifampin, Rifapentine
AntiretroviralsAny antiretroviral drug that is 
not part of the study regimen
GI Motility Agents Cisapride
Herbal/Natural Supplements St. John’s Wort, Echinaccea
Oral Hypoglycemic AgentMetformin: close monitoring is recommended. 
Adose adjustment of Metformin may be 
necessary. Limit total daily doses of Metformin to 
1000mg either when starting or at study entry.
*Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the
duration of the study. 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page48 20 November 2015Table5-2. Prior and Concomitant Medications (E/C/F/TAF, E/C/F/TDF , and 
ATV+RTV+FTC/TDF Regimens)
Drug Class Agents Disallowed*
Alpha-1 Adrenoreceptor Antagonist Alfuzosin
Antiarrhythmic Agent Amiodarone, Dronedarone
Anticonvulsants Phenytoin, Carbamazepine and Phenytoin
Antimycobacterials Rifampin
Antipsychotics Lurasidone, Pimozide
Antiretrovirals Any antiretroviral drug that is not part of the study regimen
GI Motility Agents Cisapride
Herbal/Natural Supplements St. John’s Wort
Anticancer drugs Irinotecana
Ergot Derivatives Ergotamine, Ergonovine, Dihydroergotamine, Methylergonovine, Ergometrine
HMG-CoA Reductase Inhibitors Simvastatin, Lovastatin
Phosphodiesterase -5 Inhibitors Sildenafil (for PAH)
Sedatives/Hypnotics Midazolam (PO), Triazolam
Calcium Channel Blockers Bepridil
Chronic angina Ranolazine
aApplied to ATV regimen only
*Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the 
duration of the study
Should subjects have a need to initiate treatment with any  excluded concomitant medication, the 
Gilead Sciences Medical Monitor must b e consulted prior to initiation of the new medication. In 
instances where an excluded medication is initiated prior to discussion with the Sponsor, the 
Investigator must notify  Gilead Sciences as soon as he/she is aware of the use of the excluded 
medicatio n.
5.5. Accountability for Investigational Medicinal Product (IMP)
The investigator is responsible for ensuring adequate accountability  of all used and unused IMP. 
This includes acknowledgement of receipt of each shipment of I MP (quantity  and condition). All 
used and unused IMP dispensed to subjects must be returned to the site.
Study Drug accountability  records will be provided to each study  site to:
Record the date received and quantity  of IMP kits 
Record the date, subject number, subject initials, the IMP ki t number dispensed
Record the date, quantity of used and unused IMP returned, along with the initials of the 
person recording the information
5.5.1. Investigational Medicinal Product Return or Disposal
Study drug return and disposal will be performed as outlined in Section9.1.7.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page49 20 November 20156. STUDY PROCEDURES
The study  procedures to be conducted for each subject enrolled in the study  are presented in 
tabular form in Appendix 2and described in the text that follows. 
The investigator must document an y deviation from protocol procedures and notify  the sponsor 
or contract research organization (CRO).
6.1. Subject Enrollment and Treatment Assignment
It is the responsibility  of the Investigator to ensure that subjects are eligible for thestudy prior to 
enrollment. Please refer to Section 6.3for details about randomization and treatment assignment.
6.2. Pretreatment Assessments
6.2.1. Screening Visit
Subjects w ill be screened within 30 daysbefore Day 1to determine eligibility  for participation in 
the study. The screening visit may  coincide with the Week 48 OLEvisit or any post-Week 48
OLEvisits in study GS-US-236-0128 or the Week 96 visit oranypost-Week 96 visits in 
studyGS-US-292-0109. The following will be performed and documented at screening: 
Obtain written informed consent
Obtain medical history  including history  of HIV-1 disease-related events
and prior 
medications within 30 days of the screening visit
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
12-lead ECG performed supine
Height 
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), 
including weight
Urine collection for the following laboratory  procedures:
Urinalysis
Blood sample collection for the following laboratory  analyses:
Serum pregnancy  test (womenof childbearing potential only ). If the test is positive, the 
subject will not be enrolled
FSH test is required for womenwho have stopped menstruating for ≥ 12 months but do 
not have documentation of ovarian hormonal failure
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page50 20 November 2015Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calci um, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, am ylase (reflex lipase 
testing is performed in subjects with total amy lase >1.5 ×ULN), and TSH
Estimated glomerular filtration rate according to the Cockcroft -Gault formula:
(140–age in years) (wt in kg)
72(serum creatinine in mg/dL)0.85 = CrCL (mL/min)
(140–age in years) (wt in kg)
72(serum creatinine in μmol/L )0.85
0. 6786CrCL(mL/sec)
Hematology  profile: complete blood count (CBC) with differential and platelet count
CD4+ cell count
Plasma HIV -1 RNA 
Hepatitis B Virus (HBV) blood panel: Hepatitis B virus surface antigen (HBsAg), 
Hepatitis B virus surface antibody  (HBsAb) and Hepatitis B virus core antibody  (HBcAb)
The following will be c onducted by  the central laboratory  if the following criteria are met:
If positive HBsAg, reflex testing for plasma HBV DNA, HBeAg (if negative, 
reflexHBeAb), and quantitative HBsAg
If positive HBcAb with negative HBs Agand negative HBsAb, reflex testing f or 
plasma HBV DNA (if positive, reflex HBeAg). If HBeAg is performed and fou nd to 
be negative, reflex HBeAb
Hepatitis C virus (HCVAb) serology . Subjects who are HCVAb positive will have a 
HCV RNA test performed
Review of adverse events and concomitant med ications
Subjects meeting all of the inclusion criteria and none of the exclusion criteria will return to the 
clinic within 30 day s after screening for the Day 1 visit.Subjects must continue to take their 
current stud y treatment regimen up until their sch eduled Day  1 visit. 
From the time of obtaining informed consent through the first administration of investigational 
medicinal product, record all serious adverse events (SAEs), as well as any adverse events 
related to protocol -mandated procedures on the a dverse events case report form (eCRF). All 
other untoward medical occurrences observed during the screening period, including 
exacerbation or changes in medical history  are to be captured on the medical history  eCRF. 
SeeSection 7Adverse Events and Toxici ty Management for additional details .
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page51 20 November 20156.2.2. Day 1Assessments
The following evaluations are to be completed at the Day1Visit. The Investigator must have 
confirmed eligibility before proceeding with the Day1visit. The subject must complete all 
study procedures before being administered the study  drug:
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of the Investigator)
Vital signs measurement (blood pressure, pulse, respiration ra te, and temperature), 
including weight
12-leadECG performed supine
Urinecollection for the following laboratory  procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2microglobulin
Urine pregnancy  test (womenof childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, the subject will not be 
able to participate.
Urine storage sample for possible additional clinical testing
Blood samplecollection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
phosphorus, magnesium, potassium, sodium, uric acid, and am ylase (reflex lipase testing 
is performed in subjects with total amy lase >1.5 ×ULN), and TSH
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collect ion) glucose and lipid panel (total ch olesterol, HDL, direct LDL , 
andtriglycerides).If the subject has not fasted prior to the visit, the visit may proceed, 
but the subject must return within 72 hours in a fasted state to draw blood for the 
metabolic ass
essments.
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
GS-9883/F/T AF 
Protocol GS-US-380-1961 
Gilead Sciences, Inc. Final 
Original 
• 
• 
• 
• -Plasma HIV-1 RNA 
-CD4+ cell cmmt 
-Plasma storage samples for safety, virology, or PK testing 
-Whole blood sample for potential virologic resistance testing and/or HIV DNA 
genotyping 
-Subjects who meet the definition ofHBV infection at Screening Visit (positive semm 
HBsAg or positive HBcAb with quantifiable HBV DNA), will have plasma HBV DNA 
tested 
PD 
Provide subject dosing diaty to all subjects in Treatment Group 1 
Dispense study dmg 
Subjects in treatment group 1 should be instructed to take study dmgs without regard to food . 
Subjects in treatinent group 2 should be instmcted to take study dmg with food. Subjects are 
required to initiate dosing of study dmgs the day of the Day 1 visit. The subject should be 
counseled regarding the impoliance of adherence and taking their study medications at 
approximately the same time each day as directed by the Investigator. 
6.3. Randomizat ion 
Once eligibility has been confinned and prior to or dming the Day 1 visit, the Investigator or 
designee will randomize the subject using the Interactive Web Response System (IWRS). Once a 
subject number has been assigned to a subject, it will not be reassigned to any other subject. The 
subject number assignment and randomization may be perfmmed up to 3 days prior to the 
in-clinic Day 1 visit provided that all screening procedmes have been completed and subject 
eligibility has been confi1med. 
6.4. Treatment Assessments (Weeks 4-48) 
The following evaluations are to be completed at the end of Weeks 4, 8, 12, 24, 36, and 48 unless 
othetwise specified. 
Study visits are to be completed within± 2 days of the protocol-specified visit date based on the 
Day 1 visit through Week 12 and completed within± 6 days at Week 24 and Week 36, unless 
othetwise specified. The visit window at Week 48 will be± 6 weeks of the protocol-specified 
visit date, and these clinical visit windows coincide with the Week 48 statistical analysis window 
for HIV-1 RNA. 
CONFIDENTIAL Page 52 20 November 2015 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page53 20 November 2015Regularly  scheduled evaluations will be made on all subjects whether or not they  continue to 
receive study  drug.
Review of AEs and changes in concomitant medications
Complete physical examination (Weeks24 and 48)(urogenital/anorectal exams will be 
performed at the discretion of the Investigator) or sy mptom-directed phy sical examination as 
needed 
Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), 
including weight
12-leadECG performed supine ( Weeks24 and 48)
Urine collection for the following laboratory  procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2microglobulin (Weeks 24 and 48)
Urine pregnancy  test (females of chil dbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, subject s on 
GS-9883/F/TAF will be discontinued.
Urine storage sample for possible additional clinical testing
Blood sample collection fo r the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium,uric acid, and amy lase 
(reflexlipase testing is performed in subjects with total amy lase >1.5 ×ULN). At 
Weeks12,24 and 48, analy ses of glucose will be done as part of the fasting metabolic 
assessments and not as part of the chemistry  profile.At Weeks 24 and 48, TSH will also 
be analyzed.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Weeks 12, 24and 48)
Estimated glomerular filtration rate according to the Cockcroft -Gault formula 
Hematology  profile: complete blood count (CBC) with differential and platelet count
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page54 20 November 2015Plasma HIV -1 RNA
CD4+ cell count
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
For subjects who meet the definition of HBV infection, the following will be 
conducted b y the central laboratory: HBsAb, HBsAg (qualitative and quantitative) 
and HBeAg (if negative, reflex HBeAb) (Weeks12, 24 and 48)
HCV RNA for subjects with positive HCVAb at screening. (Weeks 24 and 48)
Plasma storage sample for safet y, virology , or PK testing
Pharmacokinetic Blood Collection for all subjects on GS-9883/F/TAF only 
(Treatment Group 1). Details of pharmacokinetic blood sampling procedures and sample 
management will be documented in the study’s laboratory manual.
Single Anytime, Trough and Post -Dose PK Sample s: (GS-9883/F/TAF –
Treatment Group 1 only)
Subjects will have a single an ytime pre or post -dose PK blood sample at 
Weeks8, 24and 36
Observed dosing at the clinic : If possible, s ubjects will have a trough PK blood 
sample collected between 20 -28 hours following the last dose a t Weeks 4 and 12.
Subjects must be instructed to not take their stud y drugs on the morning of their visit 
for the trough sample collection .  Subjects will then take an obs erved dos e of study  
drug at the clinic. If the subject has taken their dose of study  drugs prior to the visit, 
the visit may  proceed, but the subject must return within 72 hours for the single 
trough PK blood sample collection . In the event a subject routinely  takes their study  
drug in the evening, a single an ytime sample may  be drawn at Weeks 4 and 12 as the 
subject will not be instructed to change their dosing time to accommodate this trough 
PK draw. AsinglePKblood sample will be collected between 1 an d 4 hours post 
dose.  
Dosing diaries will be collected from subjects for the single an ytime PK and trough 
PK collection. If a dosing diary  is not returned the site may  ask the subject for the 
time of the last dose and if it was taken with or without food.
Provide subject dosing diary  to all subjects in Treatment Group 1 (Weeks4, 8, 12 and 24)
Document study drug dispensation and accountability  for all study  drugs dispense d
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page55 20 November 2015Subjects who meet the criteria for virologic rebound will be managed according to the 
Management of Virologic Rebound Section 6.13.1.
HIV-1 genotype/phenotype testing for subjects with virologic failure (Week 48)
6.5. Treatment Assessments ( Post Week 48
)
6.5.1. Post Week 48 Assessments
Atthe Week 48 Visit,subjects who completed 48 weeks of stud y drug treatment and are in a 
country where GS -9883/F/TAF FDC is not available will be given the option to receive 
GS-9883/F/TAF FDC for an additional 48 weeks and attend study  visits every  12 weeks or until 
the product becomes accessible to subject through an access program, or until Gilead Sciences 
elects to discontinue the study  in that country , whichever occurs first . 
Subjects who continue participation in the study  and receive GS -9883/F/TAF will return for 
study visits every  12 weeks. Study visits are t o be completed within ± 6 days of the 
protocol-specified visit date unless otherwise specified.
Subjects participating in the study post Week 48 will be required to return for study  visits 
according to the schedule presented in Appendix 2StudyProcedures Table and described in the 
text below:
Review of AEs and changes in concomitant medications
Symptom-directed phy sical examination as needed
Vital signs measurement (blood pressure, pulse, respiration ra te, and temperature), 
including weight
Urinecollection for the following laboratory  procedures:
Urinalysis
Urine albumin, urine creatinine, urine protein, retinol binding protein and 
beta-2microglobulin. (Every 24 weeks)
Urine pregnancy  test (females of childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test. If the test is positive, subject s on 
GS-9883/F/TAF will be discontinued
Urine storage sample for possible additional clinical testing 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page56 20 November 2015Blood samplecollection for the following laboratory  analyses:
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amy lase 
(reflexlipase testing is performed in subjects with total amy lase >1.5 ×ULN)TSHwill 
be analyzed every 24 weeks.
Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to 
blood collection) glucose and lipid panel (total cholest erol, HDL, direct LDL , and 
triglycerides). If the subject has not fasted prior to the visit, the visit may  proceed, but the 
subject must return within 72 hours in a fasted state to draw blood for the metabolic 
assessments. (Every 24 Weeks)
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
For subjects who meet the definition of HBV infection, the following will be 
conducted b y the central laboratory: HBsAb, HBsAg (qualitative and quantitative) 
and HBeAg (if negative, reflex HBeAb) (Every 24 Weeks)
HCV RNA for subjects with positive HCVAb at screening. 
(Every 24 Weeks)
Plasma storage samples for safet y, virology , or PK testing
Subjects who meet the criteria for virologic rebound will be managed according to the 
Management of Virologic Rebound Section 6.13.1
Document study drug dispensation an d accountability  for all study  drugs dispensed.
6.6. Post-Treatment Assessments
6.6.1. Early Study Drugs Discontinuation (ESDD)Assessments
If the subject discontinues study  drug prior to the Week 48 Visit, the subject will be asked to 
return to the clinic within 72hours of stopping study  drugfor the Earl y Study Drugs 
Discontinuation Visit. The subject will be asked to continue attending the scheduled study visits 
through the 
Week 48 Visit.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page57 20 November 2015At the Early Study Drugs Discontinuation Visit, any evaluations showing a bnormal results 
indicating that there is a possible or probable causal relationship with the study drug , will 
be repeated weekly (or as often as deemed prudent by the Investigator) until the 
abnormality is resolved, returns to baseline , or is otherwise explained.
The following evaluations are to be completed at the Earl y Study Drugs Discontinuation Visit:
Review of AEs and changes in concomitant medications
Complete phy sical examination (urogenital/anorectal exams will be performed at the 
discretion of t he Investigator)
12-lead ECG performed supine
Vital signs measurement (blood pressure, pulse, respiration ra te, and temperature), 
including weight
Urine collection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (womenof childbea ring potential only ); positive urine pregnancy  
tests will be confirmed with a serum test.
Urine storage sample for possible additional clinical testing
Blood sample collection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amy lase 
(reflexlipase testing is performed in subjects with total amy lase >1.5 ×ULN), and TSH
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
Plasma HIV -1 RNA
CD4+ cell count
Plasma storage samples for safet y, virology , or PK testing
Plasma HBV DNA (for subjects who meet the definition of HBV infection)
HIV-1 genotype/phenotype testing for subjects with virologic failure
Drug accountability
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page58 20 November 20156.6.2. 30 Day Follow Up
Subjects who complete the study  through the Week 48 visit and do not continue participation in
the study will be required to return to the clinic 30 days after the completion of study  drug for the 
30-Day Follow-Up Visit. 
Subjects who permanently discontinue stud y drug and refuse to continue in the study  through the 
Week 48 visit will be asked to return to the clinic 30 days after the completion of the 
EarlyStudyDrugs Discontinuation 
Visit for the 30- Day Follow-Up Visit.
Those subjects who permanently discontinue study drug and continue in the study through 
at least one subsequent visit after the Early Study Drug Discontinuation Visit will notbe 
required to complete the 30 -Day Follow -Up Visit.
Subjects who participate post Week 48 will complete a 30 -Day Follow-Up Visit 30 days after 
last doseof study drug.   
For the purpose of scheduling a 30 -Day Follow-Up Visit, a ± 6 days window may  be used. 
Thefollowing evaluations are to be completed at the 30 -Day Follow-Up Visit:
Review of AEs and changes in concomitant medications
Symptom-directed phy sical examination
Vital signs measurement (blood pressure, pulse, respiration ra te, and temperature), 
including weight 
Urine collection for the following laboratory  procedures:
Urinalysis
Urine pregnancy  test (womenof childbearing potential only ); positive urine pregnancy  
tests will be confirmed with a serum test.
Blood samplecollection for the following laboratory  analyses:
Chemistry  profile: alkaline phosphatase, AST, ALT, GGT, tot al bilirubin, direct and 
indirect bilirubin, total protein, albumin, bicarbonate, BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amy lase 
(reflexlipase testing is performed in subjects with total amy lase >1.5 ×ULN).
Estimated glomerular filtration rate according to the Cockcroft -Gault formula
Hematology  profile: complete blood count (CBC) with differential and platelet count
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page59 20 November 2015Plasma HIV -1 RNA
CD4+ cell count
At the 30-Day Follow-Up Visit, any  evaluatio ns showing abnormal results believed to be a 
reasonable possibility  of a causal relationship with the study  drugswill be repeated weekl y 
(orasoften as deemed prudent by  the Investigator) until the abnormality  is resolved, returns to 
baseline, or is othe rwise explained. 
6.7. Criteria for Discontinuation of Study Treatment
Study medication may  be discontinued in the following instances:
Intercurrent illness that would, in the judgment of the investigator, affect assessments of 
clinical status to a significant degree. Following resolution of intercurrent illness, the subject 
may resume study  dosing at the discretion of the investigator.
Unacceptable toxicity , or toxicity  that, in the judgment of the investigator, compromises the 
ability to continue study -specific procedures or is considered to not be in the subject’s best 
interest
Lack of efficacy  
Subject request to discontinue for an y reason
Subject noncompliance
Pregnancy  during the study ; refer to Appendix 6
Development of active tuberculosis infection
Discontinuation of the study at the request of Gilead, a regula tory agency or an 
institutional review board or independent ethics committee (I RB/IEC)
6.8. Other Evaluations
6.8.1. Markers of Renal Tubular Function
For all subjects, urine will be collected for selected evaluations of renal tubular function, which 
will include but arenot limited to urine albumin, urine creatinine, urine protein, retinol binding 
protein and beta -2-microglobulin at theDay1 Visit, Weeks 24, 48, and every  24weeks post 
Week 48. At the conclusion of this study , these samples may  b
e retained in storage by  
GileadSciences for a period up to 15 years.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page60 20 November 20156.9. Blood and Urine Storage
A portion of the blood and urine samples drawn at all visits (except the Screening Visit, 30- day 
follow-up VisitandUnscheduled Visits) will be frozen and stored. These stored blood and urine 
samples may  beused by the Sponsor or its research partners to help answer questions about t he 
study drug, about the disease and its associated condition sand/or to provide additional safety 
data. No human genetic testing will be performed without expressed consent of study  subjects. 
At the conclusion of this study ,these samples may be retained in storage by Gilea d Sciences for 
a period up to 15 years. 
6.10. Assessments for Premature Disc ontinuation f rom Study
If a subject discontinues study  dosing (for example, as a result of an AE), every  attempt should 
be made to keep the subject in the study  and continue to perform the required study -related 
follow-up and procedures (see 
Section 6.7, C riteria for Discontinuation of Study  Treatment ). If 
this is not possible or acceptable to the subject or investigator, the subject may  be withdrawn 
from the study .
6.11. End of Study
The end of stud y will be the last patient’s last observation (or visit). 
6.12. PostStudy Care
After a subject has completed/terminated their participation in the study , long-term care for the 
subject will remain the responsibility  of their primary  treating ph ysician. 
6.13.
Virologic Failure
Virologic failure is defined as virologic rebound o r having HIV -1 RNA ≥ 50 copies/mL  at study 
drug discontinuation or Week 48 .  
6.13.1. Management of Virologic Rebound
Subjects who meet the criteria listed below will be considered to have virologic rebound:
At any post Day  1 visit, a rebound in HIV -1 RNA ≥ 50 copies/mL , which is subsequently
confirmed at the following scheduled or unscheduled visit; 
OR
Any subject with HIV RNA ≥ 50 copies/mL  at studydrugdiscontinuation
Following the unconfirmed virologic rebound, subjects will be asked to return to the clini c for a 
scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that resulted 
in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is 
confirmed at the scheduled or unscheduled visit and the HIV -1 RNA is ≥ 200 copies/mL , the 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page61 20 November 2015blood sample from the confirmation visit will be the primary sample used for HIV -1 genotypic 
and phenot ypic testing. Subjects with documented non -adherence within 72 hours of the visit 
may not be tested for resistance. After a subject’s first post -Day 1 resistance test, additional 
testing will be conducted on a case -by-case basis. Any  subject may  be discontinued at 
Investigator’s discretion or per local treatment guidelines.
If no resistance is detected from the genot ypeor phenoty pe, the subject may  remain on study
drugs and a repeat HIV -1 RNA should be repeated (2 to 3 weeks after date of te st with 
HIV-1RNA ≥ 50 copies/mL ). Investigators should carefully  evaluate the benefits and risks of 
remaining on stud y drug for ea ch individual subject and document this assessment in the on- site 
medical record. 
Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per 
the Investigator’s discretion or local treatment guidelines. Investigators who o pt to discontinue 
study drugs for an individual subject must discuss with the Medical Monitor prior to study  drug 
discontinuation. 
For subjects who are off study  drug but remain on study , it will be the Investigator’s discretion to 
manage virologic reboun d.
Please refer to Figure6-1for the management of subjects who meet the criteria for virologic 
rebound.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page62 20 November 2015Figure6-1. Virologic Rebound Schema
a If virologic rebound is not confirmed, the subject will remain on their current regimen .
bIfvirologic rebound is confirmed and the HIV -1 RNA is ≥200 copies/mL ,the HIV-
1 genotype an d phenotype 
(reversetranscriptase , protease, and integrase) will be analyzed .
cBasedon the results of the genotype and phenotype assays, the subject will remain on study drugs or study drugs will be 
discontinued. If genotyping or phenotyping fails, a new ARV regimen maybe configured at the discretion of the 
Investigator .
d
If no resistance is detected, HIV-1 RNA will be repeate d (2-3 weeks later). Investigator reviews study drug 
continuation/discontinuation options and discuss with the Medical Monitor prior to study drug discontinuation.
e A new ARV regimen will be configured, at the Investigator’s discretion, and the subject wi ll remain in the study . 
6.13.2. Subjectswith HIV -1 RNA ≥ 50 copies/mL at Study Discontinuation or 
Week48
Subjects with HI V-1 RNA ≥ 50 copies/mL  at studydrugdiscontinuation or last visit will be 
considered virologic failures. Subjects with HIV- 1 RNA ≥ 50 copies/mL  at Week 48 will be 
asked to return for an unscheduled visit within the visit window for a retest. 
Subjects with HI V-1 RNA ≥ 200 copies/mL  at studydrug discontinuation, last visit or Week 48
will also have resistance testing condu cted.  

GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page63 20 November 20157. ADVERSE EVENTS AND TOXICITY  MANAGEMENT
7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events
7.1.1. Adverse Events
An adverse event (AE) is any  untoward medical occurrence in a clinical study  subject 
administered a medicinal product,which does not necessarily  have a causal relationship with th e
treatment. An AE can therefore be an y unfavorable and/or unintended sign, sy mptom, or disease 
temporally  associated with the use of a medicinal product, whether or not considered related to 
the medicinal product. AEs may also include pre -or post-treatment complications that occur as a 
result of protocol specified procedures, lack of efficacy , overdose, drug ab use/misuse reports
, or 
occupational exposure . Preexisting events that increase in severit y or change in nature during or 
as a consequence of participation in the clinical study  will also be considered AEs.
An AE does not include the following:
Medical or s urgical procedures such assurgery, endoscopy , tooth extraction, andtransfusion.
The condition that led to the procedure may be an adverse event and must be reported.
Pre-existing diseases, conditions, or laboratory  abnormalities present or detected before the 
screening visit that do not worsen
Situations where an untoward medical occurrence has not occurred (e.g., hospitalization for 
elective surgery , social and/or convenience admissions)
Overdose with out clinical sequelae ( see Section 7.6.1)  
Any medical condition or clinically  significant laboratory  abnormality  with an onset date 
before the consent form is signed and not related to a protocol -associated procedure is not an 
AE. It is considered to be pre -existing and should be documented on the medical history  
eCRF.
7.1.2. Serious Adverse Events
A serious adverse event (SAE) is defined as an event that, at an y dose, results in the following:
Death
Life-threatening (Note: The term “life -threatening” in the def inition of “serious” refers to an 
event in which the subject was at risk of death at the time of the event; it does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.)
In-patient hospitalization or prolongation of exi sting hospitalization
Persistent or significant disability /incapacit y
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page64 20 November 2015A congenital anomal y/birth defect
A medicall y important event or reaction: such events may not be immediately 
life-threatening or result in death or hospitalization but may  jeopardize th e subject or may  
require intervention to prevent one of the other outcomes constituting SAEs. Medical and 
scientific judgment must be exercised to determine whether such an event is a reportable 
under expedited reporting rules. Examples of medically  important events include intensive 
treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization; and development of drug dependency  or 
drug abuse. For the avoidance of doubt, infection s resulting from contaminated medicinal 
product will be considered a medicall y important event and subject to expedited reporting 
requirements.
7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
Adverse Events or Serious Adverse Events
Laboratory  abnormalities without clinical significance are not recorded as AEs or SAEs. 
However, laboratory  abnormalities (eg, clinical chemistry , hematology , and urinaly sis) that 
require medical or surgical intervention or lead to IMP interruption, modifi cation, or 
discontinuation must be recorded as an AE, as well as an SAE, if applicable. I n addition, 
laboratory  or other abnormal assessments (eg, electrocardiogram, x- rays, vital signs) that are 
associated with signs and/or sy mptoms must be recorded as an AE or SAE if they  meet the 
definition of an AE or SAE as described in Sections 7.1.1and7.1.2. If the laboratory  
abnormality is part of a sy ndrome, record the s yndrome or diagnosis (eg, anemia), not the 
laboratory  result (ie, decreased hemoglobin).
For specific information on handling of clinical laboratory  abnormalities in this study , please 
refer to Section 7.5.
7.2.
Assessment of Adverse Events and Serious Adverse Events
The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for 
causality and severity , and for final review and confirmation of accuracy  of event information 
and assessments.
7.2.1. Assessment of Causality for Study Drugs and Procedures
The investigator or qualified subinvestigator is responsible for assessing t he relationship to IMP
therapy using clinical judgment and the following considerations:
No:Evidence exists that the adverse event has an etiology  other than the IMP. For SAEs, an 
alternative causality must be provided (eg, pre -
existing condition, underl ying disease, 
intercurrent illness, or concomitant medication).
Yes:There is reasonable possibility  that the event may  have been caused by the 
investigational medicinal product.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page65 20 November 2015It should be emphasized that ineffective treatment should not be considered as cau sally related in 
the context of adverse event reporting.
The relationship to study  procedures (eg, invasive procedures such as venipuncture or biops y) 
should be assessed using the following considerations:
No:Evidence exists that the adverse event has an etiology other than the study  procedure.
Yes:Theadverse event occurred as a result of protocol procedures ,(eg,venipuncture)
7.2.2. Assessment of Severity
AE severity should be recorded and graded according to the GSI Grading Scale for Severity of 
Adverse Events and Laboratory  Abnormalities ( Appendix 4). For adverse events associated with 
laboratory  abnormalities, the event should be graded on the basis of the clinical severit y in the 
context of the underly ing conditions; this may  or may not be in agreement wit h the grading of 
the laboratory abnormality .
The distinction between the seriousness and the severity  of an adverse event should be noted. 
Severe is a measure of intensity ; thus, a severe reaction is not necessaril y a serious reaction. For 
example, a heada che may be severe in intensity , but would not be classified as serious unless it 
met one of the criteria for serious events.
For AEs associated with laboratory  abnormalities, the event should be graded on the basis of the 
clinical severit y in the context o f the underly ing conditions; this may  or may not be in agreement 
with the grading of the laboratory  abnormality .
7.3. Investigator Requirements and Instructions for Reporting Adverse Events 
and Serious Adverse Events to Gilead 
Requirements for collection prior to study drug initiation:
After informed consent, but prior to initiation of study  medication, the following t ypes of events 
should be report ed on the case report form ( eCRF): 
All SAEs and 
adverse events related to protocol -mandated procedures.
7.3.1. Adverse Events
Following initiation of study  medication, collect all AEs, regardless of cause or relationship, 
until 30 day s after last administration of study  IMP must be reported to the eCRF database as 
instructed.
All AEs should be followed up until resolution or until the adverse event is stable, if possible. 
Gilead Sciences may  request that certain AEs be followed bey ond the protocol defined follow up 
period.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page66 20 November 20157.3.2. Serious Adverse Events
All SAEs, regardless of cause or relationship, that occurs after the subject first consents to 
participate in the stud y (ie, signing the informed consent) and throughout the duration of the 
study, including the protocol -required post treatment follow -up period, must be reported to the 
eCRF database and Gilead Drug Safet y and Public Health (DSPH) as instructed. This also 
includes an y SAEs resulting from protocol-associated procedures performed after informed 
consent is signed.
Any SAEs and deaths that occur after the post treatment follow -up visit but within 30 days of the 
last dose of study  IMP, regardless of causalit y, should also be reported. 
Investigators are not obligated to activel y seek SAEs after the protocol defined follow up period; 
however, if the investigator learns of an y SAEs that occur after stud y participation has con cluded 
and the event is deemed relevant to the use of Study  IMP, he/she should promptly  document and 
report the event to Gilead DSPH .
Electronic Serious Adverse Event (eSAE) Reporting Process
Site personnel record all SAE data in the eCRF database and from there transmit the SAE 
information to Gilead DSPH within 24 hours of the investigator’s knowledge of the event. 
Detailed instructions can be found in the eCRF completion guidelines.
If for any reason it is not possible to record the SAE information electr onically, ie, the eCRF 
database is not functioning, record the SAE on the paper serious adverse event reporting 
form and submit within 24 hours to:
Gilead DSPH 
contactinformation:Fax:
E-mail:+1 (650) 522-5477
Safety_FC@gilead.com
As soon as it is possi ble to do so, any SAE reported via paper must be transcribed into the 
eCRF Database according to instructions in the eCRF completion guidelines.
If an SAE has been reported via a paper form because the eCRF database has been locked, no 
further action is ne cessary.
All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the 
eCRF completion guideline.
Additional information may  be requested to ensure the timely  completion of accurate safet y 
reports.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page67 20 November 2015Any medications necessary  for treatment of the SAE must be recorded onto the concomitant 
medication section of the subject’s eCRF and the event description section of the SAE form
For fatal or life -threatening events, copies of hospital case reports, autops y reports, and other 
documents are also to be submitted by  e-mail or fax only  when requested and applicable. 
Transmission of such documents should occur without personal subject identification, 
maintaining the traceability  of a document to the subject identifiers.
7.4. Gilead Reporting R equirements
Depending on relevant local legislation or regulations, including the applicable US FDA 
CodeofFederal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant 
updates, and other country- specific legislation or regulations, Gilead may  be required to expedite 
to worldwide regulatory  agencies reports of SAEs, serious adverse drug reactions (SADRs), or 
suspected unexpected serious adverse reactions (SUSARs). I n accordance with the EU 
Clinical Trials Directive (2001/20/EC), Gilead or a specified designee will notify  worldwide 
regulatory  agencies and the relevant IEC in concerned Member States of applicable SUSARs as
outlined in current regulations.
Assessment of expectedness for SAEs will be determined by  Gilead using reference safety  
information specified in the investigator’s brochure or relevant local label as applicable. 
All investigators will receive a safet y letter notify ing them of relevant SUSAR reports associated 
with any study IMP. The investigator should notify  the IRB or IEC of SUSAR reports as soon as 
is practical, where this is required b y local regulatory agencies, and in accordance with the local 
institutional policy . 
7.5. Toxicity Management
All clinical and clinically significant laboratory toxicities will be managed according to uniform 
guidelines detailed in Appendix 3as outlined below.
Clinical events and clinically significant laboratory  abnormalities will be graded according to 
the GSIGrading Scale for Severit y of Adverse Events and Laboratory Abnormalities 
(Appendix 4). 
Grade 3 and 4 clinicall y significant laboratory  abnormalities should be confirmed by  repeat 
testing within 3 calendar days of receipt of results and before investigational medicinal 
product discontinuation, unless such a delay  is not consistent with good medical practice
Any questions regarding toxicity  management should be directed to the 
GileadMedicalMonitor.
7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event
Continue study  drug at the discretion of the Investigator.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page68 20 November 20157.5.2. Grade 3 Laboratory Abnormality or Clinical Event
For Grade 3 clinically  significant laboratory  abnormality  or clinical event, investigational 
medicinal product may  be continued if the event is considered to be unrelated t 
investigational medicinal product.
For a Grade 3 clinical event, or clinicall y significant laboratory abnormality confirmed b y 
repeat testing, that is considered to be related to inv estigational medicinal product, 
investigational medicinal product should be withheld until the toxicity  returns to 
≤Grade2.When restarting investigational medicinal product following resolution of the 
adverse event, the investigational medicinal product should be restarted at full dose upon 
discussion with the Gilead Sciences Medical Monitor.
If a laboratory  abnormality  recurs to ≥ Grade 3 following rechallenge with investigational 
medicinal product and is considered related to investigational medicinal p roduct, then 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. Recurrence of laboratory  abnormalities considered 
unrelated to investigational medicinal product may not require permanen t discontinuation but 
requires discussion with the Gilead Sciences Medical Monitor.
7.5.3.
Grade 4 Laboratory Abnormality or Clinical Event
For a Grade 4 clinical event or clinicall y significant Grade 4 laboratory abnormality 
confirmed b y repeat testing that is c onsidered related to investigational medicinal product, 
investigational medicinal product should be permanently  discontinued and the subject 
managed according to local practice. The subject should be followed as clinically  indicated 
until the laboratory  abnormality  returns to baseline or is otherwise explained, whichever 
occurs first. A clinically  significant Grade 4 laboratory abnormalit y that is not confirmed b y 
repeat testing should be managed according to the algorithm for the new toxicity  grade.
Investigational medicinal product may  be continued without dose interruption for a clinically  
non-significant Grade 4 laboratory  abnormality  (eg, Grade 4 CK after strenuous exercise, or 
triglyceride elevation that is nonfasting or that can be medicall y managed) or a clinical event 
considered unrelated to investigational medicinal product requ ires discussion with the 
GileadSciences Medical Monitor .
7.5.4. On-Treatment ALT Flare and Post -Treatment Exacerbation of Hepatitis B 
Management
An On-Treatment ALT Flare is defined as:
Confirmed (within 3 day s of receipt of initial laboratory  results) serum ALT > 2 × Day1 value 
and >10 × ULN, with or without associated sy mptoms
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page69 20 November 20157.5.4.1. Management of ALT Flare in Subjects Receiving Study  Medication
If laboratory  results indicate elevation of ALT > 2 × Day 1 value and > 10 × ULN, the following 
is recommended:
Schedule the subject to return to the clinic as soon as possible (ideall y within 3 days after 
initial laboratory  results were drawn). During the visit, a clinical assessment of the subject 
will be performed. The assessment should include a physical examination and evaluation of 
the subject’s mental status.
If the ALT elevation is confirmed, request the central clinical laboratory  to conduct reflex
testing for plasma HBV DNA, HBV serology  (HBsAg and HBsAb), HDV, HAV IgM, and 
HCV serology
Check the following laboratory  parameters: serum AL T and AST, total bilirubin, I NR, and serum 
albumin. Based on the results of the confirmatory  tests, the following treatment modifications are 
recommended:
Elevated Liver Enzymes, Normal or Stable Relative to Day 1 Liver Function Tests
If ALT levels are elevated (i.e., 2 ×Day 1 and 10 
× ULN) with normal or stable total 
bilirubin and I NR relative to Day  1, the subject may  remain on study  medication and should be 
monitored weekl y as long as ALT levels return to normal or Day  1 level. During monitoring, if 
the ALT values remain persistently  elevated, the Investigator should discuss with the 
GileadMedical Monitor whe ther the stud y drug should be discontinued.
Elevated Liver Enzymes, Elevated Liver Function Tests
If ALT values are elevated (i.e., > 2 ×Day 1 and > 10 ×ULN), and total bilirubin is confirmed to 
be 2 x Day  1 value, and INR is 0.5 above 
Day 1, provided both are > ULN,the investigator 
should consider discontinuing stud y medication (upon dis cussion with the 
GileadMedicalMonitor, unless the safet y of the patient is of immediate concern). The subject 
should be monitored weekly  as long as ALT, total bilirubi n, and INR values remain elevated or 
above Day 1 values.
During monitoring, if the AL T values and the liver function tests remain persistently  elevated, 
the Investigator should discuss with the Gilead Medical Monitor whether the study  drug should 
be discontinued.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page70 20 November 20157.5.4.2. Management of Exacerbation of Hepatitis B in Subje cts Who Have Discontinued 
Study Medication
If laboratory  results indicate (1) an ALT elevation > 2 ×Day 1 and > 10 ×ULN alone OR 
associated with (2) abnormal laboratory  parameters suggestive of wo rsening hepatic function 
(total bilirubin 2 × Day  1, INR 0.5 above Day  1, provided both are > ULN) and the subject is on 
no post-study therapy for HBV, the following is recommended:
Schedule the subject to return to the clinic as soon as possible (ideall y no later than 3 days 
after the initial laboratory values were drawn). During the visit, perform a clinical assessment 
of the subject.
Check the following laboratory  parameters: serum AL T and AST, bilirubin, INR, and 
albumin.
If the ALT elevation is confirm ed, request the clinical laboratory  to conduct reflex testing for 
plasma HBV DNA, HBV serology  (HBsAg and HBsAb), HDV, HAV IgM and HCV. If 
serum HBV DNA is increasing, the investigator should consider immediate initiation of 
approved therap y.
The subject s hould be followed until laboratory  parameters (ALT, total bilirubin, I NR) return 
to normal or Day  1 up to a maximum of 6 months after the initial occurrence of the event.
7.5.5. Management of Hyperbilirubinemia
Most patients taking atazanavir sulfate experience asymptomatic elevations in indirect 
(unconjugated) bilirubin related to inhibition of UDP- glucuronyl transferase (UGT). Hepatic 
transaminase elevations that occur with h yperbilirubinemia should be evaluated for alternative 
etiologies. Dose modification of 
atazanavir sulfate is not permitted. Subjects who experience 
unacceptable jaundice/scleral icterus can be discontinued from study  at the discretion of the 
Investigator.
Subjects with bilirubin levels of 5 -10 ×ULN, if isolated and not accompanied by  
unacceptable clinical jaundice (scleral icterus or cutaneous jaundice) may  continue on study , 
if agreed upon b y the subject and the Investigator. All subjects with serum bilirubin le vels 
5-10 ×ULN must have bilirubin, AST and AL T repeated at least once within 7 days of the 
Investigator being notified of the elevated bilirubin level. Thereafter, serum bilirubin levels 
5-10 ×ULN without clinically  significant elevation in AST or AL T should be followed 
according to the clinical judgment of the Investigator.
Subjects whose hy perbilirubinemia (5 -10 ×ULN) is accompanied b y ≥ Grade 2 ALT or AST 
elevation or who experience a one Grade worsening in ALT or AST do not qualify  as having 
isolated hy perbilirubinemia and will be discontinued.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page71 20 November 2015Confirmed hy perbilirubinemia > 10 × ULN will require discontinuation.
Elevation of conjugated (direct) bilirubin > 2 mg/dL in association with Grade 2 ALT or 
AST elevation will require discontinuation.
7.5.6. On-Treatment Hepatitis C Management
If a subject tests positive for HCV RNA at screening or develops signs or sy mptoms of active 
Hepatitis C virus Gilead recommends that local medical practice is followed at the discretion of 
the Investigator. Investigational medicinal product may  be continued without dose interruption. 
Should the I nvestigator decide to initiate Hepatitis C treatment the Investigator must contact the 
Gilead Medical Monitor to confirm that no drug -drug interactions are expected. Subjects should 
return to the clinic for scheduled or unscheduled follow up visit(s) according to local medical 
practice for laboratory  evaluations. If Hepatitis C treatment is initiated, Investigators should use 
the Gilead provided retest laboratory  kits to manage the active Hepatitis C.
7.5.7. Management of Potential Nephrotoxicity
Estimated glomerular filtration rate according to the Cockcroft -Gault formula (eGFR C-G), will be 
followed post -baseline during the stud y. All subjects with estimated GFR < 50mL/min 
(0.83mL/sec) must have serum creatinine and subj ect’s weight measured again within 
3calendardays of receipt of results.
If a subject has confirmed eGFRC-G< 50 mL/min, the Medical Monitor should be notified and 
discontinuation of the study  drug should be discussed. For subjects with confirmed eGFR C-G
<50 mL/min who are not discontinued based on toxicity  management procedures above and are 
considered to have stable renal function per Principal I nvestigator and Medical Monitor, it is not 
mandatory  to repeat eGFR assessments within 3 day s.
7.6. Special Situat ions Reports
7.6.1. Definitions of Special Situations
Special situation reports include all reports of medication error, abuse, misuse, overdose , reports 
of adverse events associated with product complaints ,and pregnancy  reports regardless of an 
associated AE.  
Medication error is any unintentional error in the prescribing, dispensing, or administration of a 
medicinal product while in the control of the health care provider, subject, or consumer.
Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by  a 
subject.
Misuse is defined as an y intentional andinappropriate use of a medicinal product that is not in 
accordance with the protocol instructions or the local prescribing information.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page72 20 November 2015An overdose is defined as an acciden tal or intentional administration of a quantity  of a medicinal 
product given per administration or cumulatively  which is above the maximum recommended 
dose as per protocol or in the product labelling (as it applies to t he daily dose of the subject 
inquestion).In cases of a discrepancy  in drug accountability , overdose will be established onl y 
when it is clear that the subject has taken the excess dose(s). Overdose cannot be established 
when the subject cannot account for the discrepancy  except in cases in which the investigator has 
reason to suspect that the subject has taken the additional dose(s).
Product complaint is defined as complaints arising from potential deviations in the manufacture, 
packaging, or distribution of the medicinal product.  
7.6.2. Instructions for Reporting Special Situations
7.6.2.1. Instructions for Reporting Pregnancies
The investigator should report pregnancies in study subjects that are identified after initiation of 
study medication and throughout the study , including the post -study drug follow -up period, to 
the Gilead DSPH using the pregnancy  report form within 24 hours of becoming aware of the 
pregnancy . 
Refer to below and the eCRF completion guidelines for full instructions on the mechanism of 
pregnancy  reporting.
The pregnancy  itself is not considered an AE nor is an induced elective abortion to terminate a 
pregnancy  without medical reasons.
Any premature termination of pregnancy  (eg, a spontaneous abortion, an induced therapeutic 
abortion due to complications or other medical reasons) must be reported with in 24hours as an 
SAE. The underl ying medical reason for this procedure should be recorded as the AEor SAE
term, as applicable .
A spontaneous abortion is alway s considered to be an SAE and will be reported as described in 
Section7.3.2.Furthermore, an y SAE occurring as an adverse pregnancy  outcome post study  
must be reported to Gilead DSPH.
The subject should receive appropriate monitoring and care until the conclusion of the 
pregnancy . The outcome should be reported to Gilead DSPH using the pregnancy  outcome report 
form. If the end of the pregnancy  occurs after the study  has been completed, the outcome should 
be reported directl y to Gilead DSPH. Gilead DSPH con
tact information is as follows:
Email: Safety _FC@gilead. com and Fax: +1 (6 50) 522-5477.
Refer to Appendix 6for Pregnancy  Precautions, Definition for Female of Childbearing Potential, 
and Contraceptive Requirements.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page73 20 November 20157.6.2.2. Reporting Other Special Situations
All other special situation reports must be reported on the special situations report form and 
forwarded to Gilead DSPH within 24 hours of the investigator becoming aware of the situation. 
These reports must consist of situations that involve study  IMPand/or Gilead concomitant 
medications, but do not apply to non-Gilead concomitant medications. 
Special situations involving non-Gilead concomitant medications does not need to be reported on 
the special situ ations report form; however, for special situations that result in AEs due to a 
non-
Gilead concomitant medication , theAE should be reported on the AE form . 
Any inappropriate use of concomitant medications prohibited by  this protocol should not be 
reported as “misuse,” but may  be more appropriately  documented as a protocol deviation.
Refer to Section 7.6and the eCRF com pletion guidelines for full instructions on the mechanism 
of special situations reporting.
All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs 
at the same time using the AE eCRF and/or the SAE report form. D etails of the sy mptoms and 
signs, clinical management, and outcome will be reported, when available.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page74 20 November 20158. STATISTICAL  CONSIDER ATIONS
8.1. Analysis Objectives and Endpoints
8.1.1. Analysis Objectives
The primary  objective of this study  is to evaluate the efficacy of switching to a GS-9883/F/TAF
FDC versus staying on baseline regimen (SBR) in virologicall y suppressed HIV-1 infected 
womenas determined b y the proportion of subjects with virologic failure 
(HIV
-1RNA
≥ 50copies/mL ) at Week48.
The secondary  objective ofthis study  is to evaluate the safety ,and tolerability  of the 
twotreatment groups through Week 48.
8.1.2. Primary Endpoint
The primary  efficacy endpoint is the proportion of subjects with virologic failure
(HIV-1RNA≥50 copies/mL ) at Week 48 as defined by  themodified FDA snapshot algorithm.
8.1.3. Secondary Endpoint
Secondary  endpoints include:
The proportion of subjects withHI V
-1 RNA < 50copies/mL at Week 48 as defined b y the 
US FDA snapshot algorithm
The change from base line in CD4+ cell count at Week48
8.2. Analysis Conventions
8.2.1. Analysis Sets
8.2.1.1. All Randomized
The randomized anal ysis set includes all subjects who are randomized into the study . This is the 
primary analysis set for by -subject listings.
8.2.1.2. Efficacy
8.2.1.2.1. Full Anal ysis Set (FAS)
The primary  analysis set for efficacy  analyses is defined as fullanalysis set(FAS), which will 
include all subjects who (1) are randomized into the study  (2) have received at least 1 dose of 
study drug. Subjects will be grouped according to the treatment to which they  were randomized.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page75 20 November 20158.2.1.2.2. Per- Protocol (PP) Anal ysis Set
The secondary  analysis set for efficacy  analyses is defined as per-protocol (PP)analysis set, 
which will include all subjects who (1) are randomized into the stud y, (2) have received at least 
1dose of study  drug (3) have not comm itted any major protocol violation, including the violation 
of key entry criteria. Subjects will be grouped according to the treatment they actuall y received.
Subjects meeting an y of the following criteria will be excluded from the Week48 
PPanalysisset:
Subjects who do not have on- treatment HIV- 1 RNA in the Week 48 analysis window, except 
when missing is due to discontinuation of study  drug for lack of efficacy . 
Subjects who meet the exclusion criterion for receiving ongoing therap y with any of the 
medications listed in the table in protocol 
Section5including drugs not to be used with 
GS-9883, FTC, TAF , EVG, COBI, ATV and RTV .
Nonadherence to stud y drug: subjects with adherence rate for active study  drugup to the 
Week 48 Visit below the 2.5th percentile .
8.2.1.3. Safety
The primary  analysis set for safety anal yses is defined as safety analysis set, whichwill include 
all subjects who (1) are randomized into the study  and (2) have received at least 1dose of stud y 
drug. All the data collected up to 30 da ys after subjects permanently  discontinue their study  drug 
will be included in the safety summaries, unless specified otherwise. Subjects will be grouped 
according to the treatment they  actually received.
8.2.1.4. Pharmacokinetics
8.2.1.4.1. Pharmacokinetic (PK) Analy sis Set
The primary  analysis set for general PK analy ses is defined as the PKanalysis set, whichwill 
include all subjects who (1) are randomized into the study , (2) have received at least 1 dose of 
GS-9883/F/TAF ,and (3) have at least 1 nonmissing PK concentration data for GS -9883under 
evaluation reported b y the PK lab. 
8.3. Data Handling Conventions
HIV-1 RNA results of ‘No HIV -1 RNA detected’ and “< 20 cp/mL  HIV-1 RNA Detected” will 
be imputed as 19 copies/mL  for analysis purpose . Laboratory  data that are continuous in nature 
but are less than the lower limit of quantitation or above the upper limit of quantitation will be 
imputed to the value of the lower or upper limit plus or minus one significant digit, respectivel y 
(e.g., if the result of a conti nuous laboratory  test is <20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for 
missing data will not be imputed. However, a missing pre -treatment laboratory  result would be 
treated as normal (ie, no toxicity  grade) for the laboratory  abnormality  summary .
All available data for subjects that do not complete the study will be included in data listings.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page76 20 November 20158.4. Demographic Data and Baseline Characteristics
Demographic and baseline chara cteristics will be summarized using standard descriptive 
methods including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for 
continuous variables and frequency  and percentages for categorical variables.
Demographic data will include race, eth nicity, and age. 
Baseline characteristics will include body  weight, height, bod y mass index, eGFR , HIV-1 
infection, and enrollment distribution will be summarized.
For categorical demographic and baseline characteristics, the Cochran–
Mantel–Haenszel (CMH)
test will be used to compare treatment groups. For continuous demographic and baseline 
characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.
8.5. Efficacy Analysis
8.5.1. Primary Analysis
The primary  efficacy endpoint is the proportion of subjects with virologic failure 
(HIV-1RNA≥50 copies/mL ) at Week 4
8 as defined by  the modified FDA snapshot algorithm. 
The primary  analysis of the efficacy  will be based on the FAS.
8.5.1.1. M odified FDA Snapshot Algorithm
The modified FDA snapshot algorithm appears below.
The analysis window at Week 48 is defined as from Study  Day 294 to Study  Day 377, inclusive. 
All HIV-1 RNA data collected on -treatment (ie, including data collected up to 1 day  after the last 
dose date of stud y drug) will be used in the snap shot algorithm. Virologic outcome will be 
defined as the following categories: 
Virologic Success: this includes subjects who have the last available on-treatment 
HIV
-1RNA < 50 copies/mL  in the Week 48 anal ysis window 
Virologic Failure: this include subj ects 
a)Who have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL  in the Week 48 
analysis window, or 
b) Who do not have on- treatment HIV -1 RNA data in the Week 48 anal ysis window and 
1)Who discontinue study  drug prior to or in the Week 48 anal ysis windo
w due to lack 
of efficacy , or 
2)Who discontinue study  drug prior to or in the Week 48 anal ysis window due to 
reasonsother than lack of efficacy  and have the last available on -treatment 
HIV-
1RNA ≥ 50 copies/mL   
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page77 20 November 2015No Virologic Data in the Week 48 Analysis Wi ndow: this includes subjects who do not 
have on-treatment HIV -1 RNA data in the Week 48 anal ysis window because of the 
following: 
a)Discontinuation of study  drug prior to or in the Week 48 analy sis window due to reasons 
other than lack of efficacy and the l ast available on-treatment HIV -1 RNA is 
<50copies/mL or,
b)Missing data during the window but on study  drug 
8.5.1.2. Analysis of Primary  Efficacy Endpoint
The null hy pothesis is that the proportion of subjects with virologic failure 
(HIV-1RNA≥ 50copies/mL ) at Week 48 in the GS-9883/F/TAF group is at least 4% higher
than the virologic failure rate in the SBR group; the alternative h ypothesis is that the virol ogic 
failure rate in the GS-9883/F/TAF group is less than 4% higher than that in the SBR group.
Non-inferiority will be assessed using the conventional conf idence interval (CI) approach. The 
point estimate of treatment difference ( GS-9883/F/TAF –SBR) and the associated 2 -sided 
95%CI will be constructed based on the exact method.  
It will be conclu ded that GS-
9883/F/TAF is non -inferior to E/C/F/TAF if the 
upperbound of the 
2-sided 95% CI of the difference between treatment group s (GS- 9883/F/TAF –SBR) in the 
virologic failure rate is less than 4% (ie, a margin of 4% is applied to non- inferiority assessment).
If non-inferiority  of GS-9883/F/TAF to SBRis established, the upper bound of the 95% CI will 
be compared to 0; if the upper bound of the 95% CI  is lessthan 0, superiority  of GS-9883/F/TAF
over SBR will be established.
8.5.2.
Secondary Analyses
The proportion of subjects with HIV -1 RNA < 50 copies/mL at Week 48 as defined by  the
USFDA snapshot algorithm will also be evaluated. The 95% CIs will be constructed in the same 
manner as for the primary efficacy  endpoint. However, non -inferiority  will be assessed using a 
margin of 10%. It will be concluded that GS-9883/F/TAF is non -inferior to SBRif the lower 
bound of the 2 -sided 95% CI of the difference between tre atment groups ( GS-9883/F/TAF -SBR) 
in the response rate is greater than −10%.
The change s from baseline in CD4+ cell count at Week 48 will be summarized by  treatment 
using descriptive statistics. The differences in changes from baseline in CD4+ cell count between 
the 2 treatment groups and the associated 95% CIs will be constructed using ANOV A models, 
including treatment ( GS-9883/F/TAF vs. SBR ) as a fixed effect in the model.
In addition, missing CD4+ cell count will be imputed using Last Observation Carried Forward 
(LOCF) methodand analy zed similarly .
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page78 20 November 20158.6. Safety Analysis
All safety analyses willbe performed using the safety  analysis set.
All safety data collected on or after the date that the study drug was first administered up to the 
date of the last dose of study  drug plus 30 day s, unless specified otherwise, will be summarized 
for subjects in the safet y analysis set according to the study  drug received.
Data for the pretreatment period and the period post the date of last dose of study  drug plus 
30days will be included in data listings for all enrolled subjec ts.
8.6.1. Extent of Exposure
A subject’s extent of exposure to study drugwill be generated from the study drug
administration page in eCRF . Exposure data will be summarized by  treatment.
Duration of exposure to study  drug will be expressed as the nu mber of week s between the 
firstand last dose of the study  drug, inclusive, regardless of temporary  interruptions in study  
drugadministration and summarized by treatment.
Dosing information for individual subjects will be listed.
8.6.2. Adverse Events
Clinical and laborator y adverse events will be coded using the Medical Dictionary for 
Regulatory  Activities (MedDRA). Sy stem Organ Class (SOC), High -Level Group Term 
(HLGT), High -Level Term (HL T), Preferred Term (PT), and Lower -Level Term (LLT) will be 
attached to the clinical database.
Events will be summarized on the basis of the date of onset for the event. A treatment -emergent 
adverse event will be defined as an y adverse event with onset date on or after the stud y drug start 
date and no later than 30 day s after the study  drug stop date; or an y adverse event leading to 
study drug discontinuation.
Summaries (number and percentage of subjects) of treatment -emergent adverse events (b y SOC, 
HLT[if applicable] , and PT) will be provided by  treatment. Additional summaries will inclu de 
summaries for adverse events by  grade, Investigator’s assessment of relationship to study  drug, 
and effect on stud y drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of 
Stage 3 Opportunistic I llnesses in HIV are indicative of an AIDS -
Defining Diagnoses. The 
Gilead medical personnel will review the possible Stage 3 events and approve the e vents that 
meet the definition. Those events that do meet the Stage 3 Opportunistic I llnesses definition of 
an AIDS-Defining Diagnosis will be listed.  
A listing of Stage 3 Opportunistic I llnesses in HIV can be found in Appendix 5.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page79 20 November 20158.6.3. Laboratory Evaluations
Selected laboratory  data (using conventional units) will be summarized using onl y observed data. 
Absolute values and changes from baseline at all scheduled visits will be summarized.
Graded laboratory  abnormalities will be defined using the grading scheme defined in Grading of 
laboratory  abnormalities attached in Appendix 4.
Incidence of treatment -emergent laborator y abnormalities, defined as values that increase at least 
1toxicity grade from baseline at an y time post baseline up to and including the date of last dose 
of study drugplus 30days, will be summarized by treatment. If baseline data are missing, then 
anygraded abnormalit y (i.e., at least a Grade 1) will be considered treatment emergent. The 
maximum postbaseline toxicity  grade will be summarized by  laboratory  parameter.
Laboratory  abnormalities that occur before the first dose of study drugor after the last dose of 
study drug plus 30 day s will be included in a data listing.
8.6.4. Other Safety Evaluations
Vital signs and safety ECG data will be summarized as appropriate .
8.7. Pharmacokinetic Analysis
For the PK anal yses, the pharmacokinetics of GS-9883 may be evaluated using descriptive 
statistics or population approaches.
TAF and FTC concentrations may  be analyzed as applicable.   
8.8. Sample Size
A total of approximately  400HIV-1 infected subjects, randomized in a 1:1 ratio to 
2treatment groups (200subjectsper treatment group ), achieves at least 80%power to detect a 
non-inferiority margin of 4%in Week 48 virologic failure rate (HIV -1 RNA ≥50 copies/mL) 
difference between the 2 treatment groups. For the sample size and power computation, it is 
assumed tha t both treatment groups have a virologic failure rate of 2%(based on the historical 
Gilead E/C
/F/TAF and STB studies) , that thenon-inferiority  margin is 4%, and that the 
significance level of the test is at a one- sided 0.025 level.
8.9. Independent Data Monitoring Committee
An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy , 
and safety data of this study while the stud y is ongoing. The committee will convene after all 
subjects enrolled complete Week 24 of the stud yor prematurely  discontinue the study  drug. 
However, Gilead will defer to the IDMC for an y decision to convene earlier or more frequentl y. 
The IDMC will examine the safet y results of the trial and also focus on logistical issues such as 
accrual, retention, quality of clinical and laboratory  data, and implications of results of external 
studies.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page80 20 November 2015No formal stopping rules will be used by  the IDMC for safet y outcomes. Rather, a clinical 
assessment will be made to determine if the nature, frequency , and severit yof adverse events 
associated with a stud y regimen warrant the earl y termination of the study  in the best interest of 
the participants.
An analysis for the Week 24 IDMC meeting will be conducted after the last subjects enrolled 
completes Week 24 of the stu dy. For each IDMC anal ysis performed prior to analy sis for the 
primary efficacy endpoint, an alpha penalty  of 0.00001 will be applied for the primary  analysis 
of the primary  efficacy endpoint.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page81 20 November 20159. RESPONSIBILITIES
9.1. Investigator Responsibilities
9.1.1. Good Clinical Pr actice
The investigator will ensure that this study  is conducted in accordance with the principles of the 
Declaration of Helsinki (as amended in Edinburgh, Toky o, Venice, Hong Kong, and 
SouthAfrica), International Conference on Harmonisation (I CH) guideli nes, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study  subject. These standards are consistent w ith the European Union 
ClinicalTrials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.
The investigator will ensure adherence to the basic principles of Good Clinical Practice, as 
outlined in 21 CFR312, subpart D, “Responsibilities of Spons ors and Investigators,” 
21 CFR,part50, 1998, and 21 CFR, part 56, 1998.
The investigator and all applicable subinvestigators will comply  with 21CFR, Part 54, 1998, 
providing documentation of their financial interest or arrangements with Gilead, or proprietary  
interests in the investigational drug under stud y. This documentation must be provided prior to 
the investigator’s (and any  subinvestigator’s) participation in the study . The investigator and 
subinvestigator agree to notify  Gilead of an y change in reportable interests during the stud y and 
for 1 year following com pletion of the study . Study completion is defined as the date when the 
last subject completes the protocol- defined activities.
9.1.2.
Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
Review and Approval
The investigator (or sponsor as appropria te according to local regulations) will submit this 
protocol, informed consent form, and an y accompanying material to be provided to the subject 
(such as advertisements, subject information sheets, or descriptions of the study  used to obtain 
informed conse nt) to anIRB/IEC. The investigator will not begin an y study subject activities 
until approval from the IRB/IEC has been documented and provided as a letter to the 
investigator.
Before implementation, the investigator will submit to and receive documented approval from 
the IRB/IEC an y modifications made to the protocol or any accompan ying material to be 
provided to the subject after initial IRB/IEC approval, with the exception of those necessary  to 
reduce immediate risk to study  subjects.
9.1.3. Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study  and before undertaking an y study-relatedprocedures. 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page82 20 November 2015Theinvestigator must use the most current IRB-or IEC-approved consent form for documenting 
written informed consent. Each informed consent (or assent as applicable) will be appropriatel y 
signed and dated b y the subject or the subject’s legal ly authorized representative and the person 
conducting the consent discussion, and also by  an impartial witness if required by IRB or IEC or
local requirements. The consent form will inform subjects about pharmacogenomic testing and 
sample retention, and their right to receive clinically  relevant pharmacogenomic anal ysis results.
9.1.4. Confidentiality
The investigator must assure that subjects’ anon ymity will be strictly  maintained and that their 
identities are protected from unauthorized parties. Only  subject in itials, date of birth, another 
unique identifier (as allowed by local law) and an identification code will be recorded on an y 
form or biological sample submitted to the Sponsor ,or laboratory . Laboratory  specimens must 
be labeled in such a way as to protec t subject identity  while allowing the results to be recorded to 
the proper subject. Refer to specific laboratory  instructions . NOTE: The investigator must keep a 
screening log showing codes, names, and addresses for all subjects screened and for all subjec ts 
enrolled in the trial. Subject data will be processed in accordance with all applicable regulations. 
The investigator agrees that all information received from Gilead, including but not limited to the 
investigator brochure, this protocol, eCRF, the IMP , and any other study  information, remain the 
sole and exclusive property  of Gilead during the conduct of the study  and thereafter. This 
information is not to be disclosed to any  third party  (except employ ees or agents directl y 
involved in the conduct of t he study or as required by  law) without prior written consent from 
Gilead. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure b y any employee or agent of the stud y site to any  third party  or otherwise into the 
public domain .
9.1.5. Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the stud y 
to be fully  documented and the study
 data to be subsequently  verified. These documents should 
be classified into at least the following two categories: (1) investigator’s study  file, and 
(2)subject clinical source documents.
The investigator’s stud y file will contain the protocol/amendments, CRF and query  forms, 
IRB/IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Subject identification (name, date of birth, gender);
Documentation that subject meets eligibility  criteria, ie, history , physical examination, and 
confirmation of diagnosis (to support inclusion and exclusion criteria);
Documentation of the reason(s) a con sented subject is not enrolled
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page83 20 November 2015Participation in study (including study number);
Study discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of efficacy  parameters, as required b y the protocol;
Start and end date (including dose regimen) of IMP, including dates of dispensing and return;
Record of all adverse events and other safety  parameters (start and end date, and including 
causality and severity);
Concomitant medication (inclu ding start and end date, dose if relevant; dose changes);
Date of study completion and reason for earl y discontinuation, if it occurs.
All clinical study  documents must be retained b y the investigator until at least 2 years or 
according to local laws, whic hever is longer, after the last approval of a marketing application in 
an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned 
marketing applications in an ICH region; or, if no application is filed or if the application is not 
approved for such indication, until 2 years after the investigation is discontinued and regulatory 
authorities have been notified. Investigators may  be required to retain documents longer if 
specified 
by regulatory  requirements, by  local regulations, or by  an agreement with Gilead. The 
investigator must notify  Gilead before destro ying any clinical study  records.
Should the investigator wish to assign the stud y records to another part y or move them to another 
location, Gilead must be notifi ed in advance.
If the investigator cannot provide for this archiving requirement at the study  site for any  or all of 
the documents, special arrangements must be made between the investigator and Gilead to store 
these 
records securel y away fromthe site so that they  can be returned sealed to the investigator 
in case of a n inspection. When source documents are required for the continued care of the 
subject, appropriate copies should be made for storage away fromthe site.
9.1.6. Case Report Forms
For each subject co nsented, an eCRF casebook will be completed by  an authorized study  staff 
member whose training for thi s function is completed in EDC. The Inclusion/Exclusion Criteria 
and Enrollment eCRFs should be completed onl y after all data related to eligibility
 have been 
received. Subsequent to data entry , a study monitor will perform source data verification within 
the EDC sy stem. System-generated or manual queries will be issued to the investigative site staff 
as data discrepancies are identified by  the monitor or i nternal Gilead staff, who routinely  review 
the data for completeness, correctness, and consistency . The site coordinator is responsible for 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page84 20 November 2015responding to the queries in a timely  manner, within the sy stem, either b y confirming the data as 
correct or updatin g the original entry , and providing the reason for the update 
(e.g.dataentryerror). Original entries as well as any  changes to data fields will be stored in the 
audit trail of the sy stem. Prior to any  interim time points or database lock (as instructed by 
Gilead), the investigator will use his/her log in credentials to confirm that the forms have been 
reviewed, and that the entries accurately reflect the information in the source documents. At the 
conclusion of the trial, Gilead will provide the site wit h a read-only archive copy  of the data 
entered by that site. This archive must be stored in accordance with the records retention 
requirements outlined in Section 9.1.5.
9.1.7. Investigational Medicinal Product Accountability and Return
Gilead recommends that used and unused IMP supplies be returned to the shipping facility  from 
which it came for eventual destruction. The stud y monitor will provide instructions for return. If 
return is not possible, the study  monitor will evaluate each study  center’s IMP disposal
procedures and provide appropriate instruction for destruction of unused IMP supplies. I f the site 
has an appropriate standard operating procedure (SOP) for drug destruction as determined b y 
Gilead QA, the site may  destroy used (empt y or partially empty) and unused I MP supplies in 
accordance with that site’s approved SOP. A cop y of the site’s approved SOP will be obtained 
for central files. 
If IMP is destro
yed on site, the investigator must maintain accurate records for all IMP 
destroyed. Records must show the identification and quantity  of each unit destroy ed, the method 
of destruction, and the person who disposed of the I MP. Upon study  completion, copies of the 
IMP accountability  records must be filed at the site. Another copy  will be returned to Gilead.
The study  monitor will review IMP supplies and associated records at periodic intervals.
9.1.8. Inspections
The investigator will make available all source documents and other records for this trial to 
Gilead’s appointed stud y monitors , to IRBs/IECs or to regulatory  authority or health authorit y 
inspectors.
9.1.9. Protocol Compliance
The investigator is responsible for ensuring the study  is conducted in accordance with the 
procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities
9.2.1. Protocol Mod ifications
Protocol modifications, except those intended to reduce immediate risk to study  subjects, may  be 
made only  by Gilead. The investigator must submit a ll protocol modifications to the IRB/IECin 
accordance with local requirements and receive docume nted IRB/IEC approval before 
modifications can be implemented.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page85 20 November 20159.2.2. Study Report and Publications
A clinical study  report (CSR) will be prepared and provided to the regulatory agenc y(ies). 
Gileadwill ensure that the report meets the standards set out in the ICH Guideline for Structure 
and Content of Clinical Study  Reports (I CHE3). Note that an abbreviated report may  be 
prepared in certain cases.
Investigators in this study  may communicate, orally  present, or publish in scientific journals or 
other scholarl ymedia only  after the following conditions have been met:
The results of the stud y in their entiret y have been publicly disclosed b y or with the consent of 
Gilead in an abstract, manuscript, or presentation form or the stud y has been completed at all 
studysites for at least 2 years.
The investigator will submit to Gilead any  proposed publication or presentation along with the 
respective scientific journal or presentation forum at least 30 day s before submission of the 
publication or presentation. 
No such communication, presentation, or publication will include Gilead’s confidential 
information (see Section 9.1.4).
The investigator will comply  with Gilead’s request to delete references to its confidential 
information (other than the study  results) in any  paper or presentation and agrees to withhold 
publication or presentation for an additional 60 days in order to obtain patent protection if 
deemed necessary .
9.3. Joint Investigator/Sponsor Responsibilities
9.3.1. Payment Reporting
Investigators and their study  staff may be asked to provide services performed under this 
protocol, e.g. attendan ce at Investigator's Meetings. If required under the applicable statutory  and 
regulatory  requirements, Gilead will capture and disclose to Federal and State agencies any  
expenses pai d or reimbursed for such services, including an y clinical trial payments, meal, travel 
expenses or reimbursements, consulting fees, and any  other transfer of value.
9.3.2. Access to Information for Monitoring
In accordance with regulations and guidelines, the stu dy monitor must have direct access to the 
investigator’s source documentation in order to verify  the accuracy of the data recorded in the 
eCRF.
The monitor is responsib le for routine review of the eCRFat regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy  of the 
data being entered on them. The monitor should have access to an y subject records needed to 
verify the entries on the 
eCRF. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected through an y type of monitoring (central, on site) are resolved.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page86 20 November 20159.3.3. Access to Information for Auditing or Inspections
Representatives of regulatory  authorities or of Gilead may  conduct inspections or audits of the 
clinicalstudy. If the investigator is notified of an inspection by  a regulatory authority  the 
investigator agrees to notify  the Gilead medical monitor immediately . The investigator agrees to 
provide to representatives of a regulatory  agency or Gilead access to re cords, facilities, and 
personnel for the effective conduct of an y inspection or audit.
9.3.4. Study Discontinuation
Both the sponsor and the investigator reserve the right to terminate the stud y at any time. Should 
this be necessary , both parties will arrange dis continuation procedures and notify  the appropriate 
regulatory  authority(ies), IRBs, and IECs. In terminating the study , Gilead and the investigator 
will assure that adequate consideration is given to the protection of the subjects’ interests.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page87 20 November 201510. REFERENCES
2202 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum 
creatinine. Nephron 1976;16:31 -41.
5125 Mocroft A, Vella S, Benfield TL , Chiesi A, Miller V, Gargalianos P, et al. 
Changing patterns of mortality  across Europe in patients infected with HIV -1. 
Lancet 1998;352 (9142):1725-30.
8284 Sterne J, Hernán M, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long -term 
effectiveness of potent antiretroviral therapy  in preventing AIDS and death: a 
prospective cohort study . Lancet 2005;366 (9483):378-84.
13585 Schneider E, Whitmore S, Gly nn KM, Dominguez K, Mitsch A, McKenna MT. 
Revised surveillance case definitions for HIV infection among adults, 
adolescents, and children aged <18 months and for HIV infection and AIDS 
among chi ldren aged 18 months to <13 y ears--United States, 2008. MMWR 
Recomm Rep 2008;57 (RR- 10):1-12.
21053 Sterrantino G, Santoro L, Bartolozzi D, Trotta M, Zaccarelli M. Self -reported 
adherence supports patient preference for the single tablet regimen (STR) in t he 
current cART era. Patient preference and adherence 2012;6:427 -33.
27881 Palella FJ, Delaney  KM, Moorman AC, L oveless MO, Fuhrer J, Satten GA, et al. 
Declining Morbidity  and Mortality  Among Patients With Advanced Human 
Immunodeficiency  Virus Infection. N Eng J Med 1998;338 (13):853 -60.
29702 Aldir I, Horta A, Serrado M. Single -tablet regimens in HI V: does it reall y make a 
difference? Curr Med Res Opin 2013;30 (1):89 -97.
29705 Costagliola D. Demographics of HIV and aging. Curr Opin HIV AIDS 2014;9 
(4):294-301.
34898 Department for Health and Human Services (DHHS). Guidelines for the Use of 
Antiretroviral Agents in HIV -1-Infected Adults and Adolescents. Developed by  
the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents –A 
Working Group of t he Office of AIDS Research Advisory  Council (OARAC). 
Downloaded from http://aidsinfo.nih.gov/guidelines on 5/11/2015. L ast Updated 
08 April, 2015.
36201 The Joint United Nations Programme oHAU. Fact Sheet: 2014 Global Statistics. 
Available at: 
http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Rep
ort_en.pdf .  2014.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page88 20 November 201511. APPENDICES
Appendix 1.Investigator Signature Page
Appendix 2.Study Procedures Table
Appendix 3.Management of Clinical and Laboratory Adverse Events
Appendix 4.GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5.Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6.Pregnancy Precautions, Definition for Female of Childbearing Potential, and 
Contraceptive Requirements
GS-98R31F/T AF 
Protocol GS-US-380-1961 Final 
Gilead Sciences, Inc. Original 
Appendix l. Investigator Signature Page 
GILEAD SCIENCES, INC. 
333 LAKESIDE DRIVE 
FOSTER CITY, CA 94404 
STUDY ACKNOWLEDGEMENT 
A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a 
Fixed Dose Combination (FDC) ofGS-9883/Emnicitabine/Tenofov ir Alafenamide 
(GS-9883/F /T AF) from Elvitegravir /Cobicistat/Emtricitabineffenofovir Alafenamide 
(6/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabinerrenofovi r Disoproxil Fumarate (E/C/F!T DF) 
or Atazanavir + Ritonavir + Emtricitabineffe nofovir Disoproxil Fumarate 
(ATV+RTV+FTCffDF) in Virologically Suppressed HIV-1 infected Women 
GS-US-380-1961 , Original, 20 Novembe a· 2015 
This protocol has been approved by Gilead Sciences, Inc. The following signature documents 
this approval. ppo--------------
Huyen Cao, MD (Printed) 
Author 
Date 
INVESTIGATOR STATEMENT 
I have read the protocol, including all appendices, and I agree that it contains all necessary details 
for me and my staff to conduct this study as described. 1 will conduct this study as outlined herein 
and wil1 make a reasonable eff01t to complete the study within the time designated. 
1 will provide aJl study personnel under my supervision copies of the protocol and access to all 
infonnation provided by Gilead Sciences , Inc. 1 will discuss this material with them to ensure 
that they are fully informed about the drugs and the study. 
Principal Investigator Name (Printed) Signature 
Date Site Number 
CONFIDEN TIAL Page 89 20 November 2015 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page90 20 November 2015Appendix 2. Study Procedures Table
Study Procedure ScreeningaDay1bEnd of WeekcPostWeek48d,v
30 Day 
Follow-UpeESDDf4 8 12 24 36 48 Every12Weeks
Informed Consent X
Medical History X
Concomitant Medications X X X X X X X X X X X
Adverse Events X X X X X X X X X X X
Complete Physical Exam X X X X X
Symptom -Directed Physical Exam X X X X X X
12-Lead ECG X X X X X
Height X
Weight  X X X X X X X X X X X
Vital SignsgX X X X X X X X X X X
Urinalysis X X X X X X X X X X X
Urine ChemistryhX X X Xw
Urine Pregnancy TestiX X X X X X X X X X
Serum Pregnancy TestiX
Chemistry ProfilejX X X X X X X X X X X
Metabolic AssessmentskX X X X Xw
Estimated GFR X X X X X X X X X X X
Hematology ProfilelX X X X X X X X X X X
Plasma HIV- 1 RNAmX X X X X X X X X X X
CD4+ Cell Count X X X X X X X X X X X
HBV Blood PlanelnX
GS-9883/F /T AF 
Protocol GS-US-380-1961 
Gilead Sciences, Inc. 
Study Procedure 
Plasma HBV DNA0 
HCVAb" 
HCVRNAP 
HIV -1 Genotype/Phenotype q 
Single PK Draw 
Trough PK Draw• 
PK Sample (post-dose)' 
Observed In-Clinic Dose• 
Provide Dosing Diatyu 
Collect Dosing DiarY' 
Plasma Sample Storage1 
Urine Sample Storage1 
Whole Blood Storage Sample1 
~PD n I 
Randomization 
Study Drug Dispensation 
Study Drug Accountability Sc.reening• 
X X 
I 
a Evaluations to be completed within 30 days prior to Day 1. Day lb 4 
X 
X X 
X 
X X 
X 
X X X X 
X 
X X 
X X 
X 
b Subjects should initiate dosing of study dmg on the same day as the Day 1 visit. 8 
X 
X 
X 
X 
X 
X 
X End ofWeE'kc 
12 24 36 48 
X X X 
X X 
~ 
X X 
X X 
X 
X X 
X 
X X 
X X X X 
X X X X 
X X X xv 
X X X X Post Week 48d,v 
Every 12 Weeks 
xw 
xw 
X 
X 
xv 
X 30Day 
Follow-up• Final 
Original 
ESDDr 
X 
xq 
X X 
X 
c All study visits should be± 2 days of the protocol-specified visit date based on the Day 1 visit through We.ek 12 and completed \.,'ithin ± 6 days at We.ek 24 and Week 36, 
lmless othetwise specified. The visit window at Week 48 will be± 6 weeks of the protocol-specified visit date. 
d At the Week 48 Visit, subjects in a cmmtry where GS-9883/F/TAF FDC is not available will be given the option to receive GS-9883/F/T AF FDC for an additional48 weeks, 
or until the product becomes accessible to subjects through an access program, or lmtil Gilead Sciences elects to discontinue the study in that cmmtry, whichever occm-s first. 
Study visits are to be completed every 12 weeks, within± 6 days of the protocol-spe .cified visit date lmless otherwise specified . 
CONFIDENTIAL Page 91 20 November 2015 
GS-9883/F /TAF 
Protocol GS-US-380-1961 
Gilead Sciences, Inc. Final 
Original 
e Must be completed 30 days after discontinuing study drug. For the purpose of scheduling a 30-Day Follow-Up Visit, a± 6 days window may be used. Required for subjects 
who permanently discontinue study drug prior to Week 48 and do not continue in the study through at least one subsequent visit after the ESDD visit. Subjects who participate 
post Week 48 will be required to return to the clinic 30 days after the completion of study drugs for the 30-Day Follow-Up Visit. 
f Early Study Drug Discontinuation visit to occur within 72 hours oflast dose of study drug. Subjects will be asked to continue attending the scheduled study visits through the 
Week 48 Visit even if the subject discontinues study drug. 
g Vital signs measurements including blood pressure, pulse, respiratory rate, and temperature 
h Urine Chemistry includes urine albumin, urine creatinine , urine protein, retinol binding protein, and beta-2 microglobulin 
Women of childbearing potential only. Positive urine pregnancy tests will be confirmed with a serum test. 
Chemistry profile: alkaline phosphatase, AST, AL T, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, bicarbonate , BUN, calcium, chloride, creatinine, 
glucose, phosphorus, magnesium, potassium, sodium, uric acid, and amylase (reflex lipase testing is performed in subjects with total amylase> 1.5 x ULN). At Day 1, 
Weeks 24, and 48 and every 24 weeks during the post Week 48 period, analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the 
chemistry profile. TSH will be collected at Screening, Day 1, Weeks 24, and 48, as well as every 24 weeks post Week 48, and ESDD if applicable. 
k Fasting glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the subject must 
return within 72 hours in a fasted state to draw blood for the metabolic assessments. 
CBC with differential and platelet count. 
m If the HIV-1 RNA value is 2: 50 copies/mL at Week 48, a retest HIV -1 RNA value must be collected within two to three weeks of the initial test. 
n Hepatitis B Virus (HBV) blood panel: Hepatitis B virus surface antigen (HBsAg), Hepatitis B virus surface antibody (HBsAb) and Hepatitis B virus core antibody (HBcAb). 
If positive HBsAg, reflex testing for plasma HBV DNA, HBeAg (if negative, reflex HBeAb), and quantitative HBsAg. If positive HBcAb with negative HBsAg and negative 
HBsAb, reflex testing for plasma HB V DNA (if positive, reflex HBeAg). If HBeAg is performed and found to be negative, reflex HBeAb. 
o For subjects who meet the definition ofHBV infection, the following will be conducted by the central laboratory: HBsAb, HBsAg (qualitative and quantitative ) and HBeAg 
(if negative, reflex HBeAb) at Days 1, 12, 24 and then every 24 weeks. 
p Subjects who are HCVAb positive will have a HCV RNA test performed at screening and every 24 weeks. 
q HIV-1 genotype/phenotype testing for subjects with HIV-1 RNA 2: 200 copies/mL and virologic rebound, at early study drug discontinuation or Week 48. Following 
unconfirmed virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to the next scheduled visit or at the next scheduled study visit, for a 
HIV-1 RNA and HIV-1 genotype/phenotype (reverse transcriptase , protease and integrase) blood draw. Based on the results of this testing, subjects should be managed 
according to the Virologic Rebound Schema (Section 6.13.1 ). 
r All subjects on GS-9883/FfrAF (Treatment Group 1 only) will have a single anytime PK blood sample collected at Weeks 8, 24 and 36. 
s Subjects on GS-9883/FfrAF (Treatment Group 1 only) will have a Trough PK blood sample collected between 20-28 hours following their last dose at Weeks 4 and 12. 
Subjects must be instructed to not take their study drugs on the morning of their visit for the trough sample collection. If the subject has taken their dose of study drugs prior 
to the visit, the visit may proceed, but the subject must return within 72 hours for the single trough PK blood sample collection. In the event a subject routinely takes their 
study drug in the evening, a single anytime sample may be drawn at Weeks 4 and 12 as the subject will not be instructed to change their dosing time to accommodate this 
trough PK draw. A post-dose PK blood sample will be collected between 1 and 4 hours post dose following an observed, in-clinic dose. 
Plasma storage samples banked for possible future protocol-related testing (safety, virology, pharmacokinetic analysis). Urine storage samples banked for ossible future 
IJrotocol-related safety testi11g includi11g urine chernist:ry. Whole blood sampl:::::.Jotential virologic resistance testing and/or HIV DNA genotyping . .__P _D _____ ___. 
u A dos1ng diary will be dispensed for all Treatment Group 1 sUDJects to complete pnor to each of the PK sample visits. 
v Open-label GS-9883/F/T AF FDC will be dispensed to subjects participating in the study post Week 48 starting at the Week 48 Visit. 
w Every 24 weeks only. 
x Dosing diaries will be collected from subjects for the single anytime PK and trough PK collection (Treatment Group 1 only). If a dosing diary is not returned the site may ask 
the subject for the time of the last dose and if it was taken with or without food. 
CONFIDENTIAL Page 92 20November 2015 
GS-9883/F/TAF 
Protocol GS-US-380-1961 Final 
Gilead Sciences, Inc. Original 
Appendix 3. Management of Clinical and Laboratory Adverse Events 
Grade I 
~-----G_r_a_d_e_2----~~ ~~ ______ G_r_a_de-3------~~ ~~ __________ G_m_d_e_4--------~ 
! 
May continue dosing Repeat lab to 
at the discretion of confirm toxicity 
the investigator grade 
If confirmed and possibly and/or probably related to investigational 
medicinal products: 
1. Withhold investigational medicinal products until ::; Grade 2 
2. Restart all investigational medicinal products at full dose 
l 
If Grade 3 or 4 recurrence that is con tinned and possibly or probably 
related to investigational medicinal products, discontinue a11 
investigational medicinal products dosing permanently Repeat lab to 
confirm toxicity 
grade 
1 1 
lfc elated to 
inve dicinal products, onfrrmed and unr 
stigationalme 
ng may contin 
he investigator dosi ue at the discretion 
oft If confirmed and 
possibly or probably 
I-+ related to 
investigational 
medicinal products, 
discontinue 
investigational 
medicinal products 
dosing permanently and 
follow at periodic 
intervals at least weekly 
until a return to 
baseline or is otherwise 
explained 
If Grade 3 or 4 recurrence that is considered unrelated to 
investigational medicinal products, continue all investigational 
medicinal products at the same dose at the discretion of the 
investigator 
CONFIDENTIAL Page 93 20 November 2015 
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page94 20 November 2015Appendix 4. GSI Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Antiviral Toxicity Grading Scale Version: 01 April 2015
HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Hemoglobin
HIV POSITIVE
Adult and Pediatric 57 Days8.5to10.0g/dL 
85 to 100 g/L7.5to 8.5g/dL 
75to85g/L6.5 to 7.5g/dL 
65 to 75g/L6.5g/dL
65g/L
HIV NEGATIVE
Adult and Pediatric 57 Days 10.0to10.9g/dL
100to109g/L
OR
Any decrease from Baseline
2.5 to 3.5g/dL
25 to 35g/L9.0 to 10.0g/dL
90 to 100g/L
OR
Any decrease from Baseline
3.5 to 4.5g/dL
35 to 45g/L7.0 to 9.0g/dL
70 to 90g/L
OR
Any decrease from Baseline
4.5g/dL
45g/L7.0g/dL
70g/L
Infant, 36 –56 Days
(HIV POSITIVE OR
NEGATIVE )8.5 to 9.4 g/dL
85 to 94g/L7.0 to 8.5g/dL
70 to 85g/L6.0 to 7.0 g/dL
60 to < 70 g/L6.0 g/dL
< 60 g/L
Infant, 22 –35 Days
(HIV POSITIVE OR
NEGATIVE )9.5 to 10.5 g/dL
95 to 105 g/L8.0 to 9.5g/dL
80 to 95g/L7.0 to 8.0g/dL
70 to 80g/L7.0g/dL
70g/L
Infant, 1–21 Days
(HIV POSITIVE OR
NEGATIVE )12.0 to 13.0 g/dL
120 to 130 g/L10.0 to 12.0g/dL
100 to 120g/L9.0 to 10.0g/dL
90 to 100g/L9.0g/dL
90g/L
Absolute Neutrophil Count  
(ANC)
Adult and Pediatric, 
≥ 7 Months#1000to1300/mm3750to1000/mm3500to750/mm3500/mm3
1.00to 1.30GI/L 0.75to 1.00 GI/L 0.50to0.75 GI/L 0.50 GI/L
Absolute CD4+ Count
HIV NEGATIVE ONLY
Adult and Pediatric 
>13Years300to400/mm3
300to400/μL200to300/mm3
200to 300/μL100to200/mm3
100to200/μL100/mm3
100/μL
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page95 20 November 2015HEMATOLOGY
Grade 1 Grade 2 Grade 3 Grade 4
Absolute Lymphocyte Count
HIV NEGATIVE ONLY
Adult and Pediatric 
13Years600 to 650/mm3
0.60 to 0.65 GI/L500 to 600/mm3
0.50 to 0.60 GI/L350 to 500/mm3
0.35 to 0.50 GI/L350/mm3
0.35 GI/L
Platelets 100,000 to < 125,000/mm3
100to125 GI/L50,000 to 100,000/mm3
50to 100 GI/L25,000 to 50,000/mm3
25 to 50 GI/L25,000/mm3
25GI/L
WBCs 2000/mm3to 2500/mm31,500 to  2,000/mm31000 to 1,500/mm31000/mm3
2.00GI/Lto 2.50GI/L 1.50to 2.00GI/L 1.00 to 1.50GI/L 1.00 GI/L
Hypofibrinogenemia 100to200mg/dL 75 to 100mg/dL 50to 75mg/dL 50mg/dL
1.00to2.00g/L 0.75to 1.00g/L 0.50 to 0.75g/L 0.50g/L
Hyperfibrinogenemia ULN to 600 mg/dL 600mg/dL — —
ULN  to 6.0 g/L 6.0g/L — —
Fibrin Split Product 20 to 40μg/mL 40to 50μg/mL 50to 60μg/mL 60μg/mL
20 to 40mg/L 40 to 50mg/L 50 to 60mg/L 60mg/L
Prothrombin Time (PT) 1.00 to 1.25 ULN 1.25 to 1.50 ULN 1.50 to 3.00 ULN 3.00 ULN 
International Normalized Ratio 
of prothrombin time (INR)1.1 to 1.5 x ULN >1.5 to 2.0 x ULN >2.0 to 3.0 x ULN >3.0 x ULN
Activated Partial
Thromboplastin Time (APTT) 1.00to 1.66ULN 1.66to 2.33ULN 2.33to 3.00ULN 3.00 ULN
Methemoglobin 5.0to10.0% 10.0to15.0% 15.0to20.0% 20.0% 
# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects. Please follow the Gilead convention of grading 
any result within the LLN and ULN a 0.  
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page96 20 November 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyponatremia 130 to <LLN mEq/L 125 to130mEq/L 121 to125mEq/L 121 mEq/L
130 to<LLN mmol/L 125 to130mmol/L 121 to125mmol/L 121 mmol/L
Hypernatremia >ULN  to 150 mEq/L 150 to 154 mEq/L 154 to 159 mEq/L 159 mEq/L
>ULN  to 150 mmol/L 150 to 154 mmol/L 154 to 159 mmol/L 159 mmol/L
Hypokalemia 
Adult and Pediatric
1 Year3.0 to  <LLN mEq/L 2.5 to3.0mEq/L 2.0 to2.5mEq/L 2.0 mEq/L
3.0 to <LLN mmol/L 2.5 to3.0mmol/L 2.0 to2.5mmol/L 2.0 mmol/L
Infant  <1 Year 3.0 to 3.4 mEq/L
3.0 to 3.4 mmol/L2.5 to3.0mEq/L                
2.5 to <3.0 mmolL2.0 to2.5mEq/L                 
2.0 t o <2.5 mmolL2.0 mEq/L                         
<2.0 mmolL
Hyperkalemia 
Adult and Pediatric
1 Year5.6 to6.0 mEq/L
5.6 to 6.0 mmol/L6.0 to 6.5 mEq/L
6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L
6.5 to 7.0 mmol/L7.0 mEq/L
7.0 mmol/L
Infant  <1 Year >ULN to 6.0 mEq/L           
>ULN to 6.0 mmol/L> 6.0 to 6.5 mEq/L
> 6.0 to 6.5 mmol/L6.5 to 7.0 mEq/L             
6.5 to 7.0 mmol/L7.0 mEq/L                  
7.0 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page97 20 November 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypoglycemia
Adult and Pediatric
1Month55 to 64mg/dL
3.03 to 3.58 mmol/L40 to55mg/dL
2.20 to3.03mmol/L30 to40mg/dL
1.64 to2.20mmol/L30mg/dL
1.64 mmol/L
Infant,1Month 50 to 54mg/dL
2.8 to 3.0 mmol/L40 to 50mg/dL
2.2 to 2.8mmol/L30 to 40mg/dL
1.7 to 2.2mmol/L30mg/dL
1.7 mmol/L
Hyperglycemia, Nonfasting 116to 160mg/dL 160 to 250 mg/dL 250 to 500 mg/dL 500mg/dL
6.42 to 8.91 mmol/L 8.91 to 13.90 mmol/L 13.90 to 27.79 mmol/L 27.79 mmol/L
Hyperglycemia, Fasting 110 to 125 mg/dL
6.08 to 6.96 mmol/L>125 to 250 mg/dL
>6.96 to 13.90 mmol/L>250 to 500 mg/dL
>13.90 to 27.79 mmol/L>500mg/dL
>27.79 mmol/L
Hypocalcemia 
(corrected for albumin if 
appropriate*)
Adult and Pediatric
2 Years7.8 <LLN mg/dL
1.94 to <LLN mmol/L7.0 to7.8mg/dL
1.74 to1.94 mmol/L6.1 to7.0mg/dL
1.51 to1.74 mmol/L6.1mg/dL
1.51mmol/L
Pediatric ≥7 days -2Years 7.8 to 8.4 mg/dL                               
1.94 to 2.10 mmol/L7.0 to <7.8 mg/dL              
1.74 to <1.94 mmolL6.1 to  <7.0 mg/dL                         
1.51 to < 1.74 mmolL< 6.1mg/dL                           
< 1.51 mmol/L
Infant,7Days 6.5 to 7.5 mg/dL
1.61 to 1.88  mmol/L6.0 to 6.5mg/dL
1.49 to < 1.61 mmol/L5.5 to 6.0mg/dL
1.36 to < 1.49 mmol/L 5.5mg/dL
< 1.36 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page98 20 November 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hypercalcemia (corrected for 
albumin if appropriate*)
Adultand Pediatric 7Days>ULN to 11.5 mg/dL 11.5 to 12.5 mg/dL 12.5 to 13.5 mg/dL 13.5mg/dL
>ULN to 2.88 mmol/L 2.88 to 3.13 mmol/L 3.13 to 3.38 mmol/L 3.38 mmol/L
Infant,7Days 11.5 to 12.4 mg/dL
2.86 to 3.10  mmol/L12.4 to 12.9 mg/dL
> 3.10 to 3.23  mmol/L12.9 to 13.5 mg/dL
> 3.23 to 3.38  mmol/L13.5mg/dL
> 3.38 mmol/L
Hypocalcemia (ionized) 3.0mg/dL toLLN 2.5 to < 3.0 mg/dL 2.0 to2.5mg/dL 2.0mg/dL
0.74 mmol/L to LLN 0.62 to0.74 mmol/L 0.49 to0.62 mmol/L 0.49 mmol/L
Hypercalcemia (ionized) ULN to 6.0 mg/dL 6.0 to 6.5 mg/dL 6.5 to 7.0 mg/dL 7.0mg/dL
ULN to 1.50 mmol/L 1.50 to 1.63 mmol/L 1.63 to 1.75 mmol/L 1.75 mmol/L
Hypomagnesemia 1.40 to  <LLN mg/dL
1.2 to <LLN mEq/L1.04 to1.40mg/dL
0.9 to   1.2 mEq/L0.67 to1.04mg/dL
0.6 to 0.9 mEq/L0.67mg/dL
0.6 mEq/L
0.58 to <LLN mmol/L 0.43 to0.58 mmol/L 0.28 to0.43 mmol/L 0.28 mmol/L
Hypophosphatemia
Adult and Pediatric
14Years2.0 to < LLN mg/dL
0.63  to LLN mmol/L1.5 to 2.0mg/dL
0.47 to 0.63 mmol/L1.0 to 1.5mg/dL
0.31 to 0.47 mmol/L1.0mg/dL
0.31 mmol/L
Pediatric 1 Year– 14 Years 3.0 to <LLN mg/dL
0.96 to <LLN mmol/L2.5 to 3.0mg/dL
0.80 to < 0.96mmol/L1.5 to 2.5mg/dL
0.47 to < 0.80 mmol/L1.5mg/dL
<0.47 mmol/L
Pediatric 1Year 3.5 to <LLN mg/dL
1.12 to <LLN mmol/L2.5 to 3.5mg/dL
0.80 to < 1.12mmol/L1.5 to 2.5mg/dL
0.47 to < 0.80 mmol/L1.5mg/dL
<0.47 mmol/L
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page99 20 November 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Hyperbilirubinemia 
Adult and Pediatric > 14Days1.0 to 1.5 ULN 1.5 to 2.5 ULN 2.5 to 5.0 ULN 5.0 ULN 
Infant, 14Days
(non-hemolytic)NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0 to 30.0 mg/dL
> 428 to 513 μmol/L30.0mg/dL
> 513 μmol/L
Infant, 14Days
(hemolytic)NA NA 20.0 to 25.0 mg/dL
342 to 428 μmol/L25.0mg/dL
> 428 μmol/L
Blood Urea Nitrogen 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Hyperuricemia >ULN to 10.0 mg/dL 10.0 to 12.0 mg/dL 12.0 to 15.0 mg/dL 15.0mg/dL
>ULN to 597 μmol/L 597 to 716 μmol/L 716 to 895 μmol/L 895 μmol/L
Hypouricemia               
Adult and Pediatric           
≥ 1 year   
Infant  < 1 Year1.5mg/dL toLLN
87 μmol/L to LLN1.0 to1.5mg/dL
57 to87 μmol/L0.5 to1.0mg/dL
27 to57 μmol/L0.5mg/dL
27 μmol/L
N/A 1.0mg/dl to <LLN -
57 μmol to <LLN0.5 to1.0mg/dL
27 to57 μmol/L0.5mg/dL
27 μmol/L
Creatinine ** 1.50 to 2.00 mg/dL
133 to 177 μmol/L2.00 to 3.00 mg/dL
177 to 265 μmol/L3.00 to 6.00 mg/dL 
265 to 530 μmol/L6.00mg/dL
530 μmol/L
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page100 20 November 2015CHEMISTRY
Grade 1 Grade 2 Grade 3 Grade 4
Bicarbonate
Adult and Pediatric 
≥ 4 Years16.0 mEq/L to LLN 11.0 to16.0 mEq/L 8.0 to11.0 mEq/L 8.0 mEq/L
16.0 mmol/L to LLN 11.0 to16.0 mmol/L 8.0 to11.0 mmol/L 8.0 mmol/L
Pediatric < 4 Years NA 11.0 mEq/Lto <LLN 8.0 to11.0 mEq/L 8.0 mEq/L
11.0 mmol/L to <LLN 8.0 to11.0 mmol/L 8.0 mmol/L
Triglycerides
(Fasting)NA 500 to 750 mg/dL
5.64–8.47 mmol/L750 to 1200 mg/dL
8.47–13.55 mmol/L1200mg/dL
13.55 mmol/L
LDL (Fasting)
Adult130 to 160 mg/dL >160 to 190 mg/dL > 190mg/dL NA
3.35 to 4.15 mmol/L >4.15 to 4.92 mmol/L >4.92 mmol/L
LDL (Fasting)
Pediatric >2 to <18 years110 to 130 mg/dL >130 to 190 mg/dL > 190mg/dL NA
2.84 to 3.37 mmol/L >3.37 to  4.92 mmol/L >4.92 mmol/L
Hypercholesterolemia
(Fasting)200 to 239 mg/dL 239 to 300 mg/dL 300mg/dL NA
5.16 to 6.19 mmol/L 6.19 to 7.77 mmol/L 7.77 mmol/L
Pediatric 18 Years 170 to 199 mg/dL
4.39 to 5.15 mmol/L199 to 300 mg/dL
5.15 to 7.77 mmol/L300mg/dL
7.77 mmol/LNA
Creatine Kinase 3.0 to6.0 ULN 6.0 to10.0 ULN 10.0 to20.0 ULN 20.0 ULN
* Calcium should be corrected for albumin if albumin is < 4.0 g/dL
**An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects > 70 yrs. Please follow the Gilead convention of grading any 
result within the LLN and ULN a 0.  
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page101 20 November 2015ENZYMES
Grade 1 Grade 2 Grade 3 Grade 4
AST (SGOT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
ALT (SGPT) 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
GGT 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Alkaline Phosphatase 1.25 to 2.50 ULN 2.50 to 5.00 ULN 5.00 to 10.00 ULN 10.00 ULN
Total Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Pancreatic Amylase 1.0 to 1.5 ULN 1.5 to 2.0 ULN 2.0 to 5.0 ULN 5.0 ULN
Lipase 1.0 to 1.5 ULN 1.5 to 3.0 ULN 3.0 to 5.0 ULN 5.0 ULN
Albumin
Pediatrics <16 years 
≥ 16 years- 2.0 to LLN g/dL
20 to LLN g/L2.0 g/dL
20 g/LNA
3.0 g/dL to LLN
30 g/L to LLN2.0 to 3.0 g/dL
20 to 30 g/L2.0 g/dL
20 g/LNA
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page102 20 November 2015URINALYSIS
Grade 1 Grade 2 Grade 3 Grade 4
Hematuria (Dipstick) 1 2 3-4+ NA
Hematuria (Quantitative) 
See Note below
                              Females >ULN -10RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
                              Males 6-10 RBC/HPF 10-75RBC/HPF > 75 RBC/HPF NA
Proteinuria (Dipstick) 1 2–3 4 NA
Proteinuria, 24 Hour Collection
Adult and Pediatric 
10 Years200 to999mg/24h >999 to1999mg/24 h >1999to3500mg/24 h 3500mg/24 h
Pediatric 3 Mo to 
<10Years201 to499mg/m2/24h >499to799mg/m2/24 h >799to1000mg/m2/24 h 1000mg/ m2/24 h
Glycosuria (Dipstick) 1+ 2-3 4 NA
Notes: 
Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to 
Dipstick Hematuria.
With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigne d Grade 0.
If theseverity of a clinical AE could fall under either one of two grades (e.g., the severity of an AE could be either Grade 2 or G rade 3), select the higher of the two grades for 
the AE.
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page103 20 November 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Cardiac Arrhythmia (general)
(By ECG or physical exam)Asymptomatic AND No 
intervention indicatedAsymptomatic AND Non -
urgent medical intervention 
indicatedSymptomatic, non -life-
threatening AND Non -urgent 
medical intervention 
indicated Life-threatening arrhythmia 
OR Urgent intervention 
indicated
Cardiac-ischemia/Infarction NA NA Symptomatic ischemia 
(stable angina) OR Testing 
consistent with ischemia Unstable angina OR Acute 
myocardial infarction
Hemorrhage (significant acute 
blood loss)NA Symptomatic AND No 
transfusion indicatedSymptomatic AND 
Transfusion of 2units 
packed RBCs (for children 
10cc/kg) indicated Life-threatening hypotension 
OR Transfusion of 2units 
packed RBCs indicated (for 
children 10cc/kg) 
indicated
Hypertension (with repeat 
testing at same visit)140–159mmHg systolic 
OR 
90–99 mmHg diastolic159–179 mmHg systolic 
OR 
99–109 mmHg diastolic179mmHg systolic 
OR 
109mmHg diastolicLife-threatening 
consequences (eg, malignant 
hypertension) OR 
Hospitalization (other than 
ER visit) indicated
Pediatric 17Years 
(withrepeat testing at same 
visit)NA 91st–94th percentile adjusted 
for age, height, and gender 
(systolic and/or diastolic)≥95th percentile adjusted for 
age, height, and gender 
(systolic and/or diastolic)Life-threatening 
consequences (eg, malignant 
hypertension) OR 
Hospitalization indicated 
(other than emergency room 
visit)
Hypotension NA Symptomatic, corrected w ith 
oral fluid replacementSymptomatic, IV fluids 
indicatedShock requiring use of 
vasopressors or mechanical 
assistance to maintain blood 
pressure
Pericardial Effusion Asymptomatic, small 
effusion requiring no 
interventionAsymptomatic, moderate or 
larger effusion requiring no 
interventionEffusion with non -life-
threatening physiologic 
consequences OR Effusion 
with nonurgent intervention 
indicatedLife-threatening 
consequences (eg, 
tamponade) OR Urgent 
intervention indicated
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page104 20 November 2015CARDIOVASCULAR
Grade 1 Grade 2 Grade 3 Grade 4
Prolonged PR Interval PR interval 
0.21 to 0.25 secPR interval
0.25 secType II 2nd degree AV block 
OR Ventricular pause 3.0 
secComplete AV block 
Pediatric 16 Years 1st degree AV block
(PR > normal for age and 
rate)Type I 2nd degree AV block Type II 2nd degree AV block Complete AV block
Prolonged QTc Asymptomatic, QTc interval 
0.45 to 0.47 sec OR Increase 
interval 0.03 sec above 
baselineAsymptomatic, QTc interval 
0.48 to 0.49 sec OR Increase 
in interval 0.03 to 0.05 sec 
above baselineAsymptomatic, QTc interval 
0.50sec OR Increase in 
interval 0.06sec above 
baselineLife-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Pediatric 16Years Asymptomatic, QTc interval 
0.450 to 0.464 sec Asymptomatic, QTc interval 
0.465 to 0.479 sec Asymptomatic, QTc interval 
0.480 sec Life-threatening 
consequences, eg, Torsade de 
pointes or other associated 
serious ventricular 
dysrhythmia
Thrombosis/Embolism NA Deep vein thrombosis AND 
No intervention indicated 
(eg, anticoagulation, lysis 
filter, invasive procedure) Deep vein thrombosis AND 
Intervention indicated (eg, 
anticoagulation, lysis filter, 
invasive procedure) Embolic event (eg, 
pulmonary embolism, life -
threatening thrombus) 
Vasovagal Episode (associated 
with a procedure of any kind)Present without loss of 
consciousness Present with transient loss of 
consciousnessNA NA
Ventricular Dysfunction 
(congestive heart failure, CHF)NA Asymptomatic diagnostic 
finding AND intervention 
indicatedNew onset with symptoms 
OR Worsening symptomatic 
CHFLife-threatening CHF
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page105 20 November 2015RESPIRATORY
Grade 1 Grade 2 Grade 3 Grade 4
Bronchospasm (acute) FEV1 or peak flow  reduced 
to 70% to 80%FEV1 or peak flow  50% to 
69%FEV1 or peak flow  25% to 
49% Cyanosis OR FEV1 or peak 
flow 25% OR Intubation
Dyspnea or Respiratory Distress Dyspnea on exertion with no 
or minimal interference with 
usual social & functional 
activities Dyspnea on exertion causing 
greater than minimal 
interference with usual social 
& functional activities Dyspnea at rest causing 
inability to perform usual 
social & functional activities Respiratory failure with 
ventilatory support indicated
Pediatric 14 Years Wheezing OR minimal 
increase in respiratory rate 
for ageNasal flaring OR Intercostal 
retractions OR Pulse 
oximetry 90% to 95%Dyspnea at rest causing 
inability to perform usual 
social & functional activities 
OR Pulse oximetry 90%Respiratory f ailure with 
ventilatory support indicated
OCULAR/VISUAL
Grade 1 Grade 2 Grade 3 Grade 4
Uveitis Asymptomatic but detectable 
on examSymptomatic anterior uveitis 
OR Medical intervention 
indicatedPosterior or pan -uveitis OR 
Operative intervention 
indicatedDisabling visual loss in 
affected eye(s) 
Visual Changes (from baseline) Visual changes causing no or 
minimal interference with 
usual social & functional 
activitiesVisual changes causing 
greater than minimal 
interference with usual social 
& functional activitiesVisual changes causing 
inability to perform usual 
social & functional activitiesDisabling visual loss in 
affected eye(s)
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page106 20 November 2015SKIN
Grade 1 Grade 2 Grade 3 Grade 4
Alopecia Thinning detectable by study 
participant or  caregiver (for 
disabled adults)Thinning or patchy hair loss 
detectable by health care 
providerComplete hair loss NA
Cutaneous Reaction –Rash Localized macular rash Diffuse macular, 
maculopapular, or 
morbilliform rash OR Target 
lesions Diffuse macular, 
maculopapular, or 
morbilliform rash with 
vesicles or limited number of 
bullae OR Superficial 
ulcerations of mucous 
membrane limited to one siteExtensive or generalized 
bullous lesions OR Stevens -
Johnson syndrome OR 
Ulceration of mucous 
membrane involving two or 
more distinct mucosal sites 
OR Toxic epidermal 
necrolysis (TEN)
Hyperpigmentation Slight or localized Marked or generalized NA NA
Hypopigmentation Slight or localized Marked or generalized NA NA
Pruritis (itching –no skin 
lesions) 
(See also Injection Site 
Reactions: Pruritis associated 
with injection)Itching causing no or 
minimal interference with 
usual social & functional 
activitiesItching causing greater than 
minimal interference with 
usual social & functional 
activitiesItching causing i nability to 
perform usual social & 
functional activities NA
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page107 20 November 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Anorexia Loss of appetite w ithout 
decreased oral intakeLoss of appetite associated 
with decreased oral intake 
without significant weight 
loss Loss of appetite associated 
with significant weight loss Life-threatening 
consequences OR 
Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutri tion]
Ascites Asymptomatic Symptomatic AND 
Intervention indicated (eg, 
diuretics or therapeutic 
paracentesis)Symptomatic despite 
interventionLife-threatening 
consequences
Cholecystitis NA Symptomatic AND Medical 
intervention indicatedRadiologic, endoscopic, or 
operative intervention 
indicatedLife-threatening 
consequences (eg, sepsis or 
perforation) 
Constipation NA Persistent constipation 
requiring regular use of 
dietary modifications, 
laxatives, or enemas Obstipation with manual 
evacuation indicatedLife-threatening 
consequences (eg, 
obstruction)
Diarrhea 
Adult and Pediatric 1Year Transient or intermittent 
episodes of unformed stools 
OR Increase of 3stools 
over baseline/24 hrPersistent episodes of 
unformed to watery stools 
OR Increase of 4 –6 stools 
over baseline per 24 hrs. Bloody diarrhea OR Increase 
of 7stools per 24 -hour 
period OR IV fluid 
replacement indicatedLife-threatening 
consequences (eg, 
hypotensive shock)
Pediatric 1Year Liquid stools (more 
unformed than usual) but 
usual number of stoolsLiquid stools with increased 
number of stools OR Mild 
dehydrationLiquid stools with moderate 
dehydrationLiquid stools resulting in 
severe dehydration with 
aggressive r ehydration 
indicated OR Hypotensive 
shock
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page108 20 November 2015GASTROINTESTINAL
Grade 1 Grade 2 Grade 3 Grade 4
Dysphagia-Odynophagia Symptomatic but able to eat 
usual dietSymptoms causing altered 
dietary intake without 
medical intervention 
indicatedSymptoms causing severely 
altered dietary intake with 
medical intervention 
indicatedLife-threatening reduction in 
oral intake
Mucositis/Stomatitis 
(clinical exam)
See also Proctitis, Dysphagia -
OdynophagiaErythema of the mucosa Patchy pseudomembranes or 
ulcerations Confluent pseudomembranes 
or ulcerations OR Mucosal 
bleeding with minor traumaTissue necrosis OR Diffuse 
spontaneous mucosal 
bleeding OR Life -threatening 
consequences (eg, aspiration, 
choking)
Nausea Transient ( 24hours) or 
intermittent nausea with no 
or minimal interference with 
oral intakePersistent nausea resulting in 
decreased oral intake for 24 –
48 hoursPersistent nausea resulting in 
minimal oral intake for  48 
hours OR Aggressive 
rehydration indicated (eg, 
IVfluids)Life-threatening 
consequences (eg, 
hypotensive shock)
Pancreatitis NA Symptomatic AND 
Hospitalization not indicated 
(other than ER visit)Symptomatic AND 
Hospitalization indicated 
(other than ER visit)Life-threatening 
consequences (eg, sepsis, 
circulatory failure, 
hemorrhage)
Proctitis (functional -
symptomatic)
Also seeMucositis/ Stomatitis 
for Clinical ExamRectal discomfort AND No 
intervention indicatedSymptoms causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Medical intervention 
indicated Symptoms causing inability 
to perform usual social/ 
functional activities OR 
Operative intervention 
indicated Life-threatening 
consequences (eg, 
perforation)
Vomiting Transient or intermittent 
vomiting with no or minimal 
interference with oral intakeFrequent episodes of 
vomiting with no or mild 
dehydrationPersistent vomiting resulting 
in orthostatic hypotension 
OR Aggressive rehydration 
indicatedLife-threatening 
consequences (eg, 
hypotensive shock)
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page109 20 November 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Alteration in Personality -
Behavior or in Mood (eg, 
agitation, anxiety, depression, 
mania, psychosis)Alteration causing no or 
minimal interference with 
usual social & functional 
activities Alteration causing greater 
than minimal interference 
with usual so cial & 
functional activities Alteration causing inability 
to perform usual social & 
functional activities Behavior potentially harmful 
to self or others (eg, 
suicidal/homicidal ideation 
or attempt, acute psychosis) 
OR Causing inability to 
perform basic s elf-care 
functions
Altered Mental Status 
For Dementia, see Cognitive 
and Behavioral/Attentional 
Disturbance (including 
dementia and ADD)Changes causing no or 
minimal interference with 
usual social & functional 
activitiesMild lethargy or somnolence 
causing greater than minimal 
interference with usual social 
& functional activitiesConfusion, memory 
impairment, lethargy, or 
somnolence causing inability 
to perform usual social & 
functional activitiesDelirium OR obtundation, 
OR coma
Ataxia Asymptomatic ataxia 
detectable on exam OR 
Minimal ataxia causing no or 
minimal interference with 
usual social & functional 
activitiesSymptomatic ataxia causing 
greater than minimal 
interference with usual social 
& functional activitiesSymptomatic ataxia causing 
inability to perform usual 
social & functional activities Disabling ataxia causing 
inability to perform basic 
self-care functions
Cognitive and 
Behavioral/Attentional 
Disturbance (including 
dementia and Attention Deficit 
Disorder) Disability cau sing no or 
minimal interference with 
usual social & functional 
activities OR Specialized 
resources not indicatedDisability causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Specialized resources on 
part-time basis indi catedDisability causing inability to 
perform usual social & 
functional activities OR 
Specialized resources on a 
full-time basis indicatedDisability causing inability to 
perform basic self -care 
functions OR 
Institutionalization indicated
CNS Ischemia
(acute)NA NA Transient ischemic attack Cerebral vascular accident 
(CVA, stroke) with 
neurological deficit 
Developmental delay –
Pediatric 16 YearsMild developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Moderate developmental 
delay, either motor or 
cognitive, as determined by 
comparison with a 
developmental screening tool 
appropriate for the setting Severe developmental delay, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting Developmental regression, 
either motor or cognitive, as 
determined by comparison 
with a developmental 
screening tool appropriate for 
the setting
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page110 20 November 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Headache Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & 
functional activitiesSymptoms causing inability 
toperform usual social & 
functional activitiesSymptoms causing inability 
to perform basic self -care 
functions OR Hospitalization 
indicated (other than ER 
visit) OR Headache with 
significant impairment of 
alertness or other neurologic 
function 
Insomnia NA Difficulty sleeping causing 
greater than minimal 
interference with usual 
social/functional activitiesDifficulty sleeping causing 
inability to perform usual 
social & functional activitiesDisabling insomnia causing 
inability to perform basic 
self-care functions
Neuromuscular Weakness 
(including myopathy & 
neuropathy) Asymptomatic with 
decreased strength on exam 
OR Minimal muscle weak -
ness causing no or minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
greater than minimal 
interference with usual social 
& functional activitiesMuscle weakness causing 
inability to perform usual 
social & functional activities Disabling muscle weakness 
causing inability to perform 
basic self -care functions OR 
Respiratory muscle weaknes s 
impairing ventilation
Neurosensory Alteration 
(including paresthesia and 
painful neuropathy)Asymptomatic with sensory 
alteration on exam or 
minimal paresthesia causing 
no or minimal interference 
with usual social & 
functional activities Sensory altera tion or 
paresthesia causing greater 
than minimal interference 
with usual social & 
functional activities Sensory alteration or 
paresthesia causing inability 
to perform usual social & 
functional activitiesDisabling sensory alteration 
or paresthesia causing
inability to perform basic 
self-care functions
Seizure: (new onset) NA 1 seizure 2–4 seizures Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or 
difficult to control (eg, 
refractory epilepsy)
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page111 20 November 2015NEUROLOGICAL
Grade 1 Grade 2 Grade 3 Grade 4
Seizure: (pre- existing) 
ForWorsening of Existing 
Epilepsy the Grades Should Be 
Based on an Increase from 
Previous Level of Control to 
Any of These LevelsNA Increased frequency of pre-
existing seizures (non -
repetitive) without change in 
seizure character OR 
infrequent breakthrough 
seizures while on stable 
meds in a previously 
controlled seizure disorderChange in seizure character 
from baseline either in 
duration or quality (eg, 
severity or focality) Seizures of any kind that are 
prolonged, repetitive (eg, 
status epilepticus), or 
difficult to control (eg, 
refractory epilepsy)
Seizure 
–Pediatric 18 YearsSeizure, generalized onset 
with or without secondary 
generalization, lasting 
< 5minutes with < 24hours 
post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 5 –20 
minutes with 
< 24 hours post ictal stateSeizure, generalized onset 
with or without secondary 
generalization, lasting 
> 20 minutes Seizure, generalized onset 
with or witho ut secondary 
generalization, requiring 
intubation and sedation
Syncope (not associated with a 
procedure)NA Present NA NA
Vertigo Vertigo causing no or 
minimal interference with 
usual social & functional 
activitiesVertigo causing greater than 
minimal interference with 
usual social & functional 
activities Vertigo causing inability to 
perform usual social & 
functional activitiesDisabling vertigo causing 
inability to perform basic 
self-care functions
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page112 20 November 2015MUSCULOSKELETAL
Grade 1 Grade 2 Grade 3 Grade 4
Arthralgia
See also ArthritisJoint pain causing no or 
minimal interference with 
usual social & functional 
activitiesJoint pain causing greater 
than minimal interference 
with usual social & 
functional activitiesJoint pain causing inability to 
perform usual social & 
functional activitiesDisabling joint pain causing 
inability to perform basic 
self-care functions
Arthritis
See also ArthralgiaStiffness or joint sw elling 
causing no or minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing greater than minimal 
interference with usual social 
& functional activitiesStiffness or joint sw elling 
causing inability to perform 
usual social & functional 
activitiesDisabling joint stiffness or 
swelling causing inability to 
perform basic self -care 
functions
Bone Mineral Loss BMD t-score or z- score
–2.5 to –1.0 BMD t-score or z- score
–2.5Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening 
consequences 
Pediatric 21Years BMD z-score 
–2.5 to –1.0BMD z-score < –2.5 Pathological fracture 
(including loss of vertebral 
height)Pathologic fracture causing 
life-threatening 
consequences 
Myalgia
(non-injection site)Muscle pain causing no or 
minimal interference with 
usual social & functional 
activitiesMuscle pain causing greater 
than minimal interference 
with usual social & 
functional activitiesMuscle pain causing inability 
to perform usual soc ial & 
functional activitiesDisabling muscle pain 
causing inability to perform 
basic self -care functions
Osteonecrosis NA Asymptomatic with 
radiographic findings AND 
No operative intervention 
indicatedSymptomatic bone pain with 
radiographic findings OR 
Operative intervention 
indicatedDisabling bone pain with 
radiographic findings 
causing inability to perform 
basic self -care functions
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page113 20 November 2015SYSTEMIC
Grade 1 Grade 2 Grade 3 Grade 4
Acute Systemic Allergic 
Reaction Localized urticaria (wheals) 
with no medical intervention 
indicatedLocalized urticaria with 
medical intervention 
indicated OR Mild 
angioedema with no medical 
intervention indicatedGeneralized urticaria OR 
Angioedema with medical 
intervention indicated OR 
Symptomatic mild 
bronchospasmAcute anaphylaxis OR Life -
threatening bronchospasm 
OR laryngeal edema
Chills Symptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & 
functional activities Symptoms causing inability 
to perform usual social & 
functional activitiesNA
Fatigue
MalaiseSymptoms causing no or 
minimal interference with 
usual social & functional 
activitiesSymptoms causing greater 
than minimal interference 
with usual social & 
functional activitiesSymptoms causing inability 
to perform usual social & 
functional activitiesIncapacitating 
fatigue/malaise symptoms 
causing inability to perform 
basic self -care functions
Fever (nonaxillary) 37.7C to 38.6C
99.8F to 101.5F38.7C to 39.3C
101.6F to 102.8F39.4C to 40.5C
102.9F to 104.9F40.5C 
104.9F
Pain-Indicate Body Site
See also Injection Site Pain, 
Headache, Arthralgia, and 
MyalgiaPain causing no or minimal 
interference with usual social 
& functional activitiesPain causing greater than 
minimal interference with 
usual social & functional 
activitiesPain causing inability to 
perform usual social & 
functional activitiesDisabling pain causing 
inability to perform basic 
self-care functions OR 
Hospitalization (other than 
ER visit) indicated
Unintentional Weight Loss NA 5% to 9% loss in body 
weight from baseline10% to 19% loss in body 
weight from baseline20% loss in body weight 
from baseline OR  
Aggressive intervention 
indicated [eg, tube feeding or 
total parenteral nutrition]
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page114 20 November 2015INJECTION SITE REACTION
Grade 1 Grade 2 Grade 3 Grade 4
Injection Site Pain (pain 
without touching)
Or Tenderness (pain when area 
is touched) Pain/tenderness causing no 
or minimal limitation of use 
of limbPain/tenderness limiting use 
of limb OR Pain/tenderness 
causing greater than minimal 
interference with usual social 
& functional activitiesPain/tenderness causing 
inability to perform usual 
social & functional activitiesPain/tenderness causing 
inability to perform basi c 
self-care function OR 
Hospitalization (other than 
ER visit) indicated for 
management of 
pain/tenderness
Injection Site Reaction 
(Localized), 15YearsErythema OR Induration
of 55cm to 99cm 
(or2581 cm2)Erythema OR Induration OR 
Edema 9cm any diameter 
(or 81cm2)Ulceration OR Secondary 
infection OR Phlebitis OR 
Sterile abscess OR DrainageNecrosis (involving dermis 
and deeper tissue)
Pediatric 15Years Erythema OR Induration OR 
Edema present but 2.5cm 
diameterErythema OR Induration OR 
Edema > 2.5cm diameter but 
<50% surface area of the 
extremity segment (eg, upper 
arm/thigh)Erythema OR Induration OR 
Edema involving 50% 
surface area of the extremity 
segment (eg, upper 
arm/thigh) OR Ulceration 
OR Secondary infection OR 
Phlebitis OR Sterile abscess 
OR DrainageNecrosis (involving dermis 
and deeper tissue)
Pruritis Associated with 
Injection 
See also Skin: Pruritis 
(itching—no skin lesions)Itching localized to injection 
site AND Relieved 
spontaneously or w ith 48h 
treatment Itching beyond the injection 
site but not generalized OR 
Itching localized to injection 
site requiring 48h 
treatment Generalized itching causing 
inability to perform usual 
social & functional activitiesNA
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page115 20 November 2015ENDOCRINE/METABOLIC
Grade1 Grade 2 Grade 3 Grade 4
Lipodystrophy (eg, back of 
neck, breasts, abdomen)Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)Detectable on physical exam 
by health care providerDisfiguring OR Obvious 
changes on casua l visual 
inspectionNA
Diabetes Mellitus NA New onset without need to 
initiate medication OR 
Modification of current meds 
to regain glucose controlNew onset with initiation of 
indicated med OR Diabetes 
uncontrolled despite 
treatment modificationLife-threatening 
consequences (eg, 
ketoacidosis, hyperosmolar 
non-ketotic coma) 
Gynecomastia Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)Detectable on physical exam 
by health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
Hyperthyroidism Asymptomatic Symptomatic causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Thyroid suppression therapy 
indicatedSymptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despite 
treatment modification Life-threatening 
consequences (eg, thyroid 
storm)
Hypothyroidism Asymptomatic Symptomatic causing greater 
than minimal interference 
with usual social & 
functional activities OR 
Thyroid replacement therapy 
indicatedSymptoms causing inability 
to perform usual social & 
functional activities OR 
Uncontrolled despite 
treatment modification Life-threatening 
consequences (eg, 
myxedema coma)
Lipoatrophy (eg, fat loss from 
the face, extremities , buttocks)Detectable by study 
participant or caregiver (for 
young children and disabled 
adults)Detectable on physical exam 
by health care providerDisfiguring OR Obvious on 
casual visual inspectionNA
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page116 20 November 2015GENITOURINARY
Grade 1 Grade 2 Grade 3 Grade 4
Intermenstrual Bleeding (IMB) Spotting observed by 
participant OR Minimal 
blood observed during 
clinical or colposcopic examIntermenstrual bleeding not 
greater in duration or amount 
than usual menstrual cycleIntermenstrual bleeding 
greater in duration or amount 
than usual menstrual cycleHemorrhage with life -
threatening hypotension OR 
Operative intervention 
indicated
Urinary Tract obstruction 
(eg,stone)NA Signs or symptoms of 
urinary tract obstruction 
without hydronephrosis or 
renal dysfunctionSigns or symptoms of 
urinary tract obstruction with 
hydronephrosis or renal 
dysfunctionObstruction causing life -
threatening consequences
INFECTION
Grade 1 Grade 2 Grade 3 Grade 4
Infection (any other than HIV 
infection)Localized, no systemic 
antiμbial treatment indicated 
AND Symptoms causing no 
or minimal interference with 
usual social & functional 
activitiesSystemic antiμbial treatment 
indicated OR Symptoms 
causing greater than minimal 
interference with usual social 
& functional activitiesSystemic an tiμbial treatment 
indicated AND Symptoms 
causing inability to perform 
usual social & functional 
activities OR Operative 
intervention (other than 
simple incision and drainage) 
indicatedLife-threatening 
consequences 
(eg, septic shock)
Basic Self-care Functions: Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.
Usual Social & Functional Activities: Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc .
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page117 20 November 2015Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV 
(CDCGuidelines)
1) Candidiasis of bronchi, trachea, or lungs
2)Candidiasis of esophagus
3)Cervical cancer, invasive
4)Coccidioidomy cosis, 
disseminated or extrapulmonary
5)Cryptococcosis, extrapulmonary
6)Cryptosporidiosis, chronic intestinal ( >1month duration)
7)Cytomegalovirus disease (other than liver, spleen or nodes)
8)Cytomegalovirus retinitis (with loss of vision)
9)Encephalopath y, HIV-related
10)
Herpes simplex: chronic ulcer(s) (>1 month duration); or bronchitis, pneumonitis or 
esophagitis
11)Histoplasmosis, disseminated or extrapulmonary
12)Isosporiasis, chronic intestinal ( >1month duration)
13)Kaposi’s sarcoma
14)Lymphoma, Burkitt’s (or equivalent term)
15)Lymphoma, immunoblastic (or equivalent term)
16)Lymphoma, primary , of brain
17)Mycobacterium avium complex or Myobacterium kansasii , disseminated or extrapulmonary
18)Mycobacterium tuberculosis , of any site,  pulmonary , disseminated or extrapulmonary
19)Mycobacterium , other species or unidentified species, disseminated or extrapulmonary
20)Pneumocy stis jirovecii (previously  known as “ Pneumocystis carinii ) pneumonia
21)Pneumonia, recurrent
22)Progressive multifocal leukoencephalopathy
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page118 20 November 201523)Salmonella septicemia, recurrent
24)Toxoplasmo sis of brain
25)Wasting sy ndrome attributed to HIV infection
CDC Stage-3-Defining Opportunistic I llnesses in HIV Infection −2014{13585}
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page119 20 November 2015Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing 
Potential, and Contraceptive Requirements
1)Definitions
a.Definition of Childbearing Potential
For the purposes of this study , a female born subject is considered of childbearing potential 
following the initiation of pubert y (Tanner stage 2) until becoming post -menopausal, unless 
permanentl y sterile or with medically  documente d ovarian failure.  
Femalesare considered to be in a postmenopausal state when they  are >54years of age with 
cessation of previously  occurring menses for > 12 month s without an alternative cause. In 
addition, females of an y age with amenorrhea of >12 months may  also be considered 
postmenopausal if their follicle stimulating hormone (FSH) level is in the postmenopausal range 
and they are not using hormonal contraception or hormonal replacement therapy .
Permanent sterilization includes hy sterectomy , bilateral oophorectom y, or bilateral 
salpingectomy  in a female subject of an y age.
2) Contraception Requirements for Women
a.Study Drug Effects on Pregnancy and Hormonal Contraception
The data on GS -9883/F/TAF in pregnant women is limited or not available. There isno 
suspicion of human teratogenicity  based on class effects or ge notoxic potential. Relevant 
non-clinical reproductive studies for human pregnancy  do not indicate a strong suspicion of 
human teratogenicit y/fetotoxicity . Data from clinical pharmacokinetic interaction studies of 
GS-9883 and F/TAF have demonstrated that there is no reduction in the clinical efficacy  of 
hormonal contraception or that the effect on hormonal contraception is insignificant. Please refer 
to the latest version of the GS-9883/F/TAF investigator’s brochure and the latest version
sof the 
E/C/F/TAF, E/C/F/TDF, ATV, RTV and FTC/TDF package inserts or investigator’s brochure s
for additional information
.  
b.Contraception Requirements for Womenof Childbearing Potential
The inclusion of female subjects of childbearing potential requires the use of highl y effective 
contraceptive measures. They must have a negative serum pregnancy  test at Screening and a 
negative pregnancy  test on the Day  1visit prior to randomization. At a minimum a pregn ancy 
test will be performed at the end of relevant s ystemic exposure. I n the event of a delay ed 
menstrual period (over one month between menstruations), a pregnancy  test must be performed 
to rule out pregnancy . This is true even for women of childbearing potential with infrequent or 
irregular periods. Female subjects must agree to one of the fo llowing from Screening until 
30days following the end of relevant sy stemic exposure .
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page120 20 November 2015Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable 
method of contraception only  when it is in line with the subject’s preferred and usual 
lifestyle. 
Or
Consistent and correct use of 1 of the following methods of birth control listed below. 
Intrauterine device (IUD) with a failure rate of < 1%per year
Intrauterine hormone -releasing s ystem (IUS) with a failure rate of < 1% per year
Tubal sterilization
Essure micro- insert system (provided confirmation of success 3 months after procedure)
Vasectom y in the male partner (provided that the partner i s the sole sexual partner and 
had confirmation of surgical success 3 months after procedure)
Or
Consistent and correct use of one hormonal method and one barrier method
Barrier methods
Diaphragm with spermicide
Cervical cap with spermicide
Male condom (with or without spermicide)
Hormonal methods
Oral contraceptives (either combined or progesterone only )
Injectable progesterone
Implants of levonorgestrel
Transdermal contraceptive patch
Contraceptive vaginal ring
Female subjects must also refrain from eg g donation and in vitro fertilization during treatment 
and until at least 30 day s after the end of relevant sy stemic exposure .  
GS-9883/F/TAF
Protocol GS -US-380-1961 Final
Gilead Sciences, Inc. Original
CONFIDENTIAL Page121 20 November 20153) Unacceptable Birth Control Methods
Birth control methods that are unacceptable include periodic abstinence (e.g., calendar, ovu lation, 
symptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides only , and 
lactational amenorrhea method (LAM). Female condom and male condom should not be used 
together.
4) Procedures to be Followed in the Event of Pregnancy
Subjects will be instructed to notify  the investigator if they  become pregnant at any  time during 
the study, or if they  become pregnant within 30days of last study  drug dose. Subjects who 
become pregnant or who suspect that they  are pregnant during the stud y must report the 
information to the investigator immediately . The investigator will counsel the subject regarding 
pregnancy  management options. Counseling will be provided regarding alternative anti -HIV 
treatment. Information on the risks and benefits of an tiretroviral therapies will be discussed, 
including the risk of ongoing fetal exposure to the study  drug versus the new alternative therap y 
and the risk of discontinuing maternal therapy .
If the subject is on GS -9883/F/TAF, they  must discontinue study  drug immediately . Subjects 
may be allowed to continue on study  drug if they  are taking E/C/F/TAF, E/C/F/TDF or 
ATV+RTV+FTC/TDF and an additional informed consent will be required .
If the subject elects to discontinue study  drugsbut remain in the study ,a new ARV regimen will 
be constructed at the Investigator’s discretion. 
The Investigator should counsel the subject on the need to inform the stud y site ofthe outcome 
of the pregnancy . Information collected will include gestatio nal dating, ultrasound report, records 
of maternal, fetal complications and pregnancy  outcome. 
Instructions for reporting pregnancy  and pregnancy  outcome are outlined in Section7.6.